# AMR release (generated on Fri Mar 13, 2015 at 14:51:00)

# ::id bio-exp_0001.1 ::date 2014-09-16T11:13:45 ::annotator ISI-AMR-01 ::preferred
# ::snt We next examined the mechanisms accounting for the increase in HER3 by MAPK pathway inhibitors in BRAF mutant thyroid cell lines .
# ::save-date Mon Sep 29, 2014 ::file bio-exp_0001_1.txt
(e / examine-01
      :ARG0 (w / we)
      :ARG1 (m / mechanism
            :ARG0-of (a / account-01
                  :ARG1 (i / increase-01
                        :ARG0 (m2 / molecular-physical-entity
                              :ARG0-of (i2 / inhibit-01
                                    :ARG1 (p / pathway :name (n3 / name :op1 "MAPK"))
                                    :location (c / cell-line
                                          :source (t / thyroid)
                                          :ARG1-of (e3 / encode-01
                                                :ARG0 (d / DNA
                                                      :part (g / gene :name (n4 / name :op1 "BRAF")
                                                            :ARG1-of (m3 / mutate-01)))))))
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "HER3")))))
      :time (n / next))

# ::id bio-exp_0001.2 ::date 2014-09-26T12:18:16 ::annotator ISI-AMR-01 ::preferred
# ::snt Upregulation of HER3 has been found to mediate resistance to PI3K/AKT ( 26 ) or HER2 ( 27 ) inhibitors in HER2-amplified breast cancer cell lines , which is caused in part through a FoxO3A-dependent induction of HER3 gene transcription .
# ::save-date Mon Oct 20, 2014 ::file bio-exp_0001_2.txt
(f / find-01
      :ARG1 (m / mediate-01
            :ARG0 (u / upregulate-01
                  :ARG1 (e / enzyme :name (n / name :op1 "HER3")))
            :ARG1 (r / resist-01
                  :ARG1 (m2 / molecular-physical-entity
                        :ARG0-of (i / inhibit-01
                              :ARG1 (o / or
                                    :op1 (p / pathway :name (n2 / name :op1 "PI3K/AKT")
                                          :ARG1-of (d2 / describe-01
                                                :ARG0 (p5 / publication
                                                      :ARG1-of (c4 / cite-01
                                                            :ARG2 26))))
                                    :op2 (p2 / protein :name (n3 / name :op1 "HER2")
                                          :ARG1-of (d3 / describe-01
                                                :ARG0 (p6 / publication
                                                      :ARG1-of (c5 / cite-01
                                                            :ARG2 27)))))))
                  :location (c / cell-line
                        :source (c2 / cancer
                              :mod (b / breast))
                        :ARG0-of (a / amplify-01
                              :ARG1 p2)))
            :ARG1-of (c3 / cause-01
                  :ARG0 (i2 / induce-01
                        :ARG1 (t / transcribe-01
                              :ARG1 (g / gene
                                    :ARG0-of (e2 / encode-01
                                          :ARG1 e)))
                        :ARG0-of (d / depend-01
                              :ARG1 (p4 / protein :name (n4 / name :op1 "FoxO3A"))))
                  :mod (p3 / part))))

# ::id bio-exp_0001.3 ::date 2014-09-26T12:18:43 ::annotator ISI-AMR-01 ::preferred
# ::snt As shown in Fig. 5A, PLX4032 treatment increased HER3 and HER2 mRNAs in all six BRAF-mutant thyroid cancer cell lines tested .
# ::save-date Mon Sep 29, 2014 ::file bio-exp_0001_3.txt
(i / increase-01
      :ARG0 (t / treat-03
            :ARG3 (s2 / small-molecule :name (n / name :op1 "PLX4032")))
      :ARG1 (m3 / mRNA
            :ARG0-of (e / encode-01
                  :ARG1 (a / and
                        :op1 (p / protein :name (n2 / name :op1 "HER3"))
                        :op2 (p2 / protein :name (n3 / name :op1 "HER2")))))
      :ARG1-of (s / show-01
            :location (f / figure :mod "5A"))
      :location (c / cell-line
            :source (c2 / cancer
                  :mod (t2 / thyroid))
            :ARG1-of (e2 / encode-01
                  :ARG0 (d / DNA
                        :part (g / gene :name (n4 / name :op1 "BRAF")
                              :ARG1-of (m2 / mutate-01))))
            :ARG1-of (i2 / include-91
                  :ARG2 (c3 / cell-line :quant 6
                        :ARG1-of (t3 / test-01))
                  :ARG3 (a2 / all))))

# ::id bio-exp_0001.4 ::date 2015-01-23T04:12:10 ::annotator SDL-AMR-09 ::preferred
# ::snt Similar results were found following treatment with the MEK inhibitor AZD6244 ( not shown ) .
# ::save-date Fri Feb 6, 2015 ::file bio-exp_0001_4.txt
(f / find-01
      :ARG1 (t / thing
            :ARG2-of (r / result-01)
            :ARG1-of (r2 / resemble-01)
            :ARG1-of (s / show-01 :polarity -))
      :ARG1-of (f2 / follow-01
            :ARG2 (t2 / treat-04
                  :ARG2 (m / molecular-physical-entity :name (n2 / name :op1 "AZD6244")
                        :ARG0-of (i / inhibit-01
                              :ARG1 (e / enzyme :name (n / name :op1 "MEK")))))))

# ::id bio-exp_0001.5 ::date 2015-02-07T10:09:52 ::annotator SDL-AMR-09 ::preferred
# ::snt The effects of the MEK inhibitor on total HER2 , HER3 protein and on pHER3 were dose dependent , and inversely associated with the degree of inhibition of pERK ( Fig. 5B ) .
# ::save-date Mon Feb 9, 2015 ::file bio-exp_0001_5.txt
(a / and
      :op1 (d / depend-01
            :ARG0 (a2 / affect-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (i / inhibit-01
                              :ARG1 (e / enzyme :name (n / name :op1 "MEK"))))
                  :ARG1 (a3 / and
                        :op1 (e2 / enzyme :name (n2 / name :op1 "HER2")
                              :mod (t / total))
                        :op2 (e3 / enzyme :name (n3 / name :op1 "HER3"))
                        :op3 (e4 / enzyme :name (n4 / name :op1 "HER3")
                              :ARG3-of (p / phosphorylate-01))))
            :ARG1 (d2 / dose-01))
      :op2 (a4 / associate-01
            :ARG1 a2
            :ARG2 (t2 / thing
                  :degree-of (i2 / inhibit-01
                        :ARG1 (e5 / enzyme :name (n5 / name :op1 "ERK")
                              :ARG3-of p)))
            :manner (i3 / inverse))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "5B")))

# ::id bio-exp_0001.6 ::date 2015-02-07T10:17:49 ::annotator SDL-AMR-09 ::preferred
# ::snt RAF or MEK inhibitors induced luciferase activity of a HER3 promoter construct spanning ~ 1 kb upstream of the transcriptional start site in 8505C cells .
# ::save-date Mon Feb 9, 2015 ::file bio-exp_0001_6.txt
(i / induce-01
      :ARG0 (o / or
            :op1 (m / molecular-physical-entity
                  :ARG0-of (i2 / inhibit-01
                        :ARG1 (e / enzyme :name (n / name :op1 "RAF"))))
            :op2 (m2 / molecular-physical-entity
                  :ARG0-of (i3 / inhibit-01
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "MEK")))))
      :ARG1 (a / act-01
            :ARG0 (c / construct-01
                  :ARG0-of (p / promote-01
                        :ARG1 (e3 / enzyme :name (n3 / name :op1 "HER3")))
                  :ARG0-of (s / span-01
                        :ARG1 (r / relative-position
                              :op1 (p2 / protein-segment
                                    :location-of (s3 / start-01
                                          :ARG1 (t / transcribe-01)))
                              :direction (u / upstream))
                        :location (c2 / cell :name (n4 / name :op1 "8505S"))
                        :quant (a2 / approximately
                              :op1 (d / distance-quantity :quant 1
                                    :unit (k / kilo-base-pair)))))
            :ARG1 (l / luciferase)))

# ::id bio-exp_0001.7 ::date 2015-02-07T10:25:54 ::annotator SDL-AMR-09 ::preferred
# ::snt Serial deletions identified a minimal HER3 promoter retaining transcriptional response to vemurafenib and AZD6244 , which was located between -401 and -42 bp ( Fig. 5C ) .
# ::save-date Sun Feb 8, 2015 ::file bio-exp_0001_7.txt
(i / identify-01
      :ARG0 (d / delete-01
            :manner (s2 / serial))
      :ARG1 (m / molecular-physical-entity
            :ARG0-of (p / promote-01
                  :ARG1 (e / enzyme :name (n / name :op1 "HER3")))
            :mod (m2 / minimal)
            :ARG0-of (r / retain-01
                  :ARG1 (t / thing
                        :ARG2-of (r2 / respond-01
                              :ARG1 (a / and
                                    :op1 (s3 / small-molecule :name (n3 / name :op1 "vemurafenib"))
                                    :op2 (s / small-molecule :name (n2 / name :op1 "AZD6244")))))
                  :mod (t2 / transcribe-01))
            :location (b / between
                  :op1 (d2 / distance-quantity :quant "-401"
                        :unit (b2 / base-pair))
                  :op2 (d3 / distance-quantity :quant "-42"
                        :unit (b3 / base-pair))))
      :ARG1-of (d4 / describe-01
            :ARG0 (f / figure :mod "5C")))

# ::id bio-exp_0001.8 ::date 2015-01-28T02:52:22 ::annotator SDL-AMR-09 ::preferred
# ::snt This region does not contain any predicted FoxO binding sites .
# ::save-date Fri Feb 6, 2015 ::file bio-exp_0001_8.txt
(c / contain-01 :polarity -
      :ARG0 (r / region
            :mod (t / this))
      :ARG1 (p3 / protein-segment
            :mod (a / any)
            :ARG1-of (p / predict-01)
            :ARG1-of (b / bind-01
                  :ARG2 (p2 / protein :name (n / name :op1 "FoxO")))))

# ::id bio-exp_0001.9 ::date 2015-02-07T10:41:21 ::annotator SDL-AMR-09 ::preferred
# ::snt Moreover , PLX4032 led to an increase in phosphorylation of FoxO1/3A between 4 – 10 h after addition of compound ( not shown ) , which is known to promote its dissociation from DNA , and likely discards involvement of these factors as transcriptional regulators of HER3 in response to MAPK pathway inhibition .
# ::save-date Sat Feb 7, 2015 ::file bio-exp_0001_9.txt
(a / and
      :op2 (l / lead-03
            :ARG0 (s / small-molecule :name (n / name :op1 "PLX4032"))
            :ARG1 (i / increase-01
                  :ARG1 (p / phosphorylate-01
                        :ARG1 (p2 / protein :name (n2 / name :op1 "FoxO1/3A")))
                  :time (a2 / after
                        :op1 (a3 / add-02
                              :ARG1 (c / compound))
                        :quant (b / between
                              :op1 (t / temporal-quantity :quant 4
                                    :unit (h / hour))
                              :op2 (t2 / temporal-quantity :quant 10
                                    :unit (h2 / hour))))
                  :ARG1-of (s2 / show-01 :polarity -)
                  :ARG0-of (p3 / promote-01
                        :ARG1 (d / dissociate-01
                              :ARG1 p2
                              :ARG2 (d2 / DNA))
                        :ARG1-of (k / know-01))
                  :ARG0-of (d3 / discard-01
                        :ARG1 (i2 / involve-01
                              :ARG1 (f / factor
                                    :mod (t3 / this))
                              :mod (m / molecular-physical-entity
                                    :ARG0-of (r / regulate-01
                                          :ARG1 (e / enzyme :name (n3 / name :op1 "HER3")))
                                    :mod (t4 / transcribe-01)))
                        :mod (l2 / likely)
                        :ARG2-of (r2 / respond-01
                              :ARG1 (i3 / inhibit-01
                                    :ARG1 (p4 / pathway :name (n4 / name :op1 "MAPK"))))))))

# ::id bio-exp_0001.10 ::date 2015-02-07T10:47:07 ::annotator SDL-AMR-09 ::preferred
# ::snt The minimal HER3 promoter region regulated by MAPK inhibitors overlaps with sequences previously described to be immunoprecipitated using antibodies against the ZFN217 transcription factor and CtBP1/CtBP2 corepressors ( 28–30 ) .
# ::save-date Mon Feb 9, 2015 ::file bio-exp_0001_10.txt
(o / overlap-01
      :ARG0 (r / region
            :part (m / molecular-physical-entity
                  :ARG0-of (p2 / promote-01
                        :ARG1 (e / enzyme :name (n / name :op1 "HER3")))
                  :mod (m2 / minimal))
            :ARG1-of (r2 / regulate-01
                  :ARG0 (m3 / molecular-physical-entity
                        :ARG0-of (i / inhibit-01
                              :ARG1 (p / pathway :name (n2 / name :op1 "MAPK"))))))
      :ARG1 (s / sequence
            :ARG1-of (i2 / immunoprecipitate-00
                  :ARG2-of (u / use-01
                        :ARG1 (a / antibody
                              :ARG0-of (o2 / oppose-01
                                    :ARG1 (a2 / and
                                          :op1 (f / factor
                                                :ARG0-of (t / transcribe-01
                                                      :ARG1 (e2 / enzyme :name (n3 / name :op1 "ZFN217"))))
                                          :op2 (o3 / or
                                                :op1 (c / corepressor :name (n4 / name :op1 "CtBP1"))
                                                :op2 (c2 / corepressor :name (n5 / name :op1 "CtBP2")))))))
                  :ARG1-of (d / describe-01
                        :time (p3 / previous))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (v / value-interval :op1 28 :op2 30)))))

# ::id bio-exp_0001.11 ::date 2015-02-07T11:00:42 ::annotator SDL-AMR-09 ::preferred
# ::snt CtBPs have also been described to negatively regulate transcriptional activity of the HER3 promoter in breast carcinoma cell lines ( 30 ) .
# ::save-date Sat Feb 7, 2015 ::file bio-exp_0001_11.txt
(d / describe-01
      :ARG1 (p / protein :name (n2 / name :op1 "CtBP"))
      :ARG2 (d2 / downregulate-01
            :ARG1 (a / act-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (p2 / promote-01
                              :ARG1 (e / enzyme :name (n / name :op1 "HER3"))))
                  :ARG1 (t / transcribe-01))
            :ARG2 p)
      :location (c / cell-line
            :mod (c2 / carcinoma
                  :mod (b / breast)))
      :mod (a2 / also)
      :ARG1-of (d3 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 30))))

# ::id bio-exp_0001.12 ::date 2015-02-05T12:19:53 ::annotator SDL-AMR-09 ::preferred
# ::snt Silencing of CtBP1 , and to a lesser extent CtBP2 , increased basal HER3 in 8505C cells , and markedly potentiated the effects of PLX4032 ( Fig. 5D and 5E ) .
# ::save-date Thu Feb 5, 2015 ::file bio-exp_0001_12.txt
(a / and
      :op1 (i / increase-01
            :ARG0 (s / silence-01
                  :ARG1 (a2 / and
                        :op1 (p / protein :name (n2 / name :op1 "CtBP1"))
                        :op2 (p2 / protein :name (n3 / name :op1 "CtBP2")
                              :degree (l / less
                                    :degree (m / more)))))
            :ARG1 (e / enzyme :name (n / name :op1 "HER3")
                  :mod (b / basal))
            :location (c / cell :name (n4 / name :op1 "8505C")))
      :op2 (p3 / potentiate-00
            :ARG0 s
            :ARG1 (a3 / affect-01
                  :ARG0 (s2 / small-molecule :name (n5 / name :op1 "PLX4032")))
            :manner (m2 / marked))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure :mod "5D")
                  :op2 (f2 / figure :mod "5E"))))

# ::id bio-exp_0001.13 ::date 2015-02-07T09:16:39 ::annotator SDL-AMR-09 ::preferred
# ::snt Knockdown of these factors modestly increased basal and PLX4032 - induced HER2 levels , which likely contributes to the remarkable increase in pHER3 we observed ( Fig. 5D and 5E ) .
# ::save-date Mon Feb 9, 2015 ::file bio-exp_0001_13.txt
(i / increase-01
      :ARG0 (k / knock-02
            :ARG1 (f / factor
                  :mod (t / this)))
      :ARG1 (a / and
            :op1 (l / level
                  :quant-of (e / enzyme :name (n / name :op1 "HER2")
                        :mod (b / basal)))
            :op2 (l2 / level
                  :quant-of (e2 / enzyme :name (n2 / name :op1 "HER2")
                        :ARG1-of (i2 / induce-01
                              :ARG0 (s / small-molecule :name (n3 / name :op1 "PLX4032"))))))
      :degree (m / modest)
      :ARG0-of (c / contribute-01
            :ARG1 (i3 / increase-01
                  :ARG1 (e3 / enzyme :name (n4 / name :op1 "HER3")
                        :ARG3-of (p / phosphorylate-01))
                  :ARG1-of (o / observe-01
                        :ARG0 (w / we))
                  :mod (r / remarkable))
            :mod (l3 / likely))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (f2 / figure :mod "5D")
                  :op2 (f3 / figure :mod "5E"))))

# ::id bio-exp_0001.14 ::date 2015-02-07T11:19:08 ::annotator SDL-AMR-09 ::preferred
# ::snt Finally , CtBP1 and CtBP2 chromatin immunoprecipitation assays showed decreased binding to the HER3 promoter after treatment with PLX4032 ( Fig. 5F ) .
# ::save-date Sat Feb 7, 2015 ::file bio-exp_0001_14.txt
(s / show-01
      :ARG0 (a / assay-00
            :ARG1 (i / immunoprecipitate-00
                  :ARG1 (a2 / and
                        :op1 (p / protein :name (n2 / name :op1 "CtBP1"))
                        :op2 (p2 / protein :name (n3 / name :op1 "CtBP2")))
                  :mod (c / chromatin)))
      :ARG1 (b / bind-01
            :ARG2 (m / molecular-physical-entity
                  :ARG0-of (p3 / promote-01
                        :ARG1 (e / enzyme :name (n / name :op1 "HER3"))))
            :ARG1-of (d / decrease-01
                  :time (a3 / after
                        :op1 (t / treat-04
                              :ARG2 (s2 / small-molecule :name (n4 / name :op1 "PLX4032"))))))
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "5F"))
      :time (f2 / final))

# ::id bio-exp_0001.15 ::date 2015-02-05T12:14:53 ::annotator SDL-AMR-09 ::preferred
# ::snt These findings were confirmed in a second cell line ( Supplementary Fig. S5A ) .
# ::save-date Sun Feb 8, 2015 ::file bio-exp_0001_15.txt
(c / confirm-01
      :ARG1 (t2 / thing
            :ARG1-of (f / find-01)
            :mod (t / this))
      :location (c2 / cell-line
            :ord (o / ordinal-entity :value 2))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "S5A"
                  :ARG2-of (s / supplement-01))))

# ::id bio-kappa_0001.1 ::date 2014-09-19T16:48:49 ::annotator ISI-AMR-01 ::preferred
# ::snt Activation of Raf occurs via a complex , yet incompletely understood mechanism requiring membrane translocation , regulatory phosphorylation / dephosphorylation events and , crucially , allosteric activation in the context of a side-to-side dimer comprising two Raf molecules or a Raf and a Ksr molecule .
# ::save-date Wed Dec 10, 2014 ::file bio-kappa_0001_1.txt
(a / activate-01
      :ARG1 (e / enzyme :name (n / name :op1 "Raf"))
      :manner (m / mechanism
            :mod (c / complex)
            :ARG1-of (u / understand-01
                  :degree (c2 / complete :polarity -))
            :ARG0-of (r / require-01
                  :ARG1 (a2 / and
                        :op1 (t / translocate-00
                              :path (m2 / membrane))
                        :op2 (p2 / phosphorylate-01
                              :ARG0-of (r2 / regulate-01))
                        :op3 (d / dephosphorylate-01
                              :ARG0-of (r3 / regulate-01))
                        :op4 (a3 / activate-01
                              :mod (a4 / allosteric)
                              :mod (c3 / crucial)
                              :condition (h / have-part-91
                                    :ARG1 (d2 / dimer
                                          :mod (s / side-to-side)
                                          :ARG1-of (c5 / comprise-01
                                                :ARG2 (o / or
                                                      :op1 (e2 / enzyme :quant 2 :name (n2 / name :op1 "Raf"))
                                                      :op2 (a5 / and
                                                            :op1 (e3 / enzyme :name (n3 / name :op1 "Raf"))
                                                            :op2 (e4 / enzyme :name (n4 / name :op1 "Ksr"))))))
                                    :ARG2 e))))))

# ::id bio-kappa_0001.2 ::date 2014-09-26T12:38:07 ::annotator ISI-AMR-01 ::preferred
# ::snt Of the three Raf kinases , only B-Raf is able to function as an allosteric activator in the context of the Raf heterodimers , a role independent of B-Raf kinase activity .
# ::save-date Wed Dec 10, 2014 ::file bio-kappa_0001_2.txt
(p / possible
      :domain (a / activate-01
            :ARG0 (k2 / kinase :name (n / name :op1 "B-Raf")
                  :ARG1-of (i / include-91
                        :ARG2 (k / kinase :quant 3 :name (n2 / name :op1 "Raf")))
                  :mod (o / only))
            :mod (a2 / allosteric)
            :condition (h2 / have-part-91
                  :ARG1 (h / heterodimer
                        :part (e / enzyme :name (n3 / name :op1 "Raf")))
                  :ARG2 k2)
            :ARG0-of (d / depend-01 :polarity -
                  :ARG1 (a3 / act-02
                        :ARG0 k2))))

# ::id bio-kappa_0001.3 ::date 2014-09-27T15:35:13 ::annotator ISI-AMR-01 ::preferred
# ::snt The molecular basis for this has recently been elucidated by the Shaw lab , who has shown that the ability of acting as an activator depends on the presence of negative charges in the Raf N-terminal acidic motif .
# ::save-date Wed Dec 10, 2014 ::file bio-kappa_0001_3.txt
(e / elucidate-01
      :ARG0 (l / lab :name (n / name :op1 "Shaw")
            :ARG0-of (s / show-01
                  :ARG1 (d / depend-01
                        :ARG0 (p / possible
                              :domain (a / activate-01))
                        :ARG1 (p2 / present
                              :domain (c / charge
                                    :mod (n2 / negative)
                                    :location (m3 / motif
                                          :mod (a2 / acid)
                                          :part-of (p3 / protein-segment :name (n3 / name :op1 "N-terminus")
                                                :part-of (e2 / enzyme :name (n4 / name :op1 "Raf")))))))))
      :ARG1 (m / mechanism
            :mod (m2 / molecule)
            :ARG2-of (b / base-02
                  :ARG1 (t / this)))
      :time (r / recent))

# ::id bio-kappa_0001.4 ::date 2015-01-19T06:33:33 ::annotator SDL-AMR-09 ::preferred
# ::snt In B-Raf , this motif is negatively charged due to the constitutive phosphorylation of Ser446 and/or 447 , and to the presence of two aspartates at position 448/9 ( Fig. 2A ) .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_4.txt
(c / charge-03
      :ARG1 (m / motif
            :mod (t / this)
            :part-of (e2 / enzyme :name (n6 / name :op1 "B-Raf")))
      :mod (n / negative)
      :ARG1-of (c2 / cause-01
            :ARG0 (a / and
                  :op1 (p / phosphorylate-01
                        :ARG1 (a6 / and-or
                              :op1 (a2 / amino-acid :mod 446 :name (n2 / name :op1 "serine"))
                              :op2 (a3 / amino-acid :mod 447 :name (n3 / name :op1 "serine")))
                        :mod (c3 / constitutive))
                  :op2 (b / be-located-at-91
                        :ARG1 (a4 / amino-acid :quant 2 :name (n4 / name :op1 "aspartate"))
                        :ARG2 (a5 / and
                              :op1 (p2 / protein-segment :mod 448)
                              :op2 (p3 / protein-segment :mod 449)))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "2A")))

# ::id bio-kappa_0001.5 ::date 2015-01-20T00:43:24 ::annotator SDL-AMR-09 ::preferred
# ::snt Allosteric activation by B-Raf induces cis-autophosporylation in the activation loop of the receiver kinase , i.e. C-Raf , and renders it able to phosphorylate Mek .
# ::save-date Thu Mar 12, 2015 ::file bio-kappa_0001_5.txt
(a3 / and
      :op1 (i / induce-01
            :ARG0 (a / activate-01
                  :ARG0 (e / enzyme :name (n / name :op1 "B-Raf"))
                  :mod (a2 / allosteric))
            :ARG1 (p / phosphorylate-01
                  :ARG1 k
                  :ARG2 k
                  :subevent-of (l / loop
                        :ARG0-of (a4 / activate-01
                              :ARG1 (k / kinase
                                    :ARG0-of (r2 / receive-01)
                                    :ARG1-of (m / mean-01
                                          :ARG2 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))))))))
      :op2 (r / render-01
            :ARG0 a
            :ARG1 (p2 / possible
                  :domain (p3 / phosphorylate-01
                        :ARG1 (e3 / enzyme :name (n3 / name :op1 "Mek"))
                        :ARG2 e2))))

# ::id bio-kappa_0001.6 ::date 2015-01-20T01:34:52 ::annotator SDL-AMR-09 ::preferred
# ::snt Mek , in turn , phosphorylates the N-terminal acidic motif in C-Raf , converting it to an allosteric activator of other Rafs ( Fig. 2B and C ) .
# ::save-date Tue Jan 27, 2015 ::file bio-kappa_0001_6.txt
(p / phosphorylate-01
      :ARG1 (m / motif
            :mod (a / acid)
            :part-of (p2 / protein-segment :name (n2 / name :op1 "N-terminus")
                  :part-of (e2 / enzyme :name (n3 / name :op1 "C-Raf")
                        :ARG1-of (c2 / convert-01
                              :ARG0 e
                              :ARG2 (e3 / enzyme
                                    :ARG0-of (a2 / activate-01
                                          :ARG1 (e4 / enzyme :name (n4 / name :op1 "Raf")
                                                :mod (o / other))
                                          :mod (a3 / allosteric)))))))
      :ARG2 (e / enzyme :name (n / name :op1 "Mek"))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure :mod "2B")
                  :op2 (f2 / figure :mod "2C")))
      :mod (i / in-turn))

# ::id bio-kappa_0001.7 ::date 2015-01-20T01:58:10 ::annotator SDL-AMR-09 ::preferred
# ::snt This model explains why C-Raf mutants devoid of kinase activity cannot function as activators , and why B-Raf can activate Mek directly as a homodimer .
# ::save-date Mon Feb 2, 2015 ::file bio-kappa_0001_7.txt
(e / explain-01
      :ARG0 (m / model
            :mod (t3 / this))
      :ARG1 (t2 / thing
            :ARG0-of (c2 / cause-01
                  :ARG1 (a6 / and
                        :op1 (p / possible :polarity -
                              :domain (a2 / activate-01
                                    :ARG0 (e2 / enzyme :name (n / name :op1 "C-Raf")
                                          :ARG2-of (m2 / mutate-01)
                                          :ARG0-of (a3 / act-01 :polarity -
                                                :ARG1 (k / kinase)))))
                        :op2 (p2 / possible
                              :domain (a4 / activate-01
                                    :ARG0 (e3 / enzyme :name (n2 / name :op1 "B-Raf")
                                          :ARG0-of (a5 / act-01
                                                :ARG1 (h / homodimer)))
                                    :ARG1 (e4 / enzyme :name (n3 / name :op1 "Mek"))
                                    :manner (d / direct)))))))

# ::id bio-kappa_0001.8 ::date 2015-01-20T02:34:12 ::annotator SDL-AMR-09 ::preferred
# ::snt Phosphorylated Ksr can also function as a transactivator ; however , since Raf binding to Ksr induces limited kinase activity , in quiescent cells the constitutive association of Ksr with B-Raf may serve to prevent C-Raf binding to B-Raf , safeguarding against undue activation of the pathway .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_8.txt
(p / possible
      :domain (t2 / transactivate-00
            :ARG0 (e / enzyme :name (n / name :op1 "Ksr")
                  :ARG3-of (p2 / phosphorylate-01))
            :mod (a / also)
            :concession-of (p3 / possible
                  :domain (s / serve-01
                        :ARG0 (a3 / associate-01
                              :ARG1 e
                              :ARG2 (e3 / enzyme :name (n3 / name :op1 "B-Raf"))
                              :mod (c2 / constitutive))
                        :ARG1 (p4 / prevent-01
                              :ARG0 a3
                              :ARG1 (b / bind-01
                                    :ARG1 (e4 / enzyme :name (n4 / name :op1 "C-Raf"))
                                    :ARG2 e3)
                              :ARG0-of (s2 / safeguard-01
                                    :ARG2 (a4 / activate-01
                                          :ARG1 (p5 / pathway)
                                          :mod (d / due :polarity -)))))
                  :location (c / cell
                        :mod (q / quiescent))
                  :ARG1-of (c3 / cause-01
                        :ARG0 (i / induce-01
                              :ARG0 (b2 / bind-01
                                    :ARG1 (e6 / enzyme :name (n6 / name :op1 "Raf"))
                                    :ARG2 e)
                              :ARG1 (a2 / act-01
                                    :ARG1 (k / kinase)
                                    :ARG1-of (l / limit-01)))))))

# ::id bio-kappa_0001.9 ::date 2015-01-20T03:20:23 ::annotator SDL-AMR-09 ::preferred
# ::snt PSPs dephosphorylate phosphoserine and phosphothreonine residues .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_9.txt
(d / dephosphorylate-01
      :ARG1 (a / and
            :op1 (r / residue
                  :mod (a2 / amino-acid :name (n / name :op1 "serine")
                        :ARG3-of (p2 / phosphorylate-01)))
            :op2 (r2 / residue
                  :mod (a3 / amino-acid :name (n2 / name :op1 "threonine")
                        :ARG3-of (p4 / phosphorylate-01))))
      :ARG2 (s / small-molecule :name (n3 / name :op1 "PSP")))

# ::id bio-kappa_0001.10 ::date 2015-01-20T03:41:50 ::annotator SDL-AMR-09 ::preferred
# ::snt One of the most abundantly expressed PSPs , protein phosphatase 2A ( PP2A ) , can regulate the Raf / Mek / Erk pathway both positively and negatively .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_10.txt
(p / possible
      :domain (a3 / and
            :op1 (u / upregulate-01
                  :ARG1 (p3 / pathway :name (n3 / name :op1 "Raf/Mek/Erk"))
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "protein" :op2 "phosphatase" :op3 "2A")
                        :ARG1-of (i / include-91
                              :ARG2 (s / small-molecule :name (n / name :op1 "PSP")
                                    :ARG2-of (e / express-03
                                          :degree (a / abundant
                                                :degree (m2 / most)))))))
            :op2 (d / downregulate-01
                  :ARG1 p3
                  :ARG2 e2)))

# ::id bio-kappa_0001.11 ::date 2015-01-20T04:54:37 ::annotator SDL-AMR-09 ::preferred
# ::snt As a positive regulator , PP2A associates with C-Raf and Ksr1 and dephosphorylates negative regulatory sites on both proteins , allowing their recruitment to the membrane and leading to Mek and Erk activation .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_11.txt
(a / and
      :op1 (a7 / associate-01
            :ARG1 (e / enzyme :name (n / name :op1 "PP2A"))
            :ARG2 (a2 / and
                  :op1 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))
                  :op2 (e3 / enzyme :name (n3 / name :op1 "Ksr1"))))
      :op2 (d / dephosphorylate-01
            :ARG1 (p2 / protein-segment
                  :ARG0-of (d2 / downregulate-01)
                  :part-of (a3 / and
                        :op1 e2
                        :op2 e3))
            :ARG2 e)
      :ARG0-of (a4 / allow-01
            :ARG1 (r / recruit-01
                  :ARG1 a2
                  :destination (m / membrane)))
      :ARG0-of (l / lead-03
            :ARG2 (a5 / activate-01
                  :ARG1 (a6 / and
                        :op1 (e4 / enzyme :name (n5 / name :op1 "Mek"))
                        :op2 (e5 / enzyme :name (n6 / name :op1 "Erk")))))
      :condition (u / upregulate-01
            :ARG2 e))

# ::id bio-kappa_0001.12 ::date 2015-01-20T05:30:27 ::annotator SDL-AMR-09 ::preferred
# ::snt A similar role in C-Raf activation has been described for the catalytic subunit of PP1C , which associates with C-Raf in Ras- and growth factor - stimulated cells .
# ::save-date Wed Jan 21, 2015 ::file bio-kappa_0001_12.txt
(d / describe-01
      :ARG1 (r / role
            :ARG1-of (r2 / resemble-01)
            :purpose (a / activate-01
                  :ARG1 (e / enzyme :name (n / name :op1 "C-Raf"))))
      :topic (p / protein-segment
            :ARG0-of (c / catalyze-01)
            :part-of (e2 / enzyme :name (n2 / name :op1 "PP1C"))
            :ARG1-of (b / bind-01
                  :ARG2 e
                  :location (c2 / cell
                        :ARG1-of (s / stimulate-01
                              :ARG0 (a2 / and
                                    :op1 (e3 / enzyme :name (n3 / name :op1 "Ras"))
                                    :op2 (s2 / small-molecule :name (n4 / name :op1 "growth" :op2 "factor"))))))))

# ::id bio-kappa_0001.13 ::date 2015-01-20T06:02:25 ::annotator SDL-AMR-09 ::preferred
# ::snt In addition to promoting C-Raf activation , PP2A is also able to dephosphorylate Erk - dependent sites on C-Raf .
# ::save-date Tue Jan 27, 2015 ::file bio-kappa_0001_13.txt
(a / and
      :op1 (p3 / promote-02
            :ARG0 e
            :ARG1 (a2 / activate-01
                  :ARG1 e3))
      :op2 (p / possible
            :domain (d / dephosphorylate-01
                  :ARG1 (p2 / protein-segment
                        :ARG0-of (d2 / depend-01
                              :ARG1 (e2 / enzyme :name (n2 / name :op1 "Erk")))
                        :part-of (e3 / enzyme :name (n3 / name :op1 "C-Raf")))
                  :ARG2 (e / enzyme :name (n / name :op1 "PP2A")))
            :mod (a3 / also)))

# ::id bio-kappa_0001.14 ::date 2015-01-20T06:22:13 ::annotator SDL-AMR-09 ::preferred
# ::snt Since the sites have been described alternatively as negative regulatory or activating , the significance of these dephosphorylation events for Raf activation is unclear .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_14.txt
(c / clear :polarity -
      :domain (s / significance
            :topic (a3 / activate-01
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "Raf")))
            :mod (d / dephosphorylate-01
                  :mod (t / this)))
      :ARG1-of (c2 / cause-01
            :ARG0 (d2 / describe-01
                  :ARG1 (p / protein-segment)
                  :ARG2 (o / or
                        :op1 (d3 / downregulate-01
                              :ARG2 p)
                        :op2 (a2 / activate-01
                              :ARG0 p))
                  :manner (a / alternative))))

# ::id bio-kappa_0001.15 ::date 2015-01-20T06:38:55 ::annotator SDL-AMR-09 ::preferred
# ::snt As a negative regulator of the pathway , PP2A can dephosphorylate the adapter protein Shc , required downstream of some tyrosine kinase receptors for the activation of the Raf / Mek / Erk module ; and it can dephosphorylate Mek and Erk proteins , thus inhibiting the cascade directly .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_15.txt
(a / and
      :op1 (p6 / possible
            :domain (d / dephosphorylate-01
                  :ARG1 (p2 / protein :name (n2 / name :op1 "Shc")
                        :mod (a2 / adapter)
                        :ARG1-of (r / require-01
                              :ARG0 (a3 / activate-01
                                    :ARG1 (p3 / pathway :name (n3 / name :op1 "Raf/Mek/Erk" :op2 "module"))
                                    :location (r3 / relative-position
                                          :op1 (p / protein :name (n7 / name :op1 "tyrosine" :op2 "kinase" :op3 "receptor")
                                                :quant (s / some))
                                          :direction (d2 / downstream)))))
                  :ARG2 (e / enzyme :name (n / name :op1 "PP2A"))
                  :condition (d5 / downregulate-01
                        :ARG1 (p4 / pathway)
                        :ARG2 e)))
      :op2 (p7 / possible
            :domain (d4 / dephosphorylate-01
                  :ARG1 (a4 / and
                        :op1 (e2 / enzyme :name (n4 / name :op1 "Mek"))
                        :op2 (e3 / enzyme :name (n5 / name :op1 "Erk")))
                  :ARG2 e
                  :ARG0-of (i / inhibit-01
                        :ARG1 (c / cascade)
                        :manner (d3 / direct)))))

# ::id bio-kappa_0001.16 ::date 2015-01-20T07:03:49 ::annotator SDL-AMR-09 ::preferred
# ::snt A further negative regulator of the cascade , at the level of C-Raf , is Protein phosphatase 5 ( PP5 ) , which associates with C-Raf via its N-terminal tetratricopeptide ( TPR ) domain in growth factor stimulated cells .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_16.txt
(d3 / downregulate-01
      :ARG0 (e3 / enzyme :name (n / name :op1 "Protein" :op2 "phosphatase" :op3 "5")
            :ARG1-of (a / associate-01
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))
                  :location (c / cell
                        :ARG1-of (s / stimulate-01
                              :ARG0 (s2 / small-molecule :name (n5 / name :op1 "growth" :op2 "factor"))))
                  :instrument (p2 / protein-segment :name (n4 / name :op1 "tetratricopeptide" :op2 "domain")
                        :part-of (p / protein-segment :name (n3 / name :op1 "N-terminal")
                              :part-of e2)))
            :mod (f / further))
      :ARG1 (c2 / cascade
            :location e2))

# ::id bio-kappa_0001.17 ::date 2015-01-20T07:23:45 ::annotator SDL-AMR-09 ::preferred
# ::snt This interaction leads to the activation of PP5 catalytic activity and to the selective dephosphorylation of the activating serine residue at position 338 , terminating the signal .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_17.txt
(l / lead-03
      :ARG0 (i2 / interact-01
            :mod (t / this))
      :ARG2 (a3 / and
            :op1 (a / activate-01
                  :ARG1 (a2 / act-01
                        :ARG0 (e / enzyme :name (n / name :op1 "PP5"))
                        :ARG1 (c2 / catalyze-01)))
            :op2 (d / dephosphorylate-01
                  :ARG1 (r / residue :mod 338
                        :mod (a4 / amino-acid :name (n2 / name :op1 "serine"))
                        :ARG0-of (a5 / activate-01))
                  :mod (s / selective))
            :ARG0-of (t2 / terminate-01
                  :ARG1 (s3 / signal))))

# ::id bio-kappa_0001.18 ::date 2015-01-20T07:43:07 ::annotator SDL-AMR-09 ::preferred
# ::snt Following ligand binding , Sos is brought from the cytoplasm to the activated receptor in a phosphotyrosine - dependent manner through adapter proteins such as Grb2 .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_18.txt
(b / bring-01
      :ARG1 (p3 / protein :name (n3 / name :op1 "Sos"))
      :ARG2 (r / receptor
            :ARG1-of (a / activate-01))
      :ARG4 (c / cytoplasm)
      :manner (d / depend-01
            :ARG0 b
            :ARG1 (a2 / amino-acid :name (n / name :op1 "tyrosine")
                  :ARG3-of (p4 / phosphorylate-01)))
      :instrument (p / protein
            :example (p2 / protein :name (n2 / name :op1 "Grb2"))
            :mod (a3 / adapter))
      :ARG1-of (f / follow-01
            :ARG2 (b2 / bind-01
                  :ARG1 (l / ligand))))

# ::id bio-kappa_0001.19 ::date 2015-01-20T08:00:15 ::annotator SDL-AMR-09 ::preferred
# ::snt Grb2 contains SH3 domains that are bound constitutively to a carboxy - terminal proline - rich region of Sos , and the Grb2 '96 Sos complex is recruited to activated receptors by interactions between the SH2 domain of Grb2 and phosphotyrosine residues on the receptor .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_19.txt
(a / and
      :op1 (c / contain-01
            :ARG0 (p / protein :name (n / name :op1 "Grb2"))
            :ARG1 (p2 / protein-segment :name (n2 / name :op1 "SH3" :op2 "domain")
                  :ARG1-of (b / bind-01
                        :ARG2 (r4 / region
                              :mod (r6 / rich
                                    :topic (a3 / amino-acid :name (n3 / name :op1 "proline")))
                              :part-of (p5 / protein-segment :name (n4 / name :op1 "carboxy-terminus")
                                    :part-of (p6 / protein :name (n5 / name :op1 "Sos"))))
                        :mod (c2 / constitutive))))
      :op2 (r5 / recruit-01
            :ARG0 (i / interact-01
                  :ARG0 (p7 / protein-segment :name (n7 / name :op1 "SH2" :op2 "domain")
                        :part-of p)
                  :ARG1 (r2 / residue
                        :location (r3 / receptor)
                        :mod (a4 / amino-acid :name (n6 / name :op1 "tyrosine")
                              :ARG3-of (p3 / phosphorylate-01))))
            :ARG1 (m2 / macro-molecular-complex
                  :part p
                  :part p6)
            :destination (r / receptor
                  :ARG1-of (a2 / activate-01))))

# ::id bio-kappa_0001.20 ::date 2015-01-20T08:03:03 ::annotator SDL-AMR-09 ::preferred
# ::snt The guanine nucleotide-binding switch in three dimensions .
# ::save-date Wed Jan 21, 2015 ::file bio-kappa_0001_20.txt
(s / switch
      :mod (p / protein :name (n / name :op1 "guanine" :op2 "nucleotide-binding"))
      :prep-in (d / dimension :quant 3))

# ::id bio-kappa_0001.21 ::date 2015-01-20T08:10:38 ::annotator SDL-AMR-09 ::preferred
# ::snt Activation requires dissociation of protein - bound GDP , an intrinsically slow process that is accelerated by guanine nucleotide '96 exchange factors ( GEFs ) .
# ::save-date Tue Jan 27, 2015 ::file bio-kappa_0001_21.txt
(r / require-01
      :ARG0 (a / activate-01)
      :ARG1 (d / dissociate-01
            :ARG1 (s / small-molecule :name (n / name :op1 "GDP")
                  :ARG1-of (b / bind-01
                        :ARG2 (p / protein)))
            :mod (s2 / slow
                  :mod (i / intrinsic))
            :ARG1-of (a2 / accelerate-01
                  :ARG0 (p2 / protein :name (n2 / name :op1 "guanine" :op2 "nucleotide" :op3 "exchange" :op4 "factor")))))

# ::id bio-kappa_0001.22 ::date 2015-01-20T08:17:10 ::annotator SDL-AMR-09 ::preferred
# ::snt This switch - ON process involves the exchange of GDP for GTP , and is , at least in principle , reversible .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_22.txt
(a / and
      :op1 (i2 / involve-01
            :ARG0 (p / process
                  :mod (t / this)
                  :mod (a3 / activate-01))
            :ARG1 (e / exchange-01
                  :ARG1 (s / small-molecule :name (n / name :op1 "GDP"))
                  :ARG3 (s2 / small-molecule :name (n2 / name :op1 "GTP"))))
      :op2 (p3 / possible
            :domain (r / reverse-01
                  :ARG1 p)
            :mod (i / in-principle
                  :mod (a2 / at-least))))

# ::id bio-kappa_0001.23 ::date 2015-01-20T08:30:46 ::annotator SDL-AMR-09 ::preferred
# ::snt The switch - OFF process is entirely different and involves hydrolysis of GTP to GDP , the guanosine triphosphatase ( GTPase ) reaction , which is basically irreversible .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_23.txt
(a / and
      :op1 (d2 / differ-02
            :ARG1 (p / process
                  :mod (d / deactivate-01))
            :degree (e / entire))
      :op2 (i / involve-01
            :ARG1 (h / hydrolyze-01
                  :ARG1 (s / small-molecule :name (n / name :op1 "GTP"))
                  :ARG3 (s2 / small-molecule :name (n2 / name :op1 "GDP"))
                  :ARG2-of (r / react-01
                        :ARG0 (e2 / enzyme :name (n3 / name :op1 "guanosine" :op2 "triphosphatase"))
                        :ARG1-of (r2 / reverse-01
                              :mod (p2 / possible :polarity -
                                    :mod (b / basic)))))
            :ARG2 p))

# ::id bio-kappa_0001.24 ::date 2015-01-20T08:41:56 ::annotator SDL-AMR-09 ::preferred
# ::snt It is also intrinsically very slow and thus has to be accelerated by GTPase - activating proteins ( GAPs ) .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_24.txt
(s / slow
      :domain (i / it)
      :degree (v / very)
      :mod (i2 / intrinsic)
      :mod (a4 / also)
      :ARG0-of (c / cause-01
            :ARG1 (o2 / obligate-01
                  :ARG2 (a / accelerate-01
                        :ARG0 (p / protein
                              :ARG0-of (a3 / activate-01
                                    :ARG1 (e / enzyme :name (n / name :op1 "GTPase"))))
                        :ARG1 i))))

# ::id bio-kappa_0001.25 ::date 2015-01-20T09:07:33 ::annotator SDL-AMR-09 ::preferred
# ::snt The mechanism of GEF action involves a series of fast reaction steps , which lead from a binary protein - nucleotide complex via a trimeric GNBP - nucleotide - GEF complex to a binary nucleotide - free complex , which is stable in the absence of nucleotide .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_25.txt
(i / involve-01
      :ARG1 (s / series
            :consist-of (s2 / step
                  :mod (f / fast)
                  :mod (r / react-01)
                  :ARG0-of (t3 / turn-02
                        :ARG2 (c2 / complex
                              :ARG1-of (f2 / free-41
                                    :ARG2 (n3 / nucleotide))
                              :mod (s3 / stable
                                    :condition (a2 / absent
                                          :domain n3)))
                        :ARG3 (m2 / macro-molecular-complex
                              :part (p2 / protein)
                              :part n3
                              :mod (b2 / binary))
                        :path (m3 / macro-molecular-complex
                              :mod (t2 / trimeric)
                              :part (p3 / protein :name (n2 / name :op1 "GNBP"))
                              :part n3
                              :part (p4 / protein :name (n4 / name :op1 "GEF"))))))
      :ARG2 (m / mechanism
            :mod (a / act-02
                  :ARG0 (p / protein :name (n / name :op1 "GEF")))))

# ::id bio-kappa_0001.26 ::date 2015-01-20T09:08:43 ::annotator SDL-AMR-09 ::preferred
# ::snt This series of reactions is reversed by rebinding of nucleotide , predominantly GTP , because of its higher concentration in the cell .
# ::save-date Thu Mar 12, 2015 ::file bio-kappa_0001_26.txt
(r / reverse-01
      :ARG0 (b / bind-01
            :ARG1 (n / nucleotide
                  :ARG1-of (m2 / mean-01
                        :ARG2 (s2 / small-molecule :name (n2 / name :op1 "GTP"))
                        :mod (p / predominant
                              :ARG1-of (c / cause-01
                                    :ARG0 (c2 / concentrate-02
                                          :ARG1 s2
                                          :mod (h / high
                                                :degree (m / more))
                                          :location (c3 / cell))))))
            :mod (a / again))
      :ARG1 (s / series
            :mod (t / this)
            :consist-of (r2 / react-01)))

# ::id bio-kappa_0001.27 ::date 2015-01-20T09:16:31 ::annotator SDL-AMR-09 ::preferred
# ::snt In principle , these reactions are fast and fully reversible , so that the GEF merely acts as a catalyst to increase the rate at which equilibrium between the GDP- and GTP - bound forms of the protein is reached .
# ::save-date Fri Feb 6, 2015 ::file bio-kappa_0001_27.txt
(a / and
      :op1 (f / fast
            :domain (r / react-01
                  :mod (t / this)))
      :op2 (p / possible
            :domain (r2 / reverse-01
                  :ARG1 r
                  :degree (f2 / full)))
      :mod (i2 / in-principle)
      :ARG0-of (c / cause-01
            :ARG1 (a2 / act-01
                  :ARG0 (p3 / protein :name (n / name :op1 "GEF"))
                  :ARG1 (c2 / catalyze-01)
                  :degree (m / mere)
                  :purpose (i / increase-01
                        :ARG0 p3
                        :ARG1 (r3 / rate
                              :degree-of (r4 / reach-01
                                    :ARG1 (e / equilibrate-01
                                          :ARG1 (a4 / and
                                                :op1 (p2 / protein
                                                      :ARG1-of (b / bind-01
                                                            :ARG2 (s / small-molecule :name (n2 / name :op1 "GDP"))))
                                                :op2 (p5 / protein
                                                      :ARG1-of (b2 / bind-01
                                                            :ARG2 (s2 / small-molecule :name (n3 / name :op1 "GTP"))))))))))))

# ::id bio.bel_0002.1 ::date 2014-09-29T14:32:03 ::annotator ISI-AMR-01 ::preferred
# ::snt Protein kinase A-dependent phosphorylation of serine 43 within the regulatory domain of Raf-1 reciprocally potentiates its interaction with Rheb and decreases its interaction with H-Ras.
# ::save-date Mon Oct 20, 2014 ::file bio_bel_0002_1.txt
(a / and
      :op1 (p / potentiate-00
            :ARG0 (p3 / phosphorylate-01
                  :ARG1 (a2 / amino-acid :mod 43 :name (n5 / name :op1 "serine")
                        :part-of (d2 / domain
                              :mod (r / regulate-01)
                              :part-of (e2 / enzyme :name (n3 / name :op1 "Raf-1"))))
                  :ARG0-of (d3 / depend-01
                        :ARG1 (e3 / enzyme :name (n4 / name :op1 "protein" :op2 "kinase" :op3 "A"))))
            :ARG1 (i / interact-01
                  :ARG0 e2
                  :ARG1 (p2 / protein :name (n / name :op1 "Rheb")))
            :mod (r2 / reciprocal))
      :op2 (d / decrease-01
            :ARG0 p3
            :ARG1 (i2 / interact-01
                  :ARG0 e2
                  :ARG1 (e / enzyme :name (n2 / name :op1 "H-Ras")))))

# ::id bio.bel_0002.2 ::date 2014-09-29T14:54:34 ::annotator ISI-AMR-01 ::preferred
# ::snt We show that wild-type B-RAF forms a complex with C-RAF in a RAS-dependent manner, whereas the mutants bind independently of RAS.
# ::save-date Wed Dec 10, 2014 ::file bio_bel_0002_2.txt
(s / show-01
      :ARG0 (w / we)
      :ARG1 (f / form-01
            :ARG1 (m / macro-molecular-complex
                  :part (e4 / enzyme :name (n / name :op1 "B-RAF")
                        :mod (w2 / wild-type))
                  :part (e / enzyme :name (n2 / name :op1 "C-RAF")))
            :ARG0-of (d / depend-01
                  :ARG1 (e3 / enzyme :name (n3 / name :op1 "RAS")))
            :ARG1-of (c / contrast-01
                  :ARG2 (b / bind-01
                        :ARG1 (e5 / enzyme :name (n4 / name :op1 "B-RAF")
                              :ARG1-of (m2 / mutate-01))
                        :ARG2 (e2 / enzyme :name (n5 / name :op1 "C-RAF")
                              :ARG1-of (m3 / mutate-01))
                        :ARG0-of (d2 / depend-01 :polarity -
                              :ARG1 e3)))))

# ::id bio.bel_0002.3 ::date 2014-09-29T15:10:36 ::annotator ISI-AMR-01 ::preferred
# ::snt Importantly, we show that wild-type B-RAF can also activate C-RAF.
# ::save-date Wed Dec 10, 2014 ::file bio_bel_0002_3.txt
(s / show-01
      :ARG0 (w / we)
      :ARG1 (p / possible
            :domain (a / activate-01
                  :ARG0 (e2 / enzyme :name (n / name :op1 "B-RAF")
                        :mod (w2 / wild-type))
                  :ARG1 (e / enzyme :name (n2 / name :op1 "C-RAF"))
                  :mod (a2 / also)))
      :mod (i / important))

# ::id bio.bel_0002.4 ::date 2015-02-05T10:13:38 ::annotator SDL-AMR-09 ::preferred
# ::snt The homologous site on B-Raf, S445, is constitutively phosphorylated, accounting for the higher basal activity of B-Raf.
# ::save-date Mon Feb 9, 2015 ::file bio_bel_0002_4.txt
(p / phosphorylate-01
      :ARG1 (a3 / amino-acid :mod 445 :name (n3 / name :op1 "serine")
            :part-of (e / enzyme :name (n4 / name :op1 "B-Raf"))
            :mod (h2 / homologue))
      :mod (c / constitutive)
      :ARG0-of (a / account-01
            :ARG1 (a2 / act-02
                  :ARG0 e
                  :mod (b / basal)
                  :mod (h / high
                        :degree (m / more)))))

# ::id bio.bel_0002.5 ::date 2015-01-23T02:19:50 ::annotator SDL-AMR-09 ::preferred
# ::snt In addition, introduction of B-Raf enhances and sustains integrin-mediated activation of ERK in wild-type primary fibroblasts
# ::save-date Fri Feb 6, 2015 ::file bio_bel_0002_5.txt
(a4 / and
      :op2 (a / and
            :op1 (e / enhance-01
                  :ARG0 (i / introduce-02
                        :ARG1 (e2 / enzyme :name (n / name :op1 "B-Raf")))
                  :ARG1 (a2 / activate-01
                        :ARG1 (e3 / enzyme :name (n2 / name :op1 "ERK"))
                        :location (f / fibroblast
                              :mod (w / wild-type)
                              :mod (p / primary))
                        :ARG1-of (m / mediate-01
                              :ARG0 (i2 / integrin))))
            :op2 (s / sustain-01
                  :ARG0 i
                  :ARG1 a2)))

# ::id bio.bel_0002.6 ::date 2015-02-05T10:37:17 ::annotator SDL-AMR-09 ::preferred
# ::snt siRNA-mediated depletion of B-Raf reduced cell proliferation by up to 65% through the inhibition of ERK1/2 activation, irrespective of the mutational status of B-Raf.
# ::save-date Thu Feb 5, 2015 ::file bio_bel_0002_6.txt
(r / reduce-01
      :ARG0 (d / deplete-01
            :ARG1 (e / enzyme :name (n2 / name :op1 "B-Raf"))
            :ARG1-of (m / mediate-01
                  :ARG0 (r2 / rna-region :name (n / name :op1 "siRNA"))))
      :ARG1 (p2 / proliferate-01
            :ARG0 (c / cell))
      :ARG2 (u / up-to
            :op1 (p / percentage-entity :value 65))
      :manner (i / inhibit-01
            :ARG1 (a / activate-01
                  :ARG1 (e2 / enzyme :name (n3 / name :op1 "ERK1/2"))))
      :concession (s / status
            :poss e
            :mod (m2 / mutate-01)))

# ::id bio.bel_0002.7 ::date 2015-02-05T10:59:48 ::annotator SDL-AMR-09 ::preferred
# ::snt Following expression of BRAFV600E in melanocytes, the majority of cells became senescent (Figure 1D and data not shown), consistent with previous studies (Michaloglou et al., 2005)
# ::save-date Mon Feb 9, 2015 ::file bio_bel_0002_7.txt
(b / become-01
      :ARG1 (c / cell
            :quant (m / majority))
      :ARG2 (s / senescent
            :domain c)
      :ARG1-of (f / follow-01
            :ARG2 (e / express-03
                  :ARG2 (e2 / enzyme :name (n / name :op1 "B-Raf")
                        :ARG2-of (m2 / mutate-01 :value "V600E"))
                  :ARG3 (m3 / melanocyte)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a / and
                  :op1 (f2 / figure :mod "1D")
                  :op2 (d3 / data
                        :ARG1-of (s2 / show-01 :polarity -))))
      :ARG1-of (c3 / consistent-41
            :ARG2 (s3 / study
                  :time (p / previous)
                  :ARG1-of (d4 / describe-01
                        :ARG0 (p2 / publication-91
                              :ARG0 (a2 / and
                                    :op1 (p3 / person :name (n2 / name :op1 "Michaloglou"))
                                    :op2 (p4 / person
                                          :mod (o / other)))
                              :time (d / date-entity :year 2005))))))

# ::id bio.bel_0002.8 ::date 2015-01-23T02:59:24 ::annotator SDL-AMR-09 ::preferred
# ::snt disruption of the KSR1/CK2 interaction or inhibition of CK2 activity significantly reduces the growth-factor-induced phosphorylation of C-Raf and B-Raf on the activating serine site in the negative-charge regulatory region (N-region).
# ::save-date Fri Feb 6, 2015 ::file bio_bel_0002_8.txt
(r / reduce-01
      :ARG0 (o / or
            :op1 (d / disrupt-01
                  :ARG1 (i / interact-01
                        :ARG0 (e3 / enzyme :name (n4 / name :op1 "KSR1"))
                        :ARG1 (e4 / enzyme :name (n5 / name :op1 "CK2"))))
            :op2 (i2 / inhibit-01
                  :ARG1 (a3 / act-02
                        :ARG0 e4)))
      :ARG1 (p / phosphorylate-01
            :ARG1 (p2 / protein-segment
                  :ARG0-of (a2 / activate-01)
                  :mod (a4 / amino-acid :name (n7 / name :op1 "serine"))
                  :part-of (r2 / region
                        :ARG0-of (r3 / regulate-01)
                        :ARG1-of (c / charge-03
                              :mod (n3 / negative))
                        :part-of (a / and
                              :op1 (e / enzyme :name (n / name :op1 "C-Raf"))
                              :op2 (e2 / enzyme :name (n2 / name :op1 "B-Raf")))))
            :ARG1-of (i3 / induce-01
                  :ARG0 (s4 / small-molecule :name (n6 / name :op1 "growth" :op2 "factor"))))
      :degree (s3 / significant))

# ::id bio.bel_0002.9 ::date 2015-01-23T03:54:56 ::annotator SDL-AMR-09 ::preferred
# ::snt Sorafenib is a potent TKI of VEGFR-2, VEGFR-3, B-RAF, and PDGFR-B
# ::save-date Thu Feb 5, 2015 ::file bio_bel_0002_9.txt
(i / inhibit-01
      :ARG0 (s2 / small-molecule :name (n2 / name :op1 "Sorafenib"))
      :ARG1 (a / and
            :op1 (k / kinase :name (n / name :op1 "VEGFR-2"))
            :op2 (k2 / kinase :name (n3 / name :op1 "VEGFR-3"))
            :op3 (k3 / kinase :name (n4 / name :op1 "B-RAF"))
            :op4 (k4 / kinase :name (n5 / name :op1 "PDGFR-B")))
      :mod (p / potent))

# ::id bio.bel_0002.10 ::date 2015-01-23T03:55:41 ::annotator SDL-AMR-09 ::preferred
# ::snt In addition, we found that Rheb inhibits the association of B-Raf with H-Ras.
# ::save-date Fri Feb 6, 2015 ::file bio_bel_0002_10.txt
(a3 / and
      :op2 (f / find-01
            :ARG0 (w / we)
            :ARG1 (i / inhibit-01
                  :ARG0 (p / protein :name (n / name :op1 "Rheb"))
                  :ARG1 (a2 / associate-01
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "B-Raf"))
                        :ARG2 (e3 / enzyme :name (n3 / name :op1 "H-Ras"))))))

# ::id bio.bel_0002.11 ::date 2015-01-23T04:01:28 ::annotator SDL-AMR-09 ::preferred
# ::snt hKSR-2 selectively inhibited the Cot-mediated activation of MEK by  60%.
# ::save-date Mon Feb 9, 2015 ::file bio_bel_0002_11.txt
(i / inhibit-01
      :ARG0 (e / enzyme :name (n / name :op1 "hKSR-2"))
      :ARG1 (a / activate-01
            :ARG1 (e2 / enzyme :name (n2 / name :op1 "MEK"))
            :ARG1-of (m / mediate-01
                  :ARG0 (e3 / enzyme :name (n3 / name :op1 "Cot"))))
      :manner (s / selective)
      :quant (p / percentage-entity :value 60))

# ::id bio.bel_0002.12 ::date 2015-02-05T12:05:33 ::annotator SDL-AMR-09 ::preferred
# ::snt In contrast, hKSR-2 up-regulated the Rafmediated MEK activation by up to 70%.
# ::save-date Thu Feb 5, 2015 ::file bio_bel_0002_12.txt
(c / contrast-01
      :ARG2 (u / upregulate-01
            :ARG1 (a / activate-01
                  :ARG1 (e / enzyme :name (n / name :op1 "MEK"))
                  :ARG1-of (m / mediate-01
                        :ARG0 (e2 / enzyme :name (n2 / name :op1 "Raf"))))
            :ARG2 (e3 / enzyme :name (n3 / name :op1 "hKSR-2"))
            :quant (u2 / up-to
                  :op1 (p / percentage-entity :value 70))))

# ::id bio.bel_0002.13 ::date 2015-02-07T09:19:06 ::annotator SDL-AMR-09 ::preferred
# ::snt GSK PI3K Phase 2, part 1: List of non-position specific phosphorylation effects on parent protein's activity, derived from existing causal assertions of position-specific phosphorylations on the parent protein activity.
# ::save-date Mon Feb 9, 2015 ::file bio_bel_0002_13.txt
(a4 / and
      :op1 (e / enzyme :name (n / name :op1 "GSK"))
      :op2 (e2 / enzyme :name (n2 / name :op1 "PI3K"))
      :mod (p8 / phase :mod 2
            :part (p9 / part :mod 1
                  :topic (l / list-01
                        :ARG1 (a / affect-01
                              :ARG0 (p / phosphorylate-01
                                    :mod (p2 / position :polarity -
                                          :mod (s / specific)))
                              :ARG1 (a2 / act-02
                                    :ARG0 (p3 / protein
                                          :mod (p4 / parent))))
                        :ARG1-of (d / derive-01
                              :ARG2 (a3 / assert-03
                                    :ARG1 (p5 / phosphorylate-01
                                          :mod (p6 / position
                                                :mod s))
                                    :ARG3 a2
                                    :ARG0-of (c / cause-01)))))))

# ::id bio.bmtr_0001.1 ::date 2014-12-03T18:05:22 ::annotator ISI-AMR-01 ::preferred
# ::snt Sasaki et al., “Ubiquitination of Ras enhances activation and facilitates binding to select downstream effectors” (PMC3437993)
# ::save-date Wed Dec 10, 2014 ::file bio_bmtr_0001_1.txt
(p / publication-91
      :ARG0 (a / and
            :op1 (p2 / person :name (n / name :op1 "Sasaki"))
            :op2 (p3 / person
                  :mod (o / other)))
      :ARG1 (a2 / and
            :op1 (e / enhance-01
                  :ARG0 (u / ubiquitinate-01
                        :ARG1 (e3 / enzyme :name (n2 / name :op1 "Ras")))
                  :ARG1 (a3 / activate-01))
            :op2 (f / facilitate-01
                  :ARG0 u
                  :ARG1 (b / bind-01
                        :ARG2 (e2 / effector
                              :location (d / downstream)
                              :mod (s2 / select)))))
      :ARG8 "PMC3437993")

# ::id bio.bmtr_0001.2 ::date 2014-12-03T21:45:59 ::annotator ISI-AMR-01 ::preferred
# ::snt We utilized an unbiased mass spectrometry-based approach to identify ubiquitination sites of Ras.
# ::save-date Wed Dec 10, 2014 ::file bio_bmtr_0001_2.txt
(u / utilize-01
      :ARG0 (w / we)
      :ARG1 (a / approach-02
            :ARG1-of (b / base-02
                  :ARG2 (s / spectrometry
                        :mod (m / mass)))
            :ARG1-of (b2 / bias-01 :polarity -))
      :purpose (i / identify-01
            :ARG0 w
            :ARG1 (p / protein-segment
                  :part-of (e / enzyme :name (n / name :op1 "Ras"))
                  :ARG1-of (u2 / ubiquitinate-01))))

# ::id bio.bmtr_0001.3 ::date 2014-12-03T21:53:14 ::annotator ISI-AMR-01 ::preferred
# ::snt His-tagged ubiquitin and Flag-tagged K-Ras4B (K-Ras hereafter) were expressed in HEK293T cells at levels similar to endogenous K-Ras (Fig. 1B) and subjected to sequential affinity chromatography.
# ::save-date Wed Dec 10, 2014 ::file bio_bmtr_0001_3.txt
(a3 / and
      :op1 (e / express-03
            :ARG2 (a / and
                  :op1 (p / protein :name (n2 / name :op1 "ubiquitin")
                        :ARG1-of (t / tag-01
                              :ARG2 (p3 / protein-segment
                                    :part (a2 / amino-acid :name (n5 / name :op1 "histidine")))))
                  :op2 (e5 / enzyme :name (n3 / name :op1 "K-Ras4B") :name (n4 / name :op1 "K-Ras")
                        :ARG1-of (t2 / tag-01
                              :ARG2 (p4 / protein-segment :name (n6 / name :op1 "Flag")))))
            :ARG3 (c / cell-line :name (n / name :op1 "HEK293T"))
            :degree (l / level
                  :ARG1-of (r / resemble-01
                        :ARG2 (l2 / level
                              :degree-of (e3 / express-03
                                    :ARG2 (e4 / enzyme :name (n7 / name :op1 "K-Ras")
                                          :mod (e2 / endogenous))
                                    :ARG3 c))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "1B")))
      :op2 (s2 / subject-01
            :ARG1 a
            :ARG2 (c2 / chromatography
                  :mod (a4 / affinity)
                  :mod (s3 / sequence))))

# ::id bio.bmtr_0001.4 ::date 2014-12-09T14:55:44 ::annotator ISI-AMR-01 ::preferred
# ::snt His-ubiquitinated proteins were purified by Co2+ metal affinity chromatography in 8M urea denaturing conditions.
# ::save-date Wed Dec 10, 2014 ::file bio_bmtr_0001_4.txt
(p / purify-01
  :ARG1 (p2 / protein
          :ARG3-of (u / ubiquitinate-01
                     :mod (a / amino-acid :name (n / name :op1 "histidine"))))
  :manner (c / chromatography
            :mod (a2 / affinity
                   :topic (m / metal :name (n2 / name :op1 "Co2+")))
            :mod (d / denature-00
                   :ARG1 p2
                   :instrument (s / small-molecule :name (n3 / name :op1 "urea")
                                 :mod (c2 / concentration-quantity :quant 8
                                        :unit (m2 / molar))))))

# ::id bio.bmtr_0001.5 ::date 2014-12-09T22:13:53 ::annotator ISI-AMR-01 ::preferred
# ::snt His-ubiquitinated K-Ras was subsequently purified with anti-Flag resin.
# ::save-date Tue Dec 9, 2014 ::file bio_bmtr_0001_5.txt
(p / purify-01
      :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
            :ARG3-of (u / ubiquitinate-01
                  :mod (a / amino-acid :name (n2 / name :op1 "histidine"))))
      :time (s / subsequent)
      :instrument (r / resin
            :ARG0-of (c / counter-01
                  :ARG1 (p2 / protein-segment :name (n3 / name :op1 "Flag")))))

# ::id bio.bmtr_0001.6 ::date 2014-12-09T22:40:15 ::annotator ISI-AMR-01 ::preferred
# ::snt Following purification, mono- and di- ubiquitinated K-Ras appeared to be the major ubiquitination forms, which is consistent with the endogenous K-Ras ubiquitination pattern (Fig. 1, A and B).
# ::save-date Wed Dec 10, 2014 ::file bio_bmtr_0001_6.txt
(a / appear-02
      :ARG1 (h / have-quant-91
            :ARG1 (u / ubiquitinate-01
                  :ARG3 (e / enzyme :name (n / name :op1 "K-Ras")))
            :ARG2 (o / or :op1 1 :op2 2)
            :degree (m / most)
            :ARG1-of (f / follow-01
                  :ARG2 (p / purify-01
                        :ARG1 e))
            :ARG1-of (c / consistent-41
                  :ARG2 (p2 / pattern
                        :topic (u2 / ubiquitinate-01
                              :ARG1 (e2 / enzyme :name (n2 / name :op1 "K-Ras")
                                    :mod (e3 / endogenous))))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (f2 / figure :mod "1A")
                  :op2 (f3 / figure :mod "1B"))))

# ::id bio.bmtr_0001.7 ::date 2014-12-09T22:54:17 ::annotator ISI-AMR-01 ::preferred
# ::snt H-Ras ubiquitination sites were also determined by the same approach.
# ::save-date Tue Dec 9, 2014 ::file bio_bmtr_0001_7.txt
(d / determine-01
      :ARG1 (p / protein-segment
            :ARG1-of (u / ubiquitinate-01)
            :part-of (e / enzyme :name (n / name :op1 "H-Ras")))
      :manner (a / approach-02
            :mod (s / same))
      :mod (a2 / also))

# ::id bio.bmtr_0001.8 ::date 2014-12-05T20:16:13 ::annotator ISI-AMR-01 ::preferred
# ::snt Tandem mass spectrometric analysis of tryptic fragments from the bands migrating at the positions expected for mono- and di-ubiquitinated Ras revealed ubiquitination at Lys residues 104 and 147 of K-Ras, and Lys residues 117, 147 and 170 for H-Ras (fig. S1C).
# ::save-date Mon Dec 15, 2014 ::file bio_bmtr_0001_8.txt
(r / reveal-01
      :ARG0 (a / analyze-01
            :ARG1 (p3 / protein-segment
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e2 / enzyme :name (n2 / name :op1 "trypsin")))
                  :source (b / band
                        :ARG0-of (m / migrate-01
                              :ARG1 (p / position
                                    :ARG2-of (b2 / be-located-at-91
                                          :ARG1 (e5 / enzyme :name (n / name :op1 "Ras")
                                                :ARG3-of (u / ubiquitinate-01
                                                      :quant (o / or :op1 1 :op2 2)))
                                          :ARG1-of (e / expect-01))))))
            :manner (s / spectrometry
                  :mod (m2 / mass)
                  :mod (t / tandem)))
      :ARG1 (u2 / ubiquitinate-01
            :ARG1 (a2 / and
                  :op1 (a8 / and
                        :op1 (r2 / residue
                              :mod (a3 / amino-acid :mod 104 :name (n3 / name :op1 "lysine")))
                        :op2 (r3 / residue
                              :mod (a4 / amino-acid :mod 147 :name (n4 / name :op1 "lysine")))
                        :part-of (e4 / enzyme :name (n5 / name :op1 "K-Ras")))
                  :op2 (a9 / and
                        :op1 (r4 / residue
                              :mod (a5 / amino-acid :mod 117 :name (n6 / name :op1 "lysine")))
                        :op2 (r5 / residue
                              :mod (a6 / amino-acid :mod 147 :name (n7 / name :op1 "lysine")))
                        :op3 (r6 / residue
                              :mod (a7 / amino-acid :mod 170 :name (n8 / name :op1 "lysine")))
                        :part-of (e3 / enzyme :name (n9 / name :op1 "H-Ras")))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "S1C")))

# ::id bio.bmtr_0001.9 ::date 2014-12-09T22:57:04 ::annotator ISI-AMR-01 ::preferred
# ::snt The tryptic peptide with ubiquitination at Lys147 (K147) was the most frequently observed peptide for both K-Ras and H-Ras, while Lys117 appeared as a secondary major ubiquitination site in H-Ras.
# ::save-date Tue Dec 9, 2014 ::file bio_bmtr_0001_9.txt
(c / contrast-01
      :ARG1 (p / peptide
            :ARG1-of (o / observe-01
                  :frequency (f / frequent
                        :degree (m / most)))
            :part-of (e2 / enzyme
                  :mod (o2 / or
                        :op1 (e3 / enzyme :name (n3 / name :op1 "K-Ras"))
                        :op2 (e4 / enzyme :name (n4 / name :op1 "H-Ras"))))
            :domain (p2 / peptide
                  :part (a / amino-acid :mod 147 :name (n / name :op1 "lysine")
                        :ARG3-of (u / ubiquitinate-01))
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e / enzyme :name (n2 / name :op1 "trypsin")))
                  :part-of e2))
      :ARG2 (a3 / appear-01
            :ARG1 (p3 / protein-segment
                  :part-of (e5 / enzyme :name (n5 / name :op1 "H-Ras"))
                  :ARG1-of (u2 / ubiquitinate-01)
                  :mod (m2 / major)
                  :mod (s / secondary)
                  :domain (a2 / amino-acid :mod 117 :name (n6 / name :op1 "lysine")))))

# ::id bio.bmtr_0001.10 ::date 2014-12-18T10:39:24 ::annotator ISI-AMR-01 ::preferred
# ::snt To examine the effect of ubiquitination on GTP loading, we purified wild-type K-Ras, oncogenic G12V-K-Ras mutant or the ubiquitinated subfraction of wild-type K-Ras from 32P-orthophosphate labeled cells and utilized thin layer chromatography (TLC) and high performance liquid chromatography (HPLC) to assess the ratio of 32P-GTP to 32P-GDP that co-purified with each form of K-Ras.
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_10.txt
(a2 / and
      :op1 (p / purify-01
            :ARG0 (w / we)
            :ARG1 (a / and
                  :op1 (o / or
                        :op1 (e / enzyme :name (n2 / name :op1 "K-Ras")
                              :mod (w2 / wild-type))
                        :op2 (e2 / enzyme :name (n3 / name :op1 "K-Ras")
                              :ARG0-of (c / cause-01
                                    :ARG1 (c2 / cancer))
                              :ARG2-of (m / mutate-01 :value "G12V"))
                        :op3 (e3 / enzyme :name (n4 / name :op1 "K-Ras")
                              :mod (w3 / wild-type)
                              :ARG3-of (u / ubiquitinate-01)
                              :mod (s2 / subfraction)))
                  :op2 s4
                  :op3 s5)
            :source (c3 / cell
                  :ARG1-of (l / label-01
                        :ARG2 (s3 / small-molecule :name (n5 / name :op1 "orthophosphate")
                              :part (p2 / phosphorus
                                    :mod (m2 / molecular-mass :value 32))))))
      :op2 (u2 / utilize-01
            :ARG0 w
            :ARG1 (a5 / and
                  :op1 (c4 / chromatography
                        :mod (l3 / layer
                              :mod (t / thin)))
                  :op2 (c5 / chromatography
                        :mod (l4 / liquid
                              :ARG0-of (p3 / perform-01
                                    :degree (h / high)))))
            :purpose (a3 / assess-01
                  :ARG0 w
                  :ARG1 (r / ratio-of
                        :op1 (s4 / small-molecule :name (n6 / name :op1 "GTP")
                              :part (p4 / phosphorus
                                    :mod (m3 / molecular-mass :value 32)))
                        :op2 (s5 / small-molecule :name (n7 / name :op1 "GDP")
                              :part (p5 / phosphorus
                                    :mod (m4 / molecular-mass :value 32))))))
      :purpose (e4 / examine-01
            :ARG0 w
            :ARG1 (a4 / affect-01
                  :ARG0 (u3 / ubiquitinate-01)
                  :ARG1 (l2 / load-01
                        :ARG2 (s / small-molecule :name (n / name :op1 "GTP"))))))

# ::id bio.bmtr_0001.11 ::date 2014-12-18T12:35:31 ::annotator ISI-AMR-01 ::preferred
# ::snt As expected based on previous studies, wild-type K-Ras bound primarily 32P-GDP, while G12V-Ras bound 32P-GTP (Fig.2, A and B).
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_11.txt
(c / contrast-01
      :ARG1 (b / bind-01
            :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                  :mod (w / wild-type))
            :ARG2 (s / small-molecule :name (n2 / name :op1 "GDP")
                  :part (p / phosphorus
                        :mod (m / molecular-mass :value 32)))
            :mod (p2 / primary))
      :ARG2 (b2 / bind-01
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "Ras")
                  :ARG2-of (m2 / mutate-01 :value "G12V"))
            :ARG2 (s2 / small-molecule :name (n4 / name :op1 "GTP")
                  :part (p3 / phosphorus
                        :mod (m3 / molecular-mass :value 32))))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f / figure :mod "2A")
                  :op2 (f2 / figure :mod "2B")))
      :ARG1-of (e3 / expect-01
            :ARG1-of (b3 / base-02
                  :ARG2 (s4 / study
                        :time (p4 / previous)))))

# ::id bio.bmtr_0001.12 ::date 2014-12-18T17:04:39 ::annotator ISI-AMR-01 ::preferred
# ::snt Interestingly, the ubiquitinated subfraction of wild-type K-Ras retained a significant amount of 32P-GTP.
# ::save-date Thu Dec 18, 2014 ::file bio_bmtr_0001_12.txt
(r / retain-01
      :ARG0 (e / enzyme :name (n / name :op1 "K-Ras")
            :mod (w / wild-type)
            :ARG3-of (u / ubiquitinate-01)
            :mod (s2 / subfraction))
      :ARG1 (s / small-molecule :name (n2 / name :op1 "GTP")
            :part (p / phosphorus
                  :mod (m / molecular-mass :value 32))
            :quant (s3 / significant))
      :ARG2-of (i / interest-01))

# ::id bio.bmtr_0001.13 ::date 2014-12-18T17:10:57 ::annotator ISI-AMR-01 ::preferred
# ::snt These results are consistent with a model in which ubiquitination of Lys147 (or Lys117), destabilizes GDP binding, allowing spontaneous GDP/GTP exchange.
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_13.txt
(c / consistent-41
      :ARG1 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / this))
      :ARG2 (m / model
            :topic (d / destabilize-01
                  :ARG0 (u / ubiquitinate-01
                        :ARG1 (o / or
                              :op1 (a / amino-acid :mod 147 :name (n2 / name :op1 "lysine"))
                              :op2 (a3 / amino-acid :mod 117 :name (n5 / name :op1 "lysine"))))
                  :ARG1 (b / bind-01
                        :ARG2 (s / small-molecule :name (n / name :op1 "GDP")))
                  :ARG0-of (a2 / allow-01
                        :ARG1 (e / exchange-01
                              :ARG1 (s3 / small-molecule :name (n3 / name :op1 "GDP"))
                              :ARG3 (s4 / small-molecule :name (n4 / name :op1 "GTP"))
                              :mod (s2 / spontaneous))))))

# ::id bio.bmtr_0001.14 ::date 2014-12-22T16:19:51 ::annotator ISI-AMR-01 ::preferred
# ::snt It could be argued that GTP loading occurs prior to ubiquitination and that the GTP bound form of K-Ras, via interaction with effectors, is preferentially mono-ubiquitinated via a feedback mechanism.
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_14.txt
(p / possible
      :domain (a / argue-01
            :ARG1 (a2 / and
                  :op1 (l / load-01
                        :ARG2 (s / small-molecule :name (n / name :op1 "GTP"))
                        :time (p2 / prior
                              :op1 (u / ubiquitinate-01)))
                  :op2 (u2 / ubiquitinate-01 :quant 1
                        :ARG1 (e / enzyme :name (n2 / name :op1 "K-Ras")
                              :ARG1-of (b / bind-01
                                    :ARG2 (s2 / small-molecule :name (n3 / name :op1 "GTP"))))
                        :ARG1-of (p3 / prefer-01)
                        :manner (i / interact-01
                              :ARG0 e
                              :ARG1 (e2 / effector))
                        :manner (f / feedback)))))

# ::id bio.bmtr_0001.15 ::date 2014-12-22T16:27:59 ::annotator ISI-AMR-01 ::preferred
# ::snt While it is difficult to eliminate this possibility, it is unlikely since, as shown in fig. S1B, the T35 mutant of K-Ras, which fails to interact with downstream effectors (fig. S1B) undergoes comparable monobuiquitination to wild type Ras.
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_15.txt
(c / contrast-01
      :ARG1 (d / difficult
            :domain (e3 / eliminate-01
                  :ARG1 (t / this
                        :mod (p / possible))))
      :ARG2 (l / likely :polarity -
            :domain t
            :ARG1-of (c2 / cause-01
                  :ARG0 (u / ubiquitinate-01 :quant 1
                        :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                              :ARG2-of (m / mutate-01 :value "T35")
                              :ARG0-of (i / interact-01 :polarity -
                                    :ARG1 (e4 / effector
                                          :location (d2 / downstream))
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 f)))
                        :ARG1-of (s / show-01
                              :ARG0 (f / figure :mod "S1B"))
                        :mod (c3 / comparable
                              :topic (u2 / ubiquitinate-01
                                    :ARG1 (e2 / enzyme :name (n2 / name :op1 "Ras")
                                          :mod (w / wild-type))))))))

# ::id bio.bmtr_0001.16 ::date 2014-12-22T16:52:11 ::annotator ISI-AMR-01 ::preferred
# ::snt These results, along with the crystal structure, support a model in which mono-ubiquitination at a Lys residue directly involved in GDP binding either enhances nucleotide exchange on K-Ras, impairs GTP hydrolysis, or both.
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_16.txt
(s3 / support-01
      :ARG0 (a / and
            :op1 (t / thing
                  :mod (t2 / this)
                  :ARG2-of (r / result-01))
            :op2 (s4 / structure
                  :poss (c / crystal)))
      :ARG1 (m / model
            :topic (o / or
                  :op1 (e2 / enhance-01
                        :ARG0 (u / ubiquitinate-01 :quant 1
                              :ARG1 (r2 / residue
                                    :mod (a2 / amino-acid :name (n4 / name :op1 "lysine"))
                                    :ARG1-of (i / involve-01
                                          :ARG2 (b / bind-01
                                                :ARG2 (s / small-molecule :name (n / name :op1 "GDP")))
                                          :manner (d / direct))))
                        :ARG1 (e3 / exchange-01
                              :ARG1 (n5 / nucleotide)
                              :ARG4 (e / enzyme :name (n2 / name :op1 "K-Ras"))))
                  :op2 (i2 / impair-01
                        :ARG0 u
                        :ARG1 (h / hydrolyze-01
                              :ARG1 (s2 / small-molecule :name (n3 / name :op1 "GTP"))))
                  :op3 (a3 / and
                        :op1 e2
                        :op2 i2))))

# ::id bio.bmtr_0001.17 ::date 2014-12-22T15:12:07 ::annotator ISI-AMR-01 ::preferred
# ::snt To corroborate this finding, we measure the activity of Ras by the GST-RBD pull-down assay.
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_17.txt
(m / measure-01
      :ARG0 (w / we)
      :ARG1 (a / act-02
            :ARG0 (e / enzyme :name (n / name :op1 "Ras")))
      :ARG2 (a2 / assay-00
            :manner (p / pull-00
                  :ARG2 (p2 / protein :name (n2 / name :op1 "GST-RBD"))))
      :purpose (c / corroborate-01
            :ARG0 m
            :ARG1 (t / thing
                  :ARG1-of (f / find-01)
                  :mod (t2 / this))))

# ::id bio.bmtr_0001.18 ::date 2014-12-22T15:16:55 ::annotator ISI-AMR-01 ::preferred
# ::snt To ensure that ubiquitinated Ras was being detected, the protein pulled down by GST-RBD was subjected to a second affinity purification on a cobalt column to purify the Flag-His-tagged K-Ras.
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_18.txt
(s / subject-01
      :ARG1 (p / protein
            :ARG1-of (p2 / pull-00
                  :ARG2 (p3 / protein :name (n3 / name :op1 "GST-RBD"))))
      :ARG2 (p4 / purify-01
            :ARG1 p
            :ord (o / ordinal-entity :value 2)
            :purpose (p5 / purify-01
                  :ARG0 p4
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "K-Ras")
                        :ARG1-of (t / tag-01
                              :ARG2 (a2 / and
                                    :op1 (p6 / protein-segment :name (n4 / name :op1 "Flag"))
                                    :op2 (p7 / protein-segment
                                          :part (a3 / amino-acid :name (n5 / name :op1 "histidine")))))))
            :mod (a / affinity)
            :location (c / column
                  :consist-of (c2 / cobalt)))
      :purpose (e3 / ensure-01
            :ARG0 s
            :ARG1 (d / detect-01
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                        :ARG3-of (u / ubiquitinate-01)))))

# ::id bio.bmtr_0001.19 ::date 2014-12-22T15:30:38 ::annotator ISI-AMR-01 ::preferred
# ::snt As predicted, only a very small fraction of wild-type K-Ras was pulled down by the GST-RBD (Fig. 2C and fig. S1D), consistent with very little wild-type K-Ras being in the GTP state under these conditions (Fig.2, A and B).
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_19.txt
(p / pull-00
      :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
            :mod (w / wild-type)
            :quant (f / fraction
                  :mod (s2 / small
                        :degree (v / very))
                  :mod (o / only)))
      :ARG2 (p2 / protein :name (n3 / name :op1 "GST-RBD"))
      :ARG1-of (p3 / predict-01)
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f2 / figure :mod "2C")
                  :op2 (f3 / figure :mod "S1D")))
      :ARG1-of (c / consistent-41
            :ARG2 (b / bind-01
                  :ARG1 (e2 / enzyme :name (n4 / name :op1 "K-Ras")
                        :mod (w2 / wild-type)
                        :quant (l / little
                              :degree (v2 / very)))
                  :ARG2 (s / small-molecule :name (n2 / name :op1 "GTP"))
                  :condition (t / this)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a2 / and
                              :op1 (f4 / figure :mod "2A")
                              :op2 (f5 / figure :mod "2B"))))))

# ::id bio.bmtr_0001.20 ::date 2014-12-22T15:36:10 ::annotator ISI-AMR-01 ::preferred
# ::snt However, a much greater fraction of the ubiquitinated-K-Ras was pulled down by the GST-RBD (Fig. 2C and fig. S1D).
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_20.txt
(c / contrast-01
      :ARG2 (p / pull-00
            :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                  :ARG3-of (u / ubiquitinate-01)
                  :quant (f / fraction
                        :mod (g / great
                              :degree (m / more)
                              :quant (m2 / much))))
            :ARG2 (p2 / protein :name (n2 / name :op1 "GST-RBD"))
            :ARG1-of (d / describe-01
                  :ARG0 (a / and
                        :op1 (f2 / figure :mod "2C")
                        :op2 (f3 / figure :mod "S1D")))))

# ::id bio.bmtr_0001.21 ::date 2014-12-22T14:32:40 ::annotator ISI-AMR-01 ::preferred
# ::snt These results are consistent with a greater fraction of ubiquitinated K-Ras being in the GTP state (Fig. 2, A and B).
# ::save-date Mon Dec 22, 2014 ::file bio_bmtr_0001_21.txt
(c / consistent-41
      :ARG1 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / this))
      :ARG2 (b / bind-01
            :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                  :ARG3-of (u / ubiquitinate-01)
                  :degree (f3 / fraction
                        :mod (g / great
                              :degree (m / more))))
            :ARG2 (s / small-molecule :name (n2 / name :op1 "GTP")))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f / figure :mod "2A")
                  :op2 (f2 / figure :mod "2B"))))

# ::id bio.bmtr_0002.1 ::date 2014-12-10T12:17:16 ::annotator ISI-AMR-01 ::preferred
# ::snt Turke et al. “MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors” (PMC3515079)
# ::save-date Wed Dec 10, 2014 ::file bio_bmtr_0002_1.txt
(p / publication-91
      :ARG0 (a / and
            :op1 (p2 / person :name (n / name :op1 "Turke"))
            :op2 (p3 / person
                  :mod (o / other)))
      :ARG1 (l / lead-03
            :ARG0 (i / inhibit-01
                  :ARG1 (e / enzyme :name (n2 / name :op1 "MEK")))
            :ARG2 (a2 / activate-01
                  :ARG1 (p4 / pathway :name (n3 / name :op1 "PI3K/AKT")))
            :manner (r / relieve-01
                  :ARG0 i
                  :ARG1 (f / feedback
                        :mod (n4 / negative)
                        :destination (r2 / receptor :name (n5 / name :op1 "ERBB")))))
      :ARG8 "PMC3515079")

# ::id bio.bmtr_0002.2 ::date 2014-12-14T20:21:31 ::annotator ISI-AMR-01 ::preferred
# ::snt We hypothesized that the MEK/ERK pathway may suppress trans-phosphorylation of ERBB3 by directly phosphorylating the JM domains of EGFR and HER2, and that this could be a dominant MEK inhibitor-induced feedback leading to AKT activation in these cancers.
# ::save-date Mon Dec 15, 2014 ::file bio_bmtr_0002_2.txt
(h / hypothesize-01
      :ARG0 (w / we)
      :ARG1 (a / and
            :op1 (p / possible
                  :domain (s / suppress-01
                        :ARG0 (p2 / pathway :name (n / name :op1 "MEK/ERK"))
                        :ARG1 (p3 / phosphorylate-01
                              :ARG1 (e / enzyme :name (n2 / name :op1 "ERBB3")))
                        :manner (p4 / phosphorylate-01
                              :ARG0 p2
                              :ARG1 (a2 / and
                                    :op1 (p5 / protein-segment :name (n3 / name :op1 "JM" :op2 "domain")
                                          :part-of (e2 / enzyme :name (n4 / name :op1 "EGFR")))
                                    :op2 (p6 / protein-segment :name (n5 / name :op1 "JM" :op2 "domain")
                                          :part-of (e3 / enzyme :name (n6 / name :op1 "HER2"))))
                              :manner (d / direct))))
            :op2 (p7 / possible
                  :domain (f / feedback
                        :ARG1-of (i / induce-01
                              :ARG0 (m / molecular-physical-entity
                                    :ARG0-of (i2 / inhibit-01
                                          :ARG1 (e4 / enzyme :name (n7 / name :op1 "MEK")))))
                        :ARG0-of (d2 / dominate-01)
                        :ARG0-of (l / lead-03
                              :ARG2 (a3 / activate-01
                                    :ARG1 (e5 / enzyme :name (n8 / name :op1 "AKT"))
                                    :location (c / cancer
                                          :mod (t / this))))
                        :domain s))))

# ::id bio.bmtr_0002.3 ::date 2014-12-14T20:37:51 ::annotator ISI-AMR-01 ::preferred
# ::snt We used tandem mass spectrometry to measure the effects of AZD6244 on phosphorylation of this JM domain threonine residue in both EGFR-mutant and HER2- amplified cancer models.
# ::save-date Mon Dec 15, 2014 ::file bio_bmtr_0002_3.txt
(u / use-01
      :ARG0 (w / we)
      :ARG1 (s / spectrometry
            :mod (m / mass)
            :mod (t / tandem))
      :ARG2 (m2 / measure-01
            :ARG0 w
            :ARG1 (a / affect-01
                  :ARG0 (s2 / small-molecule :name (n / name :op1 "AZD6244"))
                  :ARG1 (p / phosphorylate-01
                        :ARG1 (r / residue
                              :mod (a2 / amino-acid :name (n2 / name :op1 "threonine"))
                              :part-of (p2 / protein-segment :name (n3 / name :op1 "JM" :op2 "domain"))
                              :mod (t2 / this)))
                  :condition (a4 / and
                        :op1 (m3 / model
                              :topic (c / cancer
                                    :mod (m4 / mutate-01
                                          :ARG1 (e / enzyme :name (n4 / name :op1 "EGFR")))))
                        :op2 (m5 / model
                              :topic (c3 / cancer
                                    :mod (a3 / amplify-01
                                          :ARG1 (e2 / enzyme :name (n5 / name :op1 "HER2")))))))))

# ::id bio.bmtr_0002.4 ::date 2014-12-14T20:53:57 ::annotator ISI-AMR-01 ::preferred
# ::snt Targeting both the phosphorylated and non-phosphorylated peptide forms, we detected a 66% average decrease in EGFR T669 phosphorylation and a 75% decrease in HER2 T677 phosphorylation upon treatment with AZD6244 (Figure 5B, Supplemental Figure 8).
# ::save-date Mon Dec 15, 2014 ::file bio_bmtr_0002_4.txt
(d / detect-01
      :ARG0 (w / we)
      :ARG1 (a / and
            :op1 (d2 / decrease-01
                  :ARG1 (p / phosphorylate-01
                        :ARG1 (a3 / amino-acid :mod 669 :name (n / name :op1 "threonine")
                              :part-of (e / enzyme :name (n2 / name :op1 "EGFR"))))
                  :ARG2 (p2 / percentage-entity :value 66
                        :ARG2-of (a2 / average-01)))
            :op2 (d3 / decrease-01
                  :ARG1 (p3 / phosphorylate-01
                        :ARG1 (a4 / amino-acid :mod 677 :name (n3 / name :op1 "threonine")
                              :part-of (e2 / enzyme :name (n4 / name :op1 "HER2"))))
                  :ARG2 (p4 / percentage-entity :value 75)))
      :ARG2 (t2 / target-01
            :ARG0 w
            :ARG1 (a6 / and
                  :op1 (p5 / protein-segment
                        :ARG3-of (p7 / phosphorylate-01))
                  :op2 (p6 / protein-segment
                        :ARG3-of (p8 / phosphorylate-01 :polarity -))))
      :condition (t / treat-04
            :ARG2 (s / small-molecule :name (n5 / name :op1 "AZD6244")))
      :ARG1-of (d4 / describe-01
            :ARG0 (a5 / and
                  :op1 (f / figure :mod "5B")
                  :op2 (f2 / figure :mod 8
                        :ARG2-of (s2 / supplement-01)))))

# ::id bio.bmtr_0002.5 ::date 2014-12-14T21:08:29 ::annotator ISI-AMR-01 ::preferred
# ::snt Phospho-specific antibodies confirmed that treatment with AZD6244 inhibited phosphorylation of T669 of EGFR and the analogous T677 of HER2 (Figure 5A).
# ::save-date Sun Dec 14, 2014 ::file bio_bmtr_0002_5.txt
(c / confirm-01
      :ARG0 (a / antibody
            :mod (s / specific
                  :topic (p / phosphorylate-01)))
      :ARG1 (i / inhibit-01
            :ARG0 (t / treat-04
                  :ARG2 (s2 / small-molecule :name (n / name :op1 "AZD6244")))
            :ARG1 (a3 / and
                  :op1 (p2 / phosphorylate-01
                        :ARG1 (a2 / amino-acid :mod 669 :name (n2 / name :op1 "threonine")
                              :part-of (e / enzyme :name (n3 / name :op1 "EGFR"))))
                  :op2 (p3 / phosphorylate-01
                        :ARG1 (a4 / amino-acid :mod 677 :name (n4 / name :op1 "threonine")
                              :mod (a5 / analogous
                                    :topic a2)
                              :part-of (e2 / enzyme :name (n5 / name :op1 "HER2"))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5A")))

# ::id bio.bmtr_0002.6 ::date 2014-12-14T21:17:43 ::annotator ISI-AMR-01 ::preferred
# ::snt Together these data indicate that loss of this inhibitory threonine phosphorylation on the JM domains of EGFR and HER2 occurs in cancer cell lines following MEK inhibition, presumably due to differential subcellular localization and/or binding proteins.
# ::save-date Mon Dec 15, 2014 ::file bio_bmtr_0002_6.txt
(i / indicate-01
      :ARG0 (d / data
            :mod (t / this)
            :mod (t2 / together))
      :ARG1 (l / lose-01
            :ARG1 (p / phosphorylate-01
                  :ARG1 (a / amino-acid :name (n / name :op1 "threonine")
                        :part-of (p2 / protein-segment :name (n2 / name :op1 "JM" :op2 "domain")
                              :part-of (o / or
                                    :op1 (e / enzyme :name (n3 / name :op1 "EGFR"))
                                    :op2 (e2 / enzyme :name (n4 / name :op1 "HER2")))))
                  :ARG0-of (i2 / inhibit-01)
                  :mod (t3 / this))
            :location (c / cell-line
                  :mod (c2 / cancer))
            :ARG1-of (f / follow-01
                  :ARG2 (i3 / inhibit-01
                        :ARG1 (e3 / enzyme :name (n5 / name :op1 "MEK"))))
            :ARG1-of (c3 / cause-01
                  :ARG0 (a2 / and-or
                        :op1 (l2 / location
                              :location (c4 / cell)
                              :ARG1-of (d2 / differ-02))
                        :op2 (p4 / protein
                              :ARG1-of (b / bind-01)
                              :ARG1-of (d3 / differ-02)))
                  :ARG1-of (p3 / presume-01))))

# ::id bio.bmtr_0002.7 ::date 2014-12-15T14:06:48 ::annotator ISI-AMR-01 ::preferred
# ::snt Mutation of T669 and T677 abrogates MEK inhibitor-induced suppression of ERBB3 Activation
# ::save-date Mon Dec 15, 2014 ::file bio_bmtr_0002_7.txt
(a / abrogate-01
      :ARG0 (m / mutate-01
            :ARG1 (a2 / and
                  :op1 (a3 / amino-acid :mod 669 :name (n / name :op1 "threonine"))
                  :op2 (a4 / amino-acid :mod 677 :name (n2 / name :op1 "threonine"))))
      :ARG1 (s / suppress-01
            :ARG1 (a5 / activate-01
                  :ARG1 (e / enzyme :name (n3 / name :op1 "ERBB3")))
            :ARG1-of (i / induce-01
                  :ARG0 (m2 / molecular-physical-entity
                        :ARG0-of (i2 / inhibit-01
                              :ARG1 (e2 / enzyme :name (n4 / name :op1 "MEK")))))))

# ::id bio.bmtr_0002.8 ::date 2014-12-15T14:16:53 ::annotator ISI-AMR-01 ::preferred
# ::snt We hypothesized that MEK inhibition activates AKT by inhibiting ERK activity, which blocks an inhibitory threonine phosphorylation on the JM domains of EGFR and HER2, thereby increasing ERBB3 phosphorylation.
# ::save-date Mon Dec 15, 2014 ::file bio_bmtr_0002_8.txt
(h / hypothesize-01
      :ARG0 (w / we)
      :ARG1 (a / activate-01
            :ARG0 (i / inhibit-01
                  :ARG1 (e / enzyme :name (n / name :op1 "MEK")))
            :ARG1 (e2 / enzyme :name (n2 / name :op1 "AKT"))
            :manner (i2 / inhibit-01
                  :ARG0 i
                  :ARG1 (a2 / act-02
                        :ARG0 (e3 / enzyme :name (n3 / name :op1 "ERK")))
                  :ARG0-of (b / block-01
                        :ARG1 (p / phosphorylate-01
                              :ARG1 (a3 / amino-acid :name (n4 / name :op1 "threonine")
                                    :part-of (p2 / protein-segment :name (n5 / name :op1 "JM" :op2 "domain")
                                          :part-of (o / or
                                                :op1 (e4 / enzyme :name (n6 / name :op1 "EGFR"))
                                                :op2 (e5 / enzyme :name (n7 / name :op1 "HER2")))))
                              :ARG0-of (i3 / inhibit-01))
                        :ARG0-of (i4 / increase-01
                              :ARG1 (p3 / phosphorylate-01
                                    :ARG1 (e6 / enzyme :name (n8 / name :op1 "ERBB3"))))))))

# ::id bio.bmtr_0002.9 ::date 2014-12-15T14:52:21 ::annotator ISI-AMR-01 ::preferred
# ::snt To test this hypothesis, we transiently transfected CHO-KI cells, which do not express ERBB receptors endogenously, with wild-type ERBB3 with either wild-type EGFR or EGFR T669A.
# ::save-date Wed Dec 17, 2014 ::file bio_bmtr_0002_9.txt
(t / transfect-00
      :ARG0 (w / we)
      :ARG1 (c / cell
            :source (c2 / cell-line :name (n / name :op1 "CHO-KI"))
            :ARG3-of (e3 / express-03 :polarity -
                  :ARG2 (r / receptor :name (n4 / name :op1 "ERBB"))
                  :mod (e4 / endogenous)))
      :ARG2 (a / and
            :op1 (e5 / enzyme :name (n5 / name :op1 "ERBB3")
                  :mod (w3 / wild-type))
            :op2 (o / or
                  :op1 (e / enzyme :name (n2 / name :op1 "EGFR")
                        :mod (w2 / wild-type))
                  :op2 (e2 / enzyme :name (n3 / name :op1 "EGFR")
                        :ARG2-of (m / mutate-01 :value "T669A"))))
      :mod (t2 / transient)
      :purpose (t3 / test-01
            :ARG0 w
            :ARG1 (t5 / thing
                  :ARG1-of (h / hypothesize-01)
                  :mod (t4 / this))))

# ::id bio.bmtr_0002.10 ::date 2014-12-15T15:05:31 ::annotator ISI-AMR-01 ::preferred
# ::snt In cells transfected with wild-type EGFR, MEK inhibition led to feedback activation of phospho-ERBB3 and phosho-EGFR, recapitulating the results we had observed in our panel of cancer cell lines (Figure 6A).
# ::save-date Wed Dec 17, 2014 ::file bio_bmtr_0002_10.txt
(l / lead-03
      :ARG0 (i / inhibit-01
            :ARG1 (e / enzyme :name (n / name :op1 "MEK")))
      :ARG2 (a / activate-01
            :ARG1 (a2 / and
                  :op1 (e3 / enzyme :name (n3 / name :op1 "ERBB3")
                        :ARG3-of (p / phosphorylate-01))
                  :op2 (e4 / enzyme :name (n4 / name :op1 "EGFR")
                        :ARG3-of (p2 / phosphorylate-01)))
            :subevent-of (f / feedback))
      :location (c / cell
            :ARG1-of (t / transfect-00
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "EGFR")
                        :mod (w / wild-type))))
      :ARG0-of (r / recapitulate-01
            :ARG1 (t2 / thing
                  :ARG2-of (r2 / result-01)
                  :ARG1-of (o / observe-01
                        :ARG0 (w2 / we)
                        :location (p3 / panel
                              :consist-of (c2 / cell-line
                                    :mod (c3 / cancer))
                              :poss w2))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "6A")))

# ::id bio.bmtr_0002.11 ::date 2014-12-17T01:40:22 ::annotator ISI-AMR-01 ::preferred
# ::snt In contrast, the EGFR T669A mutant increased both basal EGFR and ERBB3 tyrosine phosphorylation that was not augmented by MEK inhibition.
# ::save-date Wed Dec 17, 2014 ::file bio_bmtr_0002_11.txt
(c / contrast-01
  :ARG2 (i / increase-01
          :ARG0 (e4 / enzyme
                  :name (n4 / name
                          :op1 "EGFR")
                  :ARG2-of (m / mutate-01
                             :value "T669A"))
          :ARG1 (a / and
                  :op1 (p2 / phosphorylate-01
                         :ARG1 (a2 / amino-acid
                                 :name (n5 / name
                                         :op1 "tyrosine")
                                 :part-of (e / enzyme
                                            :name (n / name
                                                    :op1 "EGFR")))
                         :mod (b / basal))
                  :op2 (p3 / phosphorylate-01
                         :ARG1 (a3 / amino-acid
                                 :name (n6 / name
                                         :op1 "tyrosine"))
                         :part-of (e2 / enzyme
                                    :name (n2 / name
                                            :op1 "ERBB3"))
                         :mod b)
                  :ARG1-of (a4 / augment-01
                             :ARG0 (i2 / inhibit-01
                                     :ARG1 (e3 / enzyme
                                             :name (n3 / name
                                                     :op1 "MEK")))
                             :polarity -))))

# ::id bio.bmtr_0002.12 ::date 2014-12-15T15:37:12 ::annotator ISI-AMR-01 ::preferred
# ::snt As a control, we treated CHO-KI cells expressing EGFR T669A with HRG ligand to induce maximal ERBB3 phosphorylation (Figure 6A), indicating that the lack of induction of phospho-ERBB3 in EGFR T669A expressing cells following MEK inhibition was not simply due to the saturation of the system with phospho-ERBB3.
# ::save-date Wed Dec 17, 2014 ::file bio_bmtr_0002_12.txt
(t / treat-04
      :ARG0 (w / we)
      :ARG1 (c / cell
            :source (c2 / cell-line :name (n / name :op1 "CHO-KI"))
            :ARG3-of (e / express-03
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "EGFR")
                        :ARG2-of (m / mutate-01 :value "T669A"))))
      :ARG2 (l / ligand :name (n3 / name :op1 "HRG"))
      :purpose (i / induce-01
            :ARG0 w
            :ARG1 (p / phosphorylate-01
                  :ARG1 (e3 / enzyme :name (n4 / name :op1 "ERBB3"))
                  :degree (m2 / maximum))
            :ARG0-of (i2 / indicate-01
                  :ARG1 (c3 / cause-01 :polarity -
                        :ARG0 (l2 / lack-01
                              :ARG1 (i3 / induce-01
                                    :ARG1 (p3 / phosphorylate-01
                                          :ARG1 e3)
                                    :location (c4 / cell
                                          :ARG3-of (e5 / express-03
                                                :ARG2 (e6 / enzyme :name (n6 / name :op1 "EGFR")
                                                      :ARG2-of (m3 / mutate-01 :value "T669A"))))
                                    :ARG2-of (f2 / follow-01
                                          :ARG1 (i4 / inhibit-01
                                                :ARG1 (e7 / enzyme :name (n7 / name :op1 "MEK"))))))
                        :ARG1 (s / saturate-01
                              :ARG1 (s2 / system)
                              :ARG2 (e4 / enzyme :name (n5 / name :op1 "ERBB3")
                                    :ARG3-of (p2 / phosphorylate-01)))
                        :mod (s3 / simple))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6A"))
      :ARG2-of (c5 / control-01))

# ::id bio.bmtr_0002.13 ::date 2014-12-15T18:12:14 ::annotator ISI-AMR-01 ::preferred
# ::snt We observed analogous results in CHO-KI cells expressing wild-type ERBB3 in combination with wild-type or T677A mutant HER2 (Figure 6B).
# ::save-date Wed Dec 17, 2014 ::file bio_bmtr_0002_13.txt
(o / observe-01
      :ARG0 (w / we)
      :ARG1 (t / thing
            :ARG2-of (r / result-01
                  :ARG1 (c / cell
                        :source (c2 / cell-line :name (n / name :op1 "CHO-KI"))
                        :ARG3-of (e / express-03
                              :ARG2 (e2 / enzyme :name (n2 / name :op1 "ERBB3")
                                    :mod (w2 / wild-type)
                                    :accompanier (o2 / or
                                          :op1 (e3 / enzyme :name (n3 / name :op1 "HER2")
                                                :mod (w3 / wild-type))
                                          :op2 (e4 / enzyme :name (n4 / name :op1 "HER2")
                                                :ARG2-of (m / mutate-01 :value "T677A")))))))
            :mod (a / analogous))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6B")))

# ::id bio.bmtr_0002.14 ::date 2014-12-15T18:52:18 ::annotator ISI-AMR-01 ::preferred
# ::snt Together these results support the hypothesis that inhibition of ERK-mediated phosphorylation of a conserved JM domain threonine residue leads to feedback activation of EGFR, HER2, and ERBB3 (Figure 7).
# ::save-date Fri Dec 19, 2014 ::file bio_bmtr_0002_14.txt
(s / support-01
      :ARG0 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / together)
            :mod (t3 / this))
      :ARG1 (h / hypothesize-01
            :ARG1 (l / lead-03
                  :ARG0 (i / inhibit-01
                        :ARG1 (p / phosphorylate-01
                              :ARG1 (r2 / residue
                                    :mod (a3 / amino-acid :name (n5 / name :op1 "threonine"))
                                    :part-of (p2 / protein-segment :name (n6 / name :op1 "JM" :op2 "domain")
                                          :ARG1-of (c / conserve-01)))
                              :ARG1-of (m / mediate-01
                                    :ARG0 (e4 / enzyme :name (n4 / name :op1 "ERK")))))
                  :ARG2 (a / activate-01
                        :ARG1 (a2 / and
                              :op1 (e / enzyme :name (n / name :op1 "EGFR"))
                              :op2 (e2 / enzyme :name (n2 / name :op1 "HER2"))
                              :op3 (e3 / enzyme :name (n3 / name :op1 "ERBB3")))
                        :subevent-of (f / feedback))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod 7)))

# ::id bio.bmtr_0002.15 ::date 2015-01-21T16:11:03 ::annotator SDL-AMR-09 ::preferred
# ::snt To determine if this feedback model explains the activation of PI3K signaling in EGFR-mutant cancers, we used shRNA to knockdown endogenous EGFR (which carries an exon 19 deletion) in the HCC827 NSCLC cell line and replaced with either EGFR (exon 19del) wild-type at T669, or EGFR (exon 19del) carrying a T669A mutation.
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0002_15.txt
(a / and
      :op1 (u / use-01
            :ARG0 (w / we)
            :ARG1 (m / macro-molecular-complex :name (n / name :op1 "shRNA"))
            :ARG2 (k / knock-02
                  :ARG0 w
                  :ARG1 (e / enzyme :name (n2 / name :op1 "EGFR")
                        :mod (e2 / endogenous)
                        :location (c2 / cell-line :name (n3 / name :op1 "HCC827" :op2 "NSCLC"))
                        :ARG2-of (d / delete-01
                              :ARG1 (e3 / exon :mod 19)))))
      :op2 (r / replace-01
            :ARG0 w
            :ARG1 e
            :ARG2 (o / or
                  :op1 (e4 / enzyme :name (n4 / name :op1 "EGFR")
                        :mod (w2 / wild-type)
                        :ARG0-of (c / carry-01)
                        :part (a2 / amino-acid :mod 669 :name (n5 / name :op1 "threonine")))
                  :op2 (e5 / enzyme :name (n6 / name :op1 "EGFR")
                        :ARG2-of d
                        :part (m2 / mutate-01 :value "T669A"))))
      :purpose (d2 / determine-01
            :ARG0 w
            :ARG1 (e6 / explain-01 :mode interrogative
                  :ARG0 (m3 / model
                        :mod (f / feedback))
                  :ARG1 (a4 / activate-01
                        :ARG1 (e8 / enzyme :name (n7 / name :op1 "PI3K")
                              :ARG0-of (s / signal-01))
                        :condition (c4 / cancer
                              :mod (m4 / mutate-01
                                    :ARG1 (e7 / enzyme :name (n8 / name :op1 "EGFR"))))))))

# ::id bio.bmtr_0002.16 ::date 2015-01-21T16:49:26 ::annotator SDL-AMR-09 ::preferred
# ::snt Of note, this is the same EGFR-mutant cell line in which we observed that EGFR T669 is phosphorylated in MEK-dependent manner (Figure 5, Supplemental Figure 8A).
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0002_16.txt
(n / note-02
      :ARG1 (s / same-41
            :ARG1 (t / this)
            :ARG2 (c / cell-line
                  :consist-of (e3 / enzyme :name (n2 / name :op1 "EGFR")
                        :ARG2-of (m / mutate-01))
                  :location-of (p / phosphorylate-01
                        :ARG1 (a / amino-acid :mod 669 :name (n3 / name :op1 "threonine")
                              :part-of (e / enzyme :name (n4 / name :op1 "EGFR")))
                        :ARG0-of (d / depend-01
                              :ARG1 (e2 / enzyme :name (n5 / name :op1 "MEK")))
                        :ARG1-of (o / observe-01
                              :ARG0 (w / we))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (a2 / and
                        :op1 (f / figure :mod 5)
                        :op2 (f2 / figure :mod "8A"
                              :ARG2-of (s2 / supplement-01))))))

# ::id bio.bmtr_0002.17 ::date 2015-01-21T17:03:45 ::annotator SDL-AMR-09 ::preferred
# ::snt When endogenous EGFR was replaced with EGFR (exon19del) wild-type at T669, MEK inhibition led to significant feedback activation of ERBB3/PI3K/AKT signaling (Figure 6C).
# ::save-date Wed Jan 21, 2015 ::file bio_bmtr_0002_17.txt
(l / lead-03
      :ARG0 (i / inhibit-01
            :ARG1 (e / enzyme :name (n / name :op1 "MEK")))
      :ARG2 (a / activate-01
            :ARG1 (p / pathway :name (n2 / name :op1 "ERBB3/PI3K/AKT")
                  :ARG0-of (s / signal-01))
            :subevent-of (f / feedback)
            :degree (s2 / significant))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "6C"))
      :time (r / replace-01
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "EGFR")
                  :mod (e4 / endogenous))
            :ARG2 (e3 / enzyme :name (n4 / name :op1 "EGFR")
                  :mod (w / wild-type)
                  :ARG2-of (d2 / delete-01
                        :ARG1 (e5 / exon :mod 19))
                  :part (a2 / amino-acid :mod 669 :name (n5 / name :op1 "threonine")))))

# ::id bio.bmtr_0002.18 ::date 2015-01-21T17:32:05 ::annotator SDL-AMR-09 ::preferred
# ::snt However, replacement with the EGFR (exon19 del) T669A mutant led to increased tyrosine phosphorylation of both EGFR and ERBB3, and activation of PI3K/AKT signaling, mimicking the effect of MEK inhibition (Figure 6C).
# ::save-date Thu Feb 5, 2015 ::file bio_bmtr_0002_18.txt
(l / lead-03
      :ARG0 (r / replace-01
            :ARG2 (e / enzyme :name (n / name :op1 "EGFR")
                  :ARG2-of (m / mutate-01 :value "T669A")
                  :ARG2-of (d / delete-01
                        :ARG1 (e2 / exon :mod 19))))
      :ARG2 (a6 / and
            :op1 (i / increase-01
                  :ARG1 (a / and
                        :op1 (p / phosphorylate-01
                              :ARG1 (a2 / amino-acid :name (n2 / name :op1 "tyrosine")
                                    :part-of (e3 / enzyme :name (n3 / name :op1 "EGFR"))))
                        :op2 (p3 / phosphorylate-01
                              :ARG1 (a3 / amino-acid :name (n4 / name :op1 "tyrosine")
                                    :part-of (e4 / enzyme :name (n7 / name :op1 "ERBB3"))))))
            :op2 (a4 / activate-01
                  :ARG1 (p2 / pathway :name (n5 / name :op1 "PI3K/AKT")
                        :ARG0-of (s / signal-01)))
            :ARG1-of (m2 / mimic-01
                  :ARG0 (a5 / affect-01
                        :ARG0 (i2 / inhibit-01
                              :ARG1 (e5 / enzyme :name (n6 / name :op1 "MEK"))))))
      :ARG1-of (h / have-concession-91)
      :ARG1-of (d2 / describe-01
            :ARG0 (f / figure :mod "6C")))

# ::id bio.bmtr_0002.19 ::date 2015-01-21T17:56:39 ::annotator SDL-AMR-09 ::preferred
# ::snt As expected, addition of AZD6244 failed to further augment ERBB3 and AKT phosphorylation in cells expressing the 669A mutant.
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0002_19.txt
(a4 / augment-01 :polarity -
      :ARG0 (a / add-02
            :ARG1 (s / small-molecule :name (n / name :op1 "AZD6244")))
      :ARG1 (p / phosphorylate-01
            :ARG1 (a3 / and
                  :op1 (e / enzyme :name (n2 / name :op1 "ERBB3"))
                  :op2 (p2 / pathway :name (n3 / name :op1 "AKT")))
            :location (c / cell
                  :ARG3-of (e2 / express-03
                        :ARG2 (a2 / amino-acid :mod 669
                              :ARG2-of (m / mutate-01)))))
      :degree (f2 / further)
      :ARG1-of (e3 / expect-01))

# ::id bio.bmtr_0002.20 ::date 2015-01-21T18:15:45 ::annotator SDL-AMR-09 ::preferred
# ::snt These results demonstrate that EGFR T669 phosphorylation is necessary for MEK/ERK to suppress EGFR-mediated activation of ERBB3.
# ::save-date Thu Feb 5, 2015 ::file bio_bmtr_0002_20.txt
(d / demonstrate-01
      :ARG0 (t / thing
            :mod (t2 / this)
            :ARG2-of (r / result-01))
      :ARG1 (n / need-01
            :ARG0 (s / suppress-01
                  :ARG0 (p2 / pathway :name (n4 / name :op1 "MEK/ERK"))
                  :ARG1 (a2 / activate-01
                        :ARG1 (e2 / enzyme :name (n5 / name :op1 "ERBB3"))
                        :ARG1-of (m / mediate-01
                              :ARG0 (e3 / enzyme :name (n6 / name :op1 "EGFR")))))
            :ARG1 (p / phosphorylate-01
                  :ARG1 (a / amino-acid :mod 669 :name (n2 / name :op1 "threonine")
                        :part-of (e / enzyme :name (n3 / name :op1 "EGFR"))))))

# ::id bio.bmtr_0002.21 ::date 2015-01-21T18:24:17 ::annotator SDL-AMR-09 ::preferred
# ::snt This supports the hypothesis that a dominant ERK feedback on ERBB3/PI3K/AKT is mediated though phosphorylation of T669 on EGFR (or T677 HER2).
# ::save-date Thu Feb 5, 2015 ::file bio_bmtr_0002_21.txt
(s / support-01
      :ARG0 (t / this)
      :ARG1 (h / hypothesize-01
            :ARG1 (m / mediate-01
                  :ARG0 (o2 / or
                        :op1 (p2 / phosphorylate-01
                              :ARG1 (a / amino-acid :mod 669 :name (n3 / name :op1 "threonine")
                                    :part-of (e2 / enzyme :name (n4 / name :op1 "EGFR"))))
                        :op2 (p3 / phosphorylate-01
                              :ARG1 (a2 / amino-acid :mod 677 :name (n5 / name :op1 "threonine")
                                    :part-of (e3 / enzyme :name (n6 / name :op1 "HER2")))))
                  :ARG1 (f / feedback
                        :ARG0-of (d / dominate-01)
                        :destination (p / pathway :name (n / name :op1 "ERBB3/PI3K/AKT"))
                        :mod (e / enzyme :name (n2 / name :op1 "ERK"))))))

# ::id bio.bmtr_0003.1 ::date 2015-01-21T23:22:38 ::annotator SDL-AMR-09 ::preferred
# ::snt Montero-Conde et al. “Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF mutant thyroid carcinomas.” (PMC3651738)
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0003_1.txt
(p / publication-91
      :ARG0 (a / and
            :op1 (p2 / person :name (n / name :op1 "Montero-Conde"))
            :op2 (p3 / person
                  :mod (o / other)))
      :ARG1 (a3 / attenuate-01
            :ARG0 (r / relieve-01
                  :ARG1 (i / inhibit-01
                        :ARG0 (m / molecular-physical-entity
                              :ARG0-of (i2 / inhibit-01
                                    :ARG1 (a2 / and
                                          :op1 (e2 / enzyme :name (n3 / name :op1 "RAF"))
                                          :op2 (e3 / enzyme :name (n4 / name :op1 "MEK")))))
                        :ARG1 (t / transcribe-01
                              :ARG1 (e / enzyme :name (n2 / name :op1 "HER3")))
                        :subevent-of (f / feedback)))
            :ARG1 (a4 / affect-01
                  :ARG0 m
                  :ARG0-of (c / counter-01
                        :ARG1 (t2 / tumor))
                  :location (c2 / carcinoma
                        :mod (t3 / thyroid)
                        :ARG1-of (e4 / encode-01
                              :ARG0 (d / DNA
                                    :part (g / gene :name (n5 / name :op1 "BRAF")
                                          :ARG2-of (m2 / mutate-01)))))))
      :ARG8 "PMC3651738")

# ::id bio.bmtr_0003.2 ::date 2015-01-23T13:38:34 ::annotator SDL-AMR-09 ::preferred
# ::snt We next examined the mechanisms accounting for the increase in HER3 by MAPK pathway inhibitors in BRAF mutant thyroid cell lines.
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0003_2.txt
(e / examine-01
      :ARG0 (w / we)
      :ARG1 (m / mechanism
            :ARG0-of (a / account-01
                  :ARG1 (i / increase-01
                        :ARG0 (m2 / molecular-physical-entity
                              :ARG0-of (i2 / inhibit-01
                                    :ARG1 (p / pathway :name (n2 / name :op1 "MAPK"))))
                        :ARG1 (e2 / enzyme :name (n / name :op1 "HER3"))
                        :location (c / cell-line
                              :source (t / thyroid)
                              :ARG1-of (e3 / encode-01
                                    :ARG0 (d / DNA
                                          :part (g / gene :name (n3 / name :op1 "BRAF")
                                                :ARG2-of (m3 / mutate-01))))))))
      :time (n4 / next))

# ::id bio.bmtr_0003.3 ::date 2015-01-23T14:45:30 ::annotator SDL-AMR-09 ::preferred
# ::snt Upregulation of HER3 has been found to mediate resistance to PI3K/AKT (26) or HER2 (27) inhibitors in HER2-amplified breast cancer cell lines, which is caused in part through a FoxO3A-dependent induction of HER3 gene transcription.
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_3.txt
(f / find-01
      :ARG1 (m / mediate-01
            :ARG0 (u / upregulate-01
                  :ARG1 (e / enzyme :name (n / name :op1 "HER3")))
            :ARG1 (r / resist-01
                  :ARG1 (m2 / molecular-physical-entity
                        :ARG0-of (i / inhibit-01
                              :ARG1 (o / or
                                    :op1 (p / pathway :name (n2 / name :op1 "PI3K/AKT")
                                          :ARG1-of (d / describe-01
                                                :ARG0 (p2 / publication
                                                      :ARG1-of (c / cite-01
                                                            :ARG2 26))))
                                    :op2 (e2 / enzyme :name (n3 / name :op1 "HER2")
                                          :ARG1-of (d2 / describe-01
                                                :ARG1-of (c2 / cite-01
                                                      :ARG2 27))))))
                  :location (c3 / cell-line
                        :source (c4 / cancer
                              :mod (b / breast))
                        :mod (a / amplify-01
                              :ARG0 e2)))
            :ARG1-of (c5 / cause-01
                  :ARG0 (i2 / induce-01
                        :ARG1 (t / transcribe-01
                              :ARG1 (g / gene
                                    :ARG0-of (e3 / encode-01
                                          :ARG1 e)))
                        :ARG0-of (d3 / depend-01
                              :ARG1 (p3 / protein :name (n4 / name :op1 "FoxO3A"))))
                  :degree (p4 / part))))

# ::id bio.bmtr_0003.4 ::date 2015-01-23T15:09:03 ::annotator SDL-AMR-09 ::preferred
# ::snt As shown in Fig. 5A, PLX4032 treatment increased HER3 and HER2 mRNAs in all six BRAF-mutant thyroid cancer cell lines tested.
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0003_4.txt
(i / increase-01
      :ARG0 (t / treat-04
            :ARG2 (s / small-molecule :name (n / name :op1 "PLX4032")))
      :ARG1 (m / mRNA
            :ARG0-of (e / encode-01
                  :ARG1 (a / and
                        :op1 (e2 / enzyme :name (n2 / name :op1 "HER3"))
                        :op2 (e3 / enzyme :name (n3 / name :op1 "HER2")))))
      :location (c / cell-line :quant 6
            :source (t2 / thyroid
                  :ARG1-of (e4 / encode-01
                        :ARG0 (d / DNA
                              :part (g / gene :name (n4 / name :op1 "BRAF")
                                    :ARG2-of (m2 / mutate-01)))))
            :mod (a2 / all)
            :ARG1-of (t3 / test-01)
            :mod (c2 / cancer))
      :ARG1-of (s2 / show-01
            :ARG0 (f / figure :mod "5A")))

# ::id bio.bmtr_0003.5 ::date 2015-01-25T14:19:38 ::annotator SDL-AMR-09 ::preferred
# ::snt Similar results were found following treatment with the MEK inhibitor AZD6244 (not shown).
# ::save-date Sun Jan 25, 2015 ::file bio_bmtr_0003_5.txt
(f / find-01
      :ARG1 (t / thing
            :ARG2-of (r / result-01)
            :ARG1-of (r2 / resemble-01))
      :ARG1-of (f2 / follow-01
            :ARG2 (t2 / treat-04
                  :ARG2 (s / small-molecule :name (n / name :op1 "AZD6244")
                        :ARG0-of (i / inhibit-01
                              :ARG1 (e / enzyme :name (n2 / name :op1 "MEK")))
                        :ARG1-of (s2 / show-01 :polarity -)))))

# ::id bio.bmtr_0003.6 ::date 2015-01-25T14:28:31 ::annotator SDL-AMR-09 ::preferred
# ::snt The effects of the MEK inhibitor on total HER2, HER3 protein and on pHER3 were dose dependent, and inversely associated with the degree of inhibition of pERK (Fig. 5B).
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0003_6.txt
(a / and
      :op1 (d / depend-01
            :ARG0 (a2 / affect-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (i / inhibit-01
                              :ARG1 (e / enzyme :name (n / name :op1 "MEK"))))
                  :ARG1 (a3 / and
                        :op1 (e2 / enzyme :name (n2 / name :op1 "HER2")
                              :mod (t / total))
                        :op2 (e3 / enzyme :name (n3 / name :op1 "HER3"))
                        :op3 (e4 / enzyme :name (n4 / name :op1 "HER3")
                              :ARG3-of (p / phosphorylate-01))))
            :ARG1 (d2 / dose-01))
      :op2 (a4 / associate-01
            :ARG1 a2
            :ARG2 (t2 / thing
                  :degree-of (i2 / inhibit-01
                        :ARG1 (e5 / enzyme :name (n5 / name :op1 "ERK")
                              :ARG1-of p)))
            :mod (i3 / inverse))
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "5B")))

# ::id bio.bmtr_0003.7 ::date 2015-01-25T14:48:37 ::annotator SDL-AMR-09 ::preferred
# ::snt RAF or MEK inhibitors induced luciferase activity of a HER3 promoter construct spanning ~ 1 kb upstream of the transcriptional start site in 8505C cells.
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_7.txt
(i / induce-01
      :ARG0 (o / or
            :op1 (m / molecular-physical-entity
                  :ARG0-of (i2 / inhibit-01
                        :ARG1 (e / enzyme :name (n / name :op1 "RAF"))))
            :op2 (m2 / molecular-physical-entity
                  :ARG0-of (i3 / inhibit-01
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "MEK")))))
      :ARG1 (a / act-01
            :ARG0 (c / construct-01
                  :ARG0-of (p / promote-01
                        :ARG1 (e3 / enzyme :name (n3 / name :op1 "HER3")))
                  :ARG1-of (s / span-01
                        :location (r / relative-position
                              :op1 (s2 / site
                                    :location-of (s3 / start-01
                                          :ARG1 (t / transcribe-01)))
                              :direction (u / upstream))
                        :quant (a2 / approximately
                              :op1 (d / distance-quantity :quant 1
                                    :unit (k / kilo-base-pair)))
                        :location (c2 / cell :name (n5 / name :op1 "8505C"))))
            :ARG1 (l / luciferase)))

# ::id bio.bmtr_0003.8 ::date 2015-01-25T15:10:43 ::annotator SDL-AMR-09 ::preferred
# ::snt Serial deletions identified a minimal HER3 promoter retaining transcriptional response to vemurafenib and AZD6244, which was located between -401 and -42 bp (Fig. 5C).
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_8.txt
(i / identify-01
      :ARG0 (d / delete-01
            :manner (s / serial))
      :ARG1 (m / molecular-physical-entity
            :ARG0-of (p / promote-01
                  :ARG1 (e / enzyme :name (n / name :op1 "HER3")))
            :mod (m2 / minimal)
            :ARG0-of (r / retain-01
                  :ARG1 (t / thing
                        :ARG2-of (r2 / respond-01
                              :ARG1 (a / and
                                    :op1 (s2 / small-molecule :name (n2 / name :op1 "vemurafenib"))
                                    :op2 (s3 / small-molecule :name (n3 / name :op1 "AZD6244"))))
                        :mod (t2 / transcribe-01)))
            :location (b / between
                  :op1 (d2 / distance-quantity :quant "-401"
                        :unit (b2 / base-pair))
                  :op2 (d3 / distance-quantity :quant "-42"
                        :unit (b3 / base-pair))))
      :ARG1-of (d4 / describe-01
            :ARG0 (f / figure :mod "5C")))

# ::id bio.bmtr_0003.9 ::date 2015-01-25T15:28:42 ::annotator SDL-AMR-09 ::preferred
# ::snt This region does not contain any predicted FoxO binding sites.
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_9.txt
(c / contain-01 :polarity -
      :ARG0 (r / region
            :mod (t / this))
      :ARG1 (p3 / protein-segment
            :part-of (p / protein :name (n / name :op1 "FoxO"))
            :ARG1-of (b / bind-01)
            :ARG1-of (p2 / predict-01)
            :mod (a / any)))

# ::id bio.bmtr_0003.10 ::date 2015-01-25T15:36:32 ::annotator SDL-AMR-09 ::preferred
# ::snt Moreover, PLX4032 led to an increase in phosphorylation of FoxO1/3A between 4–10h after addition of compound (not shown), which is known to promote its dissociation from DNA, and likely discards involvement of these factors as transcriptional regulators of HER3 in response to MAPK pathway inhibition.
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_10.txt
(a / and
      :op2 (l / lead-03
            :ARG0 (s / small-molecule :name (n / name :op1 "PLX4032"))
            :ARG1 (i / increase-01
                  :ARG1 (p / phosphorylate-01
                        :ARG1 (p2 / protein :name (n2 / name :op1 "FoxO1/3A")))
                  :time (a2 / after
                        :op1 (a3 / add-02
                              :ARG1 (c / compound))
                        :quant (b / between
                              :op1 (t / temporal-quantity :quant 4
                                    :unit (h / hour))
                              :op2 (t2 / temporal-quantity :quant 10
                                    :unit (h2 / hour))))
                  :ARG1-of (s2 / show-01 :polarity -)
                  :ARG0-of (p3 / promote-01
                        :ARG1 (d / dissociate-01
                              :ARG1 p2
                              :ARG2 (d2 / DNA))
                        :ARG1-of (k / know-01))
                  :ARG0-of (d3 / discard-01
                        :ARG1 (i2 / involve-01
                              :ARG1 (f / factor
                                    :mod (t3 / this))
                              :mod (m / molecular-physical-entity
                                    :ARG0-of (r / regulate-01
                                          :ARG1 (e / enzyme :name (n3 / name :op1 "HER3")))
                                    :mod (t4 / transcribe-01)))
                        :mod (l2 / likely)
                        :ARG2-of (r2 / respond-01
                              :ARG1 (i3 / inhibit-01
                                    :ARG1 (p4 / pathway :name (n4 / name :op1 "MAPK"))))))))

# ::id bio.bmtr_0003.11 ::date 2015-01-25T15:59:16 ::annotator SDL-AMR-09 ::preferred
# ::snt The minimal HER3 promoter region regulated by MAPK inhibitors overlaps with sequences previously described to be immunoprecipitated using antibodies against the ZFN217 transcription factor and CtBP1/CtBP2 corepressors (28–30).
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_11.txt
(o / overlap-01
      :ARG0 (r / region
            :mod (m2 / molecular-physical-entity
                  :ARG0-of (p / promote-01
                        :ARG1 (e / enzyme :name (n / name :op1 "HER3"))
                        :mod (m / minimal)))
            :ARG1-of (r2 / regulate-01
                  :ARG0 (m3 / molecular-physical-entity
                        :ARG0-of (i / inhibit-01
                              :ARG1 (p2 / pathway :name (n2 / name :op1 "MAPK"))))))
      :ARG1 (s / sequence
            :ARG1-of (i2 / immunoprecipitate-00
                  :ARG2-of (u / use-01
                        :ARG1 (a / antibody
                              :ARG0-of (o2 / oppose-01
                                    :ARG1 (a2 / and
                                          :op1 (f / factor
                                                :ARG0-of (t / transcribe-01
                                                      :ARG1 (e2 / enzyme :name (n3 / name :op1 "ZFN217"))))
                                          :op2 (o3 / or
                                                :op1 (c / corepressor :name (n4 / name :op1 "CtBP1"))
                                                :op2 (c2 / corepressor :name (n5 / name :op1 "CtBP2")))))))
                  :ARG1-of (d / describe-01
                        :time (p4 / previous))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (v / value-interval :op1 28 :op2 30)))))

# ::id bio.bmtr_0003.12 ::date 2015-01-25T16:16:54 ::annotator SDL-AMR-09 ::preferred
# ::snt CtBPs have also been described to negatively regulate transcriptional activity of the HER3 promoter in breast carcinoma cell lines (30).
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_12.txt
(d / describe-01
      :ARG1 (p / protein :name (n / name :op1 "CtBP"))
      :ARG2 (r / regulate-01
            :ARG0 p
            :ARG1 (a2 / act-01
                  :ARG0 (m / molecular-physical-entity
                        :ARG0-of (p2 / promote-01
                              :ARG1 (e / enzyme :name (n2 / name :op1 "HER3"))))
                  :ARG1 (t / transcribe-01))
            :manner (n3 / negative)
            :location (c / cell-line
                  :mod (c2 / carcinoma
                        :mod (b / breast))))
      :mod (a / also)
      :ARG1-of (d2 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 30))))

# ::id bio.bmtr_0003.13 ::date 2015-01-25T16:25:03 ::annotator SDL-AMR-09 ::preferred
# ::snt Silencing of CtBP1, and to a lesser extent CtBP2, increased basal HER3 in 8505C cells, and markedly potentiated the effects of PLX4032 (Fig. 5D and 5E).
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_13.txt
(a / and
      :op1 (i / increase-01
            :ARG0 (s / silence-01
                  :ARG1 (a2 / and
                        :op1 (p / protein :name (n / name :op1 "CtBP1"))
                        :op2 (p2 / protein :name (n2 / name :op1 "CtBP2")
                              :degree (l / less
                                    :degree (m / more)))))
            :ARG1 (e / enzyme :name (n3 / name :op1 "HER3")
                  :mod (b / basal))
            :location (c / cell :name (n4 / name :op1 "8505C")))
      :op2 (p3 / potentiate-00
            :ARG0 s
            :ARG1 (a3 / affect-01
                  :ARG0 (s2 / small-molecule :name (n5 / name :op1 "PLX4032")))
            :manner (m2 / marked))
      :ARG1-of (d / describe-01
            :ARG0 (a4 / and
                  :op1 (f / figure :mod "5D")
                  :op2 (f2 / figure :mod "5E"))))

# ::id bio.bmtr_0003.14 ::date 2015-01-25T16:32:44 ::annotator SDL-AMR-09 ::preferred
# ::snt Knockdown of these factors modestly increased basal and PLX4032-induced HER2 levels, which likely contributes to the remarkable increase in pHER3 we observed (Fig. 5D and 5E).
# ::save-date Mon Feb 9, 2015 ::file bio_bmtr_0003_14.txt
(i / increase-01
      :ARG0 (k / knock-02
            :ARG1 (f / factor
                  :mod (t / this)))
      :ARG1 (a / and
            :op1 (l2 / level
                  :mod (e / enzyme :name (n / name :op1 "HER2")
                        :mod (b / basal)))
            :op2 (l3 / level
                  :mod (e2 / enzyme :name (n2 / name :op1 "HER2")
                        :ARG1-of (i2 / induce-01
                              :ARG0 (s / small-molecule :name (n3 / name :op1 "PLX4032"))))))
      :degree (m / modest)
      :ARG0-of (c / contribute-01
            :ARG1 (i3 / increase-01
                  :ARG1 (e3 / enzyme :name (n4 / name :op1 "HER3")
                        :ARG3-of (p / phosphorylate-01))
                  :mod (r / remarkable)
                  :ARG1-of (o / observe-01
                        :ARG0 (w / we)))
            :mod (l / likely))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (f2 / figure :mod "5D")
                  :op2 (f3 / figure :mod "5E"))))

# ::id bio.bmtr_0003.15 ::date 2015-01-25T16:39:57 ::annotator SDL-AMR-09 ::preferred
# ::snt Finally, CtBP1 and CtBP2 chromatin immunoprecipitation assays showed decreased binding to the HER3 promoter after treatment with PLX4032 (Fig. 5F).
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_15.txt
(s / show-01
      :ARG0 (a / assay-00
            :ARG1 (i / immunoprecipitate-00
                  :ARG1 (a2 / and
                        :op1 (p / protein :name (n / name :op1 "CtBP1"))
                        :op2 (p2 / protein :name (n2 / name :op1 "CtBP2")))
                  :mod (c / chromatin)))
      :ARG1 (b / bind-01
            :ARG2 (m / molecular-physical-entity
                  :ARG0-of (p3 / promote-01
                        :ARG1 (e / enzyme :name (n3 / name :op1 "HER3"))))
            :ARG1-of (d / decrease-01
                  :time (a3 / after
                        :op1 (t / treat-04
                              :ARG2 (s2 / small-molecule :name (n4 / name :op1 "PLX4032"))))))
      :time (f / final)
      :ARG1-of (d2 / describe-01
            :ARG0 (f2 / figure :mod "5F")))

# ::id bio.bmtr_0003.16 ::date 2015-01-25T16:48:03 ::annotator SDL-AMR-09 ::preferred
# ::snt These findings were confirmed in a second cell line (Supplementary Fig. S5A).
# ::save-date Sun Jan 25, 2015 ::file bio_bmtr_0003_16.txt
(c / confirm-01
      :ARG0 (t / thing
            :ARG1-of (f / find-01)
            :mod (t2 / this))
      :location (c2 / cell-line
            :ord (o / ordinal-entity :value 2))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "S5A"
                  :ARG2-of (s / supplement-01))))

# ::id bio.bmtr_0003.17 ::date 2015-01-25T16:51:39 ::annotator SDL-AMR-09 ::preferred
# ::snt The increase in expression of HER3 after MAPK inhibition is due to activation of gene transcription, which was associated with a reduction of binding of the transcriptional repressors CTBP1 and CTBP2 to the HER3 gene promoter.
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_17.txt
(c / cause-01
      :ARG0 (a2 / activate-01
            :ARG1 (t / transcribe-01
                  :ARG1 (g / gene))
            :ARG1-of (a3 / associate-01
                  :ARG2 (r / reduce-01
                        :ARG1 (b / bind-01
                              :ARG1 (a4 / and
                                    :op1 (p3 / protein :name (n3 / name :op1 "CTBP1")
                                          :ARG0-of (r2 / repress-01))
                                    :op2 (p4 / protein :name (n4 / name :op1 "CTBP2")
                                          :ARG0-of r2)
                                    :ARG0-of (t2 / transcribe-01))
                              :ARG2 (m / molecular-physical-entity
                                    :ARG0-of (p2 / promote-01
                                          :ARG1 (g2 / gene
                                                :ARG0-of (e3 / encode-01
                                                      :ARG1 e2))))))))
      :ARG1 (i / increase-01
            :ARG1 (e / express-03
                  :ARG1 (e2 / enzyme :name (n / name :op1 "HER3")))
            :time (a / after
                  :op1 (i2 / inhibit-01
                        :ARG1 (p / pathway :name (n2 / name :op1 "MAPK"))))))

# ::id bio.bmtr_0003.18 ::date 2015-01-25T17:00:21 ::annotator SDL-AMR-09 ::preferred
# ::snt These corepressors have been previously linked to inhibition of HER3 transcription through promoter regions that show overlapping occupancy with ZNF217, a transcription factor also involved in HER3 regulation (30).
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_18.txt
(l / link-01
      :ARG1 (a / and
            :op1 (c / corepressor
                  :mod (t / this))
            :op2 (i / inhibit-01
                  :ARG1 (t2 / transcribe-01
                        :ARG1 (e / enzyme :name (n / name :op1 "HER3")))))
      :ARG2 (r / region
            :ARG0-of (p2 / promote-01)
            :ARG0-of (s / show-01
                  :ARG1 (o / occupy-01
                        :ARG0 (p3 / protein :name (n2 / name :op1 "ZNF217")
                              :mod (f / factor
                                    :ARG0-of (t3 / transcribe-01)
                                    :ARG1-of (i2 / involve-01
                                          :ARG2 (r2 / regulate-01
                                                :ARG1 e)
                                          :mod (a2 / also))))
                        :ARG1 r
                        :ARG0-of (o2 / overlap-01))))
      :time (p / previous)
      :ARG1-of (d / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 30))))

# ::id bio.bmtr_0003.19 ::date 2015-01-25T17:07:41 ::annotator SDL-AMR-09 ::preferred
# ::snt Accordingly, knockdown of CTBPs acutely induced HER3 expression and phosphorylation in thyroid cancer cells.
# ::save-date Sun Jan 25, 2015 ::file bio_bmtr_0003_19.txt
(i / induce-01
      :ARG0 (k / knock-02
            :ARG1 (p / protein :name (n / name :op1 "CTBP")))
      :ARG1 (a2 / and
            :op1 (e / express-03
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "HER3")))
            :op2 (p2 / phosphorylate-01
                  :ARG1 e2)
            :location (c / cell
                  :mod (c2 / cancer)
                  :source (t / thyroid)))
      :manner (a / acute)
      :manner (a3 / accordingly))

# ::id bio.bmtr_0003.20 ::date 2015-01-25T17:14:26 ::annotator SDL-AMR-09 ::preferred
# ::snt MAPK inhibition may dictate a chromatin redistribution of these repressors, and thus activate HER3 transcription.
# ::save-date Sun Jan 25, 2015 ::file bio_bmtr_0003_20.txt
(p / possible
      :domain (d / dictate-01
            :ARG0 (i / inhibit-01
                  :ARG1 (p2 / pathway :name (n / name :op1 "MAPK")))
            :ARG1 (r / redistribute-01
                  :ARG1 (m / molecular-physical-entity
                        :mod (t / this)
                        :ARG0-of (r2 / repress-01))
                  :mod (c / chromatin)))
      :ARG0-of (c2 / cause-01
            :ARG1 (a2 / activate-01
                  :ARG0 i
                  :ARG1 (t2 / transcribe-01
                        :ARG1 (e / enzyme :name (n2 / name :op1 "HER3"))))))

# ::id bio.bmtr_0003.21 ::date 2015-01-25T17:19:05 ::annotator SDL-AMR-09 ::preferred
# ::snt The biochemical mechanisms involved in delocalization of CtBPs by MAPK inhibition have not been explored, but posttranslational modifications are known to regulate the repressive activity of CtBPs either by translocation to the cytoplasm or by targeting them for degradation (36, 37).
# ::save-date Wed Feb 4, 2015 ::file bio_bmtr_0003_21.txt
(c / contrast-01
      :ARG1 (e / explore-01 :polarity -
            :ARG1 (m / mechanism
                  :mod (b / biochemical)
                  :ARG1-of (i / involve-01
                        :ARG2 (d / delocalize-00
                              :ARG0 (i2 / inhibit-01
                                    :ARG1 (p / pathway :name (n / name :op1 "MAPK")))
                              :ARG1 (p2 / protein :name (n2 / name :op1 "CtBP"))))))
      :ARG2 (k / know-01
            :ARG1 (r / regulate-01
                  :ARG0 (m2 / modify-01
                        :time (a3 / after
                              :op1 (t3 / translation)))
                  :ARG1 (a / act-02
                        :ARG0 p2
                        :mod (r2 / repress-01))
                  :manner (o / or
                        :op1 (t / translocate-00
                              :ARG1 p2
                              :location (c2 / cytoplasm))
                        :op2 (t2 / target-01
                              :ARG1 p2
                              :purpose (d2 / degrade-01
                                    :ARG1 p2)))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c3 / cite-01
                        :ARG2 (a2 / and :op1 36 :op2 37)))))

# ::id bio.mskcc_0001.1 ::date 2014-11-03T12:55:43 ::annotator ISI-AMR-01 ::preferred
# ::snt We identify four S/TP sites of B-Raf phosphorylated by activated ERK and find that feedback phosphorylation of B-Raf inhibits binding to activated Ras and disrupts heterodimerization with C-Raf, which is dependent on the B-Raf pS729/14-3-3 binding site.
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_1.txt
(a / and
      :op1 (i / identify-01
            :ARG0 (w / we)
            :ARG1 (p / protein-segment :quant 4
                  :part (a5 / amino-acid
                        :ARG3-of (p2 / phosphorylate-01
                              :ARG2 (e / enzyme :name (n3 / name :op1 "ERK")
                                    :ARG1-of (a2 / activate-01))
                              :subevent-of (f2 / feedback))
                        :mod (o / or
                              :op1 (a6 / amino-acid :name (n / name :op1 "serine"))
                              :op2 (a7 / amino-acid :name (n9 / name :op1 "threonine"))))
                  :part-of (e4 / enzyme :name (n2 / name :op1 "B-Raf"))))
      :op2 (f / find-01
            :ARG0 w
            :ARG1 (a3 / and
                  :op1 (i2 / inhibit-01
                        :ARG0 p2
                        :ARG1 (b / bind-01
                              :ARG1 e4
                              :ARG2 (e3 / enzyme :name (n4 / name :op1 "Ras")
                                    :ARG1-of (a4 / activate-01))))
                  :op2 (d / disrupt-01
                        :ARG0 p2
                        :ARG1 (h / heterodimerize-00
                              :ARG1 e4
                              :ARG2 (e2 / enzyme :name (n5 / name :op1 "C-Raf"))
                              :ARG0-of (d2 / depend-01
                                    :ARG1 (a8 / amino-acid :mod 729 :name (n10 / name :op1 "serine")
                                          :ARG3-of (p4 / phosphorylate-01)
                                          :ARG1-of (b2 / bind-01
                                                :ARG2 (p3 / protein :name (n6 / name :op1 "14-3-3")))
                                          :part-of e4)))))))

# ::id bio.mskcc_0001.2 ::date 2014-11-03T19:18:55 ::annotator ISI-AMR-01 ::preferred
# ::snt 14-3-3 dimers bind to phosphorylation sites present in both the N- and C-terminal regions and stabilize the autoinhibited state (22).
# ::save-date Wed Nov 5, 2014 ::file bio_mskcc_0001_2.txt
(a / and
      :op1 (b / bind-01
            :ARG1 (d / dimer :name (n / name :op1 "14-3-3"))
            :ARG2 (p9 / protein-segment
                  :ARG1-of (p / phosphorylate-01)
                  :part-of (p2 / protein-segment :name (n2 / name :op1 "N-terminus")
                        :part-of (p5 / protein))))
      :op2 (b2 / bind-01
            :ARG1 d
            :ARG2 (p10 / protein-segment
                  :ARG1-of (p3 / phosphorylate-01)
                  :part-of (p4 / protein-segment :name (n3 / name :op1 "C-terminus")
                        :part-of p5)))
      :op3 (s3 / stabilize-01
            :ARG0 d
            :ARG1 (i / inhibit-01
                  :ARG0 (p6 / protein-segment
                        :part-of p5)
                  :ARG1 (p7 / protein-segment
                        :part-of p5)))
      :ARG1-of (d2 / describe-01
            :ARG0 (p8 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 22))))

# ::id bio.mskcc_0001.3 ::date 2014-11-03T19:35:08 ::annotator ISI-AMR-01 ::preferred
# ::snt To activate the Raf proteins, autoinhibition mediated by the N terminus must be relieved and the kinase domain must adopt the active catalytic conformation
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_3.txt
(r / require-01
      :ARG0 (a / activate-01
            :ARG1 (e / enzyme :name (n / name :op1 "Raf")))
      :ARG1 (a2 / and
            :op1 (r2 / relieve-01
                  :ARG1 (i / inhibit-01
                        :ARG0 (p2 / protein-segment
                              :part-of e)
                        :ARG1 (p3 / protein-segment
                              :part-of e)
                        :ARG1-of (m / mediate-01
                              :ARG0 (p5 / protein-segment :name (n2 / name :op1 "N-terminus")
                                    :part-of e))))
            :op2 (a3 / activate-01
                  :ARG1 (d / domain
                        :mod (k / kinase)
                        :part-of e
                        :ARG0-of (c / catalyze-01)))))

# ::id bio.mskcc_0001.4 ::date 2014-11-03T20:16:00 ::annotator ISI-AMR-01 ::preferred
# ::snt Under normal signaling conditions, Ras activation helps mediate these events by recruiting the Raf proteins to the plasma membrane, which induces the release of 14-3-3 from the N-terminal binding site and facilitates phosphorylation of the Raf kinase domain (19).
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_4.txt
(h / help-01
      :ARG0 (a / activate-01
            :ARG1 (e3 / enzyme :name (n / name :op1 "Ras")))
      :ARG1 (m / mediate-01
            :ARG0 a
            :ARG1 (e / event
                  :mod (t / this)))
      :manner (r / recruit-01
            :ARG0 a
            :ARG1 (e2 / enzyme :name (n6 / name :op1 "Raf"))
            :destination (m2 / membrane
                  :mod (p2 / plasma))
            :ARG0-of (i / induce-01
                  :ARG1 (r2 / release-01
                        :ARG1 (p3 / protein :name (n2 / name :op1 "14-3-3"))
                        :ARG2 (p8 / protein-segment
                              :part-of (p4 / protein-segment :name (n3 / name :op1 "N-terminus"))
                              :ARG1-of (b / bind-01))))
            :ARG0-of (f / facilitate-01
                  :ARG1 (p5 / phosphorylate-01
                        :ARG1 (d / domain
                              :mod (k / kinase)
                              :part-of e2))))
      :condition (n5 / normal
            :domain (s2 / signal-01
                  :ARG0 e3))
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 19))))

# ::id bio.mskcc_0001.5 ::date 2014-11-03T20:23:34 ::annotator ISI-AMR-01 ::preferred
# ::snt Once activated, either by upstream signaling or by mutational events, all Raf proteins are capable of initiating the phosphorylation cascade that results in the sequential activation of MEK and ERK.
# ::save-date Wed Nov 19, 2014 ::file bio_mskcc_0001_5.txt
(c / capable-41
      :ARG1 (e3 / enzyme :name (n / name :op1 "Raf")
            :mod (a / all))
      :ARG2 (i / initiate-01
            :ARG0 e3
            :ARG1 (c2 / cascade
                  :subevent (p3 / phosphorylate-01)
                  :ARG1-of (r / result-01
                        :ARG2 (a3 / and
                              :op1 (a2 / activate-01
                                    :ARG1 (e / enzyme :name (n2 / name :op1 "MEK")))
                              :op2 (a4 / activate-01
                                    :ARG1 (e2 / enzyme :name (n3 / name :op1 "ERK"))
                                    :ARG2-of (f / follow-01
                                          :ARG1 a2))))))
      :time (a6 / activate-01
            :ARG0 (o / or
                  :op1 (s / signal-01
                        :source (u / upstream))
                  :op2 (m / mutate-01))
            :ARG1 e3))

# ::id bio.mskcc_0001.6 ::date 2014-11-03T20:34:01 ::annotator ISI-AMR-01 ::preferred
# ::snt Strikingly, the Raf proteins themselves are also substrates of activated ERK.
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_6.txt
(c / catalyze-01
      :ARG0 (e / enzyme :name (n / name :op1 "ERK")
            :ARG1-of (a / activate-01))
      :ARG1 (e2 / enzyme :name (n2 / name :op1 "Raf"))
      :ARG1-of (s / strike-04))

# ::id bio.mskcc_0001.7 ::date 2014-11-05T22:08:42 ::annotator ISI-AMR-01 ::preferred
# ::snt In regard to C-Raf, ERK-dependent feedback phosphorylation has been shown to instigate a regulatory cycle whereby phosphorylation of the feedback sites down-modulates C-Raf signaling, after which the hyperphosphorylated C-Raf protein is dephosphorylated and returned to a signaling-competent state through dephosphorylation events involving protein phosphatase 2A (PP2A) and the Pin1 prolyl-isomerase (8).
# ::save-date Fri Nov 21, 2014 ::file bio_mskcc_0001_7.txt
(s / show-01
      :ARG0 (p3 / publication
            :ARG1-of (c2 / cite-01
                  :ARG2 8))
      :ARG1 (i / instigate-01
            :ARG0 (p / phosphorylate-01
                  :ARG1 (p2 / protein-segment
                        :part-of (e / enzyme :name (n / name :op1 "C-Raf"))
                        :destination-of (f / feedback))
                  :ARG0-of (d / depend-01
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "ERK"))))
            :ARG1 (c / cycle
                  :mod (r / regulate-01)
                  :subevent (d2 / downmodulate-00
                        :ARG0 p
                        :ARG1 (s2 / signal-01
                              :ARG0 e)
                        :op1-of (a / after
                              :time-of (d3 / dephosphorylate-01
                                    :ARG1 (e3 / enzyme :name (n3 / name :op1 "C-Raf")
                                          :ARG3-of (h / hyperphosphorylate-00))
                                    :ARG0-of (a2 / activate-01
                                          :ARG1 s2)
                                    :ARG1-of (i2 / involve-01
                                          :ARG2 (a3 / and
                                                :op1 (e4 / enzyme :name (n4 / name :op1 "protein" :op2 "phosphatase" :op3 "2A"))
                                                :op2 (p4 / prolyl-isomerase :name (n5 / name :op1 "Pin1"))))))))))

# ::id bio.mskcc_0001.8 ::date 2014-11-06T21:40:56 ::annotator ISI-AMR-01 ::preferred
# ::snt For B-Raf, two ERK-dependent feedback sites, S750 and T753, have been identified, and phosphorylation of these sites has been reported to have a negative regulatory effect
# ::save-date Sun Dec 7, 2014 ::file bio_mskcc_0001_8.txt
(a / and
      :op1 (i / identify-01
            :ARG1 (a2 / and
                  :op1 (a3 / amino-acid :mod 750 :name (n4 / name :op1 "serine"))
                  :op2 (a4 / amino-acid :mod 753 :name (n3 / name :op1 "threonine"))
                  :part-of (e / enzyme :name (n / name :op1 "B-Raf"))
                  :destination-of (f / feedback
                        :ARG0-of (d / depend-01
                              :ARG1 (e2 / enzyme :name (n2 / name :op1 "ERK"))))))
      :op2 (r / report-01
            :ARG1 (a5 / affect-01
                  :ARG0 (p / phosphorylate-01
                        :ARG1 a2)
                  :ARG1 (d2 / downregulate-01))))

# ::id bio.mskcc_0001.9 ::date 2014-11-06T21:57:03 ::annotator ISI-AMR-01 ::preferred
# ::snt Here we find that both normal and oncogenic B-Raf proteins are phosphorylated on four S/TP sites (S151, T401, S750, and T753) by activated ERK.
# ::save-date Fri Nov 14, 2014 ::file bio_mskcc_0001_9.txt
(f / find-01
      :ARG0 (w / we)
      :ARG1 (p / phosphorylate-01
            :ARG1 (a / and
                  :op1 (a2 / amino-acid :mod 151 :name (n / name :op1 "serine"))
                  :op2 (a3 / amino-acid :mod 401 :name (n2 / name :op1 "threonine"))
                  :op3 (a4 / amino-acid :mod 750 :name (n3 / name :op1 "serine"))
                  :op4 (a5 / amino-acid :mod 753 :name (n4 / name :op1 "threonine"))
                  :part-of (e / enzyme :name (n5 / name :op1 "B-Raf")))
            :ARG2 (e2 / enzyme :name (n7 / name :op1 "ERK")
                  :ARG1-of (a6 / activate-01))
            :condition (o / or
                  :op1 (n6 / normal
                        :domain e)
                  :op2 (c / cause-01
                        :ARG0 e
                        :ARG1 (c2 / cancer))))
      :medium (h / here))

# ::id bio.mskcc_0001.10 ::date 2014-11-06T22:59:41 ::annotator ISI-AMR-01 ::preferred
# ::snt Previously, we found that in response to growth factor treatment, signaling from C-Raf is downregulated by ERK-dependent feedback phosphorylation on S/TP sites and that C-Raf is subsequently dephosphorylated and returned to a signaling-competent state through the activities of PP2A and the Pin1 prolyl-isomerase (8)
# ::save-date Fri Nov 14, 2014 ::file bio_mskcc_0001_10.txt
(f2 / find-01
      :ARG0 (w / we)
      :ARG1 (a / and
            :op1 (d2 / downregulate-01
                  :ARG0 (p / phosphorylate-01
                        :ARG1 (a4 / amino-acid
                              :mod (o / or
                                    :op1 (a6 / amino-acid :name (n7 / name :op1 "serine"))
                                    :op2 (a7 / amino-acid :name (n8 / name :op1 "threonine")))
                              :part-of (e / enzyme :name (n / name :op1 "C-Raf"))
                              :destination-of (f / feedback))
                        :ARG0-of (d / depend-01
                              :ARG1 (e2 / enzyme :name (n2 / name :op1 "ERK"))))
                  :ARG1 (s2 / signal-01
                        :ARG0 e))
            :op2 (d3 / dephosphorylate-01
                  :ARG1 (e3 / enzyme :name (n3 / name :op1 "C-Raf"))
                  :ARG2 (a3 / and
                        :op1 (e4 / enzyme :name (n4 / name :op1 "PP2A"))
                        :op2 (p4 / prolyl-isomerase :name (n5 / name :op1 "Pin1")))
                  :ARG0-of (a2 / activate-01
                        :ARG1 s2)
                  :time (a5 / after
                        :op1 d2))
            :ARG0-of (r2 / respond-01
                  :ARG1 (t / treat-04
                        :ARG2 (s / small-molecule :name (n6 / name :op1 "growth" :op2 "factor")))))
      :ARG1-of (d4 / describe-01
            :ARG0 (p3 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 8)))
      :time (p2 / previous))

# ::id bio.mskcc_0001.11 ::date 2014-11-09T19:29:37 ::annotator ISI-AMR-01 ::preferred
# ::snt The Pin1 prolyl-isomerase binds specifically to phosphorylated S/TP (pS/TP) motifs (33), and isomerization of the pS/TP bond is required for PP2A to efficiently dephosphorylate certain proteins, such as cdc25C, Myc, and C-Raf (16).
# ::save-date Fri Nov 21, 2014 ::file bio_mskcc_0001_11.txt
(a / and
      :op1 (b / bind-01
            :ARG1 (p7 / prolyl-isomerase :name (n / name :op1 "Pin1"))
            :ARG2 (p / protein-segment :value "S/TP"
                  :ARG3-of (p2 / phosphorylate-01))
            :mod (s / specific)
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c / cite-01
                              :ARG2 33))))
      :op2 (r / require-01
            :ARG0 (d2 / dephosphorylate-01
                  :ARG1 (p4 / protein
                        :example (a2 / and
                              :op1 (e3 / enzyme :name (n3 / name :op1 "cdc25C"))
                              :op2 (p5 / protein :name (n4 / name :op1 "Myc"))
                              :op3 (e4 / enzyme :name (n5 / name :op1 "C-Raf")))
                        :mod (c3 / certain))
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "PP2A"))
                  :ARG2-of (e5 / efficient-41
                        :ARG1 e2))
            :ARG1 (i / isomerize-00
                  :ARG1 (b2 / bond
                        :part-of p))
            :ARG1-of (d3 / describe-01
                  :ARG0 (p6 / publication
                        :ARG1-of (c2 / cite-01
                              :ARG2 16)))))

# ::id bio.mskcc_0001.12 ::date 2014-11-09T20:58:01 ::annotator ISI-AMR-01 ::preferred
# ::snt Complex formation between B-Raf and Pin1 correlated with the phosphorylation of B-Raf on S/TP sites (Fig. 1C) and this interaction could be blocked when the MEK inhibitor U0126 was used to prevent ERK activation and the S/TP phosphorylation of B-Raf (Fig. 1D).
# ::save-date Sun Nov 9, 2014 ::file bio_mskcc_0001_12.txt
(a / and
      :op1 (c / correlate-01
            :ARG1 (f / form-01
                  :ARG1 (m / macro-molecular-complex)
                  :ARG2 (a2 / and
                        :op1 (e / enzyme :name (n / name :op1 "B-Raf"))
                        :op2 (e2 / enzyme :name (n2 / name :op1 "Pin1"))))
            :ARG2 (p / phosphorylate-01
                  :ARG1 (p2 / protein-segment :value "S/TP"
                        :part-of e))
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure :mod "1C")))
      :op2 (p3 / possible
            :domain (b / block-01
                  :ARG1 f)
            :condition (u / use-01
                  :ARG1 (s / small-molecule :name (n3 / name :op1 "U0126")
                        :ARG0-of (i / inhibit-01
                              :ARG1 (e3 / enzyme :name (n4 / name :op1 "MEK"))))
                  :ARG2 (p4 / prevent-01
                        :ARG0 s
                        :ARG1 (a3 / and
                              :op1 (a4 / activate-01
                                    :ARG1 (e4 / enzyme :name (n5 / name :op1 "ERK")))
                              :op2 (p5 / phosphorylate-01
                                    :ARG1 p2))))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f3 / figure :mod "1D"))))

# ::id bio.mskcc_0001.13 ::date 2014-11-16T16:37:31 ::annotator ISI-AMR-01 ::preferred
# ::snt Together, these findings indicate that Pin1 is needed for the efficient dephosphorylation of B-Raf and are consistent with the model that S/TP phosphorylation inhibits Raf signaling.
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_13.txt
(a / and
      :op1 (i / indicate-01
            :ARG0 (t / thing
                  :ARG1-of (f / find-01)
                  :mod (t3 / this))
            :ARG1 (n4 / need-01
                  :ARG1 (e / enzyme :name (n2 / name :op1 "Pin1"))
                  :purpose (d / dephosphorylate-01
                        :ARG1 (e2 / enzyme :name (n / name :op1 "B-Raf"))
                        :ARG2-of (e3 / efficient-41))))
      :op2 (c / consistent-41
            :ARG1 t
            :ARG2 (m / model
                  :topic (i2 / inhibit-01
                        :ARG0 (p / phosphorylate-01
                              :ARG1 (p2 / protein-segment :value "S/TP"))
                        :ARG1 (s / signal-01
                              :ARG0 (e4 / enzyme :name (n3 / name :op1 "Raf"))))))
      :mod (t2 / together))

# ::id bio.mskcc_0001.14 ::date 2014-11-16T16:54:17 ::annotator ISI-AMR-01 ::preferred
# ::snt Eluting in HPLC fractions 78 to 79 was a peptide phosphorylated on S750 and T753, the previously identified ERK sites, and eluting in fractions 26 and 58 to 59 were peptides phosphorylated at S151 and T401, respectively.
# ::save-date Mon Nov 17, 2014 ::file bio_mskcc_0001_14.txt
(a / and
      :op1 (e / elute-00
            :ARG1 (p / peptide
                  :part (a2 / amino-acid :mod 750 :name (n / name :op1 "serine")
                        :ARG3-of (p2 / phosphorylate-01)
                        :part-of (p4 / protein-segment
                              :part-of (e2 / enzyme :name (n3 / name :op1 "ERK"))
                              :ARG1-of (i / identify-01
                                    :time (p5 / previous))))
                  :part (a3 / amino-acid :mod 753 :name (n2 / name :op1 "threonine")
                        :ARG3-of (p3 / phosphorylate-01)
                        :part-of p4))
            :ARG3 (f / fraction
                  :mod (h / HPLC)
                  :mod (b / between :op1 78 :op2 79)))
      :op2 (e3 / elute-00
            :ARG1 (p6 / peptide
                  :part (a5 / amino-acid :mod 151 :name (n4 / name :op1 "serine")
                        :ARG3-of (p7 / phosphorylate-01)))
            :ARG3 (f3 / fraction :mod 26))
      :op3 (e4 / elute-00
            :ARG1 (p9 / peptide
                  :part (a6 / amino-acid :mod 401 :name (n5 / name :op1 "threonine")
                        :ARG3-of (p8 / phosphorylate-01)))
            :ARG3 (f4 / fraction
                  :mod (b2 / between :op1 58 :op2 59))))

# ::id bio.mskcc_0001.15 ::date 2014-11-16T17:31:43 ::annotator ISI-AMR-01 ::preferred
# ::snt All four of these identified sites are followed by a proline residue, and their phosphorylation could be blocked by pretreating cells with the MEK inhibitor U0126 (Fig. 2A), suggesting that these residues are feedback targets of the proline-directed kinase, ERK.
# ::save-date Fri Nov 21, 2014 ::file bio_mskcc_0001_15.txt
(a / and
      :op1 (f / follow-01
            :ARG1 (r / residue
                  :mod (a3 / amino-acid :name (n / name :op1 "proline")))
            :ARG2 (p / protein-segment :quant 4
                  :mod (a2 / all)
                  :mod (t / this)
                  :ARG1-of (i2 / identify-01)))
      :op2 (p2 / possible
            :domain (b / block-01
                  :ARG0 (t2 / treat-04
                        :ARG1 (c / cell)
                        :ARG2 (s / small-molecule :name (n2 / name :op1 "U0126")
                              :ARG0-of (i / inhibit-01
                                    :ARG1 (e / enzyme :name (n3 / name :op1 "MEK"))))
                        :time (b2 / before))
                  :ARG1 (p3 / phosphorylate-01
                        :ARG1 p))
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure :mod "2A")))
      :ARG0-of (s2 / suggest-01
            :ARG1 (f3 / feedback
                  :destination r
                  :source (k / kinase :name (n4 / name :op1 "ERK")
                        :ARG1-of (d2 / direct-01
                              :ARG2 p)))))

# ::id bio.mskcc_0001.16 ::date 2014-11-16T17:46:13 ::annotator ISI-AMR-01 ::preferred
# ::snt Consistent with this model, we found that when purified activated ERK was incubated with kinase-dead B-Raf(K375M) in vitro, ERK strongly phosphorylated B-Raf on the S151, S750, and T753 sites, with phosphorylation of T401 also observed (Fig. 2B).
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_16.txt
(f / find-01
      :ARG0 (w / we)
      :ARG1 (a6 / and
            :op1 (p / phosphorylate-01
                  :ARG1 (a2 / and
                        :op1 (a3 / amino-acid :mod 151 :name (n4 / name :op1 "serine")
                              :part-of e2)
                        :op2 (a4 / amino-acid :mod 750 :name (n5 / name :op1 "serine")
                              :part-of e2)
                        :op3 (a5 / amino-acid :mod 753 :name (n6 / name :op1 "threonine")
                              :part-of e2))
                  :ARG2 (e / enzyme :name (n / name :op1 "ERK")
                        :ARG1-of (a / activate-01)
                        :ARG1-of (p2 / purify-01))
                  :degree (s / strong))
            :op2 (p3 / phosphorylate-01
                  :ARG1 (a7 / amino-acid :mod 401 :name (n7 / name :op1 "threonine")
                        :part-of e2)
                  :ARG2 e
                  :ARG1-of (o / observe-01
                        :mod (a8 / also)))
            :condition (i / incubate-01
                  :ARG1 e
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "B-Raf")
                        :ARG2-of (m2 / mutate-01 :value "K375M")
                        :ARG0-of (f2 / function-01 :polarity -
                              :ARG1 (k / kinase)))
                  :manner (i2 / in-vitro))
            :ARG1-of (d / describe-01
                  :ARG0 (f3 / figure :mod "2B")))
      :ARG1-of (c / consistent-41
            :ARG2 (m / model
                  :mod (t / this))))

# ::id bio.mskcc_0001.17 ::date 2014-11-16T18:19:06 ::annotator ISI-AMR-01 ::preferred
# ::snt These findings are similar to what has been observed for C-Raf (8) and suggest that feedback phosphorylation is a conserved mechanism used to disrupt the Ras/Raf interaction.
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_17.txt
(a / and
      :op1 (r / resemble-01
            :ARG1 (t / thing
                  :ARG1-of (f / find-01)
                  :mod (t2 / this))
            :ARG2 (t3 / thing
                  :ARG1-of (o / observe-01)
                  :topic (e / enzyme :name (n / name :op1 "C-Raf")))
            :ARG1-of (d / describe-01
                  :ARG0 (p / publication
                        :ARG1-of (c / cite-01
                              :ARG2 8))))
      :op2 (s / suggest-01
            :ARG0 t
            :ARG1 (m / mechanism
                  :ARG1-of (c2 / conserve-01)
                  :ARG1-of (u / use-01
                        :ARG2 (d2 / disrupt-01
                              :ARG0 m
                              :ARG1 (i / interact-01
                                    :ARG0 (e3 / enzyme :name (n3 / name :op1 "Ras"))
                                    :ARG1 (e2 / enzyme :name (n2 / name :op1 "Raf")))))
                  :domain (p3 / phosphorylate-01
                        :subevent-of (f2 / feedback)))))

# ::id bio.mskcc_0001.18 ::date 2014-11-16T20:11:46 ::annotator ISI-AMR-01 ::preferred
# ::snt Consistent with these data, we found that B-Raf interacted with C-Raf in an inducible and transient manner following growth factor treatment (Fig. 3B and C).
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_18.txt
(f / find-01
      :ARG0 (w / we)
      :ARG1 (i / interact-01
            :ARG0 (e / enzyme :name (n / name :op1 "B-Raf"))
            :ARG1 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))
            :ARG1-of (i2 / induce-01)
            :duration (t2 / transient)
            :ARG2-of (f4 / follow-01
                  :ARG1 (t3 / treat-04
                        :ARG2 (s / small-molecule :name (n3 / name :op1 "growth" :op2 "factor")))))
      :ARG1-of (c / consistent-41
            :ARG2 (d / data
                  :mod (t / this)))
      :ARG1-of (d2 / describe-01
            :ARG0 (a2 / and
                  :op1 (f2 / figure :mod "3B")
                  :op2 (f3 / figure :mod "3C"))))

# ::id bio.mskcc_0001.19 ::date 2014-11-21T12:13:54 ::annotator ISI-AMR-01 ::preferred
# ::snt In addition, when B-Raf feedback phosphorylation was prevented, either by U0126 treatment or by mutation of all the feedback sites, an increase in the basal level of heterodimerization with C-Raf was observed, and heterodimerization in response to growth factor treatment was increased and prolonged (Fig. 3B and C).
# ::save-date Fri Nov 21, 2014 ::file bio_mskcc_0001_19.txt
(a2 / and
      :op2 (a / and
            :op1 (o / observe-01
                  :ARG1 (i / increase-01
                        :ARG1 (l / level
                              :mod (b / basal)
                              :degree-of (h / heterodimerize-00
                                    :ARG1 e
                                    :ARG2 (e2 / enzyme :name (n3 / name :op1 "C-Raf"))))))
            :op2 (i2 / increase-01
                  :ARG1 (h2 / heterodimerize-00
                        :ARG0-of (r / respond-01
                              :ARG1 (t2 / treat-04
                                    :ARG2 (s2 / small-molecule :name (n4 / name :op1 "growth" :op2 "factor"))))))
            :op3 (p / prolong-01
                  :ARG1 h2)
            :condition (p2 / prevent-01
                  :ARG0 (o2 / or
                        :op1 (t / treat-04
                              :ARG2 (s / small-molecule :name (n2 / name :op1 "U0126")))
                        :op2 (m / mutate-01
                              :ARG1 (p4 / protein-segment
                                    :part-of e
                                    :destination-of f
                                    :mod (a3 / all))))
                  :ARG1 (p3 / phosphorylate-01
                        :ARG1 (e / enzyme :name (n / name :op1 "B-Raf"))
                        :subevent-of (f / feedback)))
            :ARG1-of (d / describe-01
                  :ARG0 (a4 / and
                        :op1 (f2 / figure :mod "3B")
                        :op2 (f3 / figure :mod "3C")))))

# ::id bio.mskcc_0001.20 ::date 2014-11-21T12:36:32 ::annotator ISI-AMR-01 ::preferred
# ::snt These findings support a model whereby feedback phosphorylation disrupts Raf heterodimerization.
# ::save-date Mon Nov 24, 2014 ::file bio_mskcc_0001_20.txt
(s / support-01
      :ARG0 (t / thing
            :ARG1-of (f / find-01)
            :mod (t2 / this))
      :ARG1 (m / model
            :topic (d / disrupt-01
                  :ARG0 (p / phosphorylate-01
                        :ARG1 e
                        :subevent-of (f2 / feedback))
                  :ARG1 (h / heterodimerize-00
                        :ARG1 (e / enzyme :name (n / name :op1 "Raf"))))))

# ::id bio.mskcc_0001.21 ::date 2014-11-21T12:49:56 ::annotator ISI-AMR-01 ::preferred
# ::snt Unlike WT B-Raf, oncogenic B-Raf proteins have been shown to heterodimerize constitutively with C-Raf in a Ras-independent manner (11).
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_21.txt
(c5 / contrast-01
      :ARG1 (h / heterodimerize-00
            :ARG1 (e / enzyme :name (n / name :op1 "B-Raf")
                  :ARG0-of (c / cause-01
                        :ARG1 (c2 / cancer)))
            :ARG2 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))
            :mod (c3 / constitutive)
            :ARG0-of (d / depend-01 :polarity -
                  :ARG1 (e4 / enzyme :name (n3 / name :op1 "Ras")))
            :ARG1-of (s / show-01
                  :ARG0 (p2 / publication
                        :ARG1-of (c4 / cite-01
                              :ARG2 11))))
      :ARG2 (h2 / heterodimerize-00
            :ARG1 (e3 / enzyme :name (n4 / name :op1 "B-Raf")
                  :mod (w / wild-type))
            :ARG2 e2
            :mod (c6 / constitutive :polarity -)))

# ::id bio.mskcc_0001.22 ::date 2014-11-28T17:28:12 ::annotator ISI-AMR-01 ::preferred
# ::snt When we next examined the effect of feedback phosphorylation on the ability of oncogenic B-Raf to form heterodimers with C-Raf, we found that the levels of endogenous C-Raf associating with B-Raf proteins of high (V600E), intermediate (G466A), and impaired (D594G) kinase activities all increased when the feedback sites were mutated, indicating that feedback phosphorylation also inhibits the heterodimerization of oncogenic B-Raf proteins (Fig. 3D).
# ::save-date Wed Dec 3, 2014 ::file bio_mskcc_0001_22.txt
(f / find-01
  :ARG0 (w / we)
  :ARG1 (i / increase-01
          :ARG1 (a / and
                  :op1 (l / level
                         :quant-of (e / enzyme :name (n / name :op1 "C-Raf")
                                     :ARG1-of (a2 / associate-01
                                                :ARG2 (e2 / enzyme :name (n2 / name :op1 "B-Raf")
                                                        :ARG2-of (m / mutate-01 :value "V600E")
                                                        :ARG0-of (a3 / act-01
                                                                   :ARG1 (k / kinase)
                                                                   :degree (h / high))))
                                     :mod (e7 / endogenous)))
                  :op2 (l2 / level
                         :quant-of (e3 / enzyme :name (n3 / name :op1 "C-Raf")
                                     :ARG1-of (a5 / associate-01
                                                :ARG2 (e5 / enzyme :name (n5 / name :op1 "B-Raf")
                                                        :ARG2-of (m2 / mutate-01 :value "G466A")
                                                        :ARG0-of (a4 / act-01
                                                                   :ARG1 (k2 / kinase)
                                                                   :degree (i2 / intermediate))))
                                     :mod (e8 / endogenous)))
                  :op3 (l3 / level
                         :quant-of (e4 / enzyme :name (n4 / name :op1 "C-Raf")
                                     :ARG1-of (a6 / associate-01
                                                :ARG2 (e6 / enzyme :name (n6 / name :op1 "B-Raf")
                                                        :ARG2-of (m3 / mutate-01 :value "D594G")
                                                        :ARG0-of (a7 / act-01
                                                                   :ARG1 (k3 / kinase)
                                                                   :ARG1-of (i3 / impair-01))))
                                     :mod (e9 / endogenous))))
          :condition (m4 / mutate-01
                       :ARG1 (p / protein-segment
                               :part-of (e10 / enzyme :name (n7 / name :op1 "B-Raf"))
                               :destination-of (f2 / feedback)))
          :ARG0-of (i4 / indicate-01
                     :ARG1 (i5 / inhibit-01
                             :ARG0 p2
                             :ARG1 (h3 / heterodimerize-00
                                     :ARG1 e12
                                     :ARG2 e13)
                             :mod (a9 / also)))
          :ARG1-of (d / describe-01
                     :ARG0 (f4 / figure :mod "3D")))
  :manner (e11 / examine-01
            :ARG0 w
            :ARG1 (a8 / affect-01
                    :ARG0 (p2 / phosphorylate-01
                            :subevent-of (f3 / feedback))
                    :ARG1 (p3 / possible
                            :domain (h2 / heterodimerize-00
                                      :ARG1 (e12 / enzyme :name (n9 / name :op1 "B-Raf")
                                              :ARG0-of (c / cause-01
                                                         :ARG1 (c2 / cancer)))
                                      :ARG2 (e13 / enzyme :name (n10 / name :op1 "C-Raf")))))
            :time (n8 / next)))

# ::id bio.mskcc_0001.23 ::date 2014-11-28T18:08:23 ::annotator ISI-AMR-01 ::preferred
# ::snt Previous studies have shown that, for both normal and oncogenic B-Raf proteins to heterodimerize with C-Raf, the C-terminal 14-3-3 binding site of C-Raf (S621) must be intact (11, 27) (Fig. 3E).
# ::save-date Sat Nov 29, 2014 ::file bio_mskcc_0001_23.txt
(s / show-01
      :ARG0 (s2 / study
            :time (p / previous)
            :ARG1-of (c / cite-01
                  :ARG2 (a / and :op1 11 :op2 27)))
      :ARG1 (a2 / and
            :op1 (r / require-01
                  :ARG0 (h / heterodimerize-00
                        :ARG1 (e / enzyme :name (n / name :op1 "B-Raf")
                              :ARG0-of (c2 / cause-01
                                    :ARG1 (c3 / cancer)))
                        :ARG2 (e2 / enzyme :name (n2 / name :op1 "C-Raf")))
                  :ARG1 (i / intact
                        :domain (a3 / amino-acid :mod 621 :name (n3 / name :op1 "serine")
                              :part-of (p2 / protein-segment :name (n4 / name :op1 "C-terminus")
                                    :part-of e2)
                              :ARG1-of (b / bind-01
                                    :ARG2 (p3 / protein :name (n5 / name :op1 "14-3-3"))))))
            :op2 (r2 / require-01
                  :ARG0 (h2 / heterodimerize-00
                        :ARG1 (e3 / enzyme :name (n6 / name :op1 "B-Raf")
                              :mod (n7 / normal))
                        :ARG2 e2)
                  :ARG1 i)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "3E"))))

# ::id bio.mskcc_0001.24 ::date 2014-11-29T14:06:52 ::annotator ISI-AMR-01 ::preferred
# ::snt To determine whether binding of 14-3-3 to B-Raf is also required for heterodimerization, B-Raf proteins containing lanine substitutions in the two 14-3-3 binding sites, S365 and S729 (2), were examined for their abilities to heterodimerize with C-Raf in response to growth factor treatment.
# ::save-date Sat Nov 29, 2014 ::file bio_mskcc_0001_24.txt
(e / examine-01
      :ARG1 (p2 / possible :mode interrogative
            :domain (h / heterodimerize-00
                  :ARG1 (e2 / enzyme :name (n / name :op1 "B-Raf")
                        :part (a / amino-acid :name (n2 / name :op1 "alanine")
                              :ARG1-of (s / substitute-01
                                    :ARG3 (a2 / amino-acid :mod 365 :name (n3 / name :op1 "serine")
                                          :ARG1-of (b / bind-01
                                                :ARG2 (p / protein :name (n6 / name :op1 "14-3-3"))))))
                        :part (a3 / amino-acid :name (n4 / name :op1 "alanine")
                              :ARG1-of (s2 / substitute-01
                                    :ARG3 (a4 / amino-acid :mod 729 :name (n5 / name :op1 "serine")
                                          :ARG1-of (b2 / bind-01
                                                :ARG2 p)))))
                  :ARG2 (e3 / enzyme :name (n7 / name :op1 "C-Raf"))
                  :ARG0-of (r / respond-01
                        :ARG1 (t / treat-04
                              :ARG2 (s3 / small-molecule :name (n8 / name :op1 "growth" :op2 "factor"))))))
      :purpose (d / determine-01
            :ARG1 (r2 / require-01 :mode interrogative
                  :ARG0 (h2 / heterodimerize-00
                        :ARG1 e4
                        :ARG2 e3)
                  :ARG1 (b3 / bind-01
                        :ARG1 p
                        :ARG2 (e4 / enzyme :name (n9 / name :op1 "B-Raf")))
                  :mod (a5 / also))))

# ::id bio.mskcc_0001.25 ::date 2014-11-29T21:20:25 ::annotator ISI-AMR-01 ::preferred
# ::snt Not surprisingly, given that mutation of the S365 14-3-3 binding site enhances the membrane localization of B-Raf (2), increased heterodimerization with C-Raf was observed for S365A B-Raf compared to WT B-Raf (Fig. 3F).
# ::save-date Sat Nov 29, 2014 ::file bio_mskcc_0001_25.txt
(o / observe-01
      :ARG1 (i / increase-01
            :ARG1 (h / heterodimerize-00
                  :ARG1 (e / enzyme :name (n / name :op1 "B-Raf")
                        :ARG2-of (m / mutate-01 :value "S365A"))
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "C-Raf")))
            :compared-to (h2 / heterodimerize-00
                  :ARG1 (e3 / enzyme :name (n3 / name :op1 "B-Raf")
                        :mod (w / wild-type))
                  :ARG2 e2)
            :ARG1-of (c / cause-01
                  :ARG0 (e4 / enhance-01
                        :ARG0 (m2 / mutate-01
                              :ARG1 (a / amino-acid :mod 365 :name (n4 / name :op1 "serine")
                                    :ARG1-of (b / bind-01
                                          :ARG2 (p / protein :name (n5 / name :op1 "14-3-3")))))
                        :ARG1 (b2 / be-located-at-91
                              :ARG1 e2
                              :ARG2 (m3 / membrane))
                        :ARG1-of (d / describe-01
                              :ARG0 (p2 / publication
                                    :ARG1-of (c2 / cite-01
                                          :ARG2 2)))))
            :ARG0-of (s / surprise-01 :polarity -)
            :ARG1-of (d2 / describe-01
                  :ARG0 (f / figure :mod "3F"))))

# ::id bio.mskcc_0001.26 ::date 2014-11-29T21:32:40 ::annotator ISI-AMR-01 ::preferred
# ::snt In contrast, S729A B-Raf failed to heterodimerize with C-Raf in response to growth factor treatment, and mutation of this site disrupted the constitutive interaction of oncogenic B-Raf proteins and C-Raf (Fig. 3F), indicating that heterodimerization with C-Raf is dependent on the C-terminal S729 14-3-3 binding site of B-Raf.
# ::save-date Sat Nov 29, 2014 ::file bio_mskcc_0001_26.txt
(c / contrast-01
      :ARG2 (a / and
            :op1 (f / fail-01
                  :ARG1 (h / heterodimerize-00
                        :ARG1 (e / enzyme :name (n / name :op1 "B-Raf")
                              :ARG2-of (m / mutate-01 :value "S729A"))
                        :ARG2 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))
                        :ARG0-of (r / respond-01
                              :ARG1 (t / treat-04
                                    :ARG2 (s / small-molecule :name (n3 / name :op1 "growth" :op2 "factor"))))))
            :op2 (d / disrupt-01
                  :ARG0 m
                  :ARG1 (i / interact-01
                        :ARG0 (e3 / enzyme :name (n4 / name :op1 "B-Raf")
                              :ARG0-of (c2 / cause-01
                                    :ARG1 (c3 / cancer)))
                        :ARG1 e2
                        :mod (c4 / constitutive)))
            :ARG1-of (d2 / describe-01
                  :ARG0 (f2 / figure :mod "3F"))
            :ARG0-of (i2 / indicate-01
                  :ARG1 (d3 / depend-01
                        :ARG0 (h2 / heterodimerize-00
                              :ARG1 (e4 / enzyme :name (n5 / name :op1 "B-Raf"))
                              :ARG2 e2)
                        :ARG1 (a2 / amino-acid :mod 729 :name (n6 / name :op1 "serine")
                              :part-of (p / protein-segment :name (n7 / name :op1 "C-terminus")
                                    :part-of e4)
                              :ARG1-of (b / bind-01
                                    :ARG2 (p2 / protein :name (n8 / name :op1 "14-3-3"))))))))

# ::id bio.mskcc_0001.27 ::date 2014-11-29T21:46:39 ::annotator ISI-AMR-03 ::preferred
# ::snt Previous studies have found that all oncogenic B-Raf proteins can activate C-Raf and that heterodimerization with C-Raf is required for kinase-impaired oncogenic B-Raf proteins to mediate ERK activation in vivo (31).
# ::save-date Sun Nov 30, 2014 ::file bio_mskcc_0001_27.txt
(f / find-01
      :ARG0 (s / study
            :time (p / previous)
            :ARG1-of (c5 / cite-01
                  :ARG2 31))
      :ARG1 (a / and
            :op1 (p2 / possible
                  :domain (a2 / activate-01
                        :ARG0 (e / enzyme :name (n / name :op1 "B-Raf")
                              :ARG0-of (c / cause-01
                                    :ARG1 (c2 / cancer))
                              :mod (a5 / all))
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))))
            :op2 (r / require-01
                  :ARG0 (m / mediate-01
                        :ARG0 e3
                        :ARG1 (a4 / activate-01
                              :ARG1 (e4 / enzyme :name (n4 / name :op1 "ERK"))
                              :manner (i2 / in-vivo)))
                  :ARG1 (h / heterodimerize-00
                        :ARG1 (e3 / enzyme :name (n3 / name :op1 "B-Raf")
                              :ARG0-of (c3 / cause-01
                                    :ARG1 (c4 / cancer))
                              :ARG0-of (a3 / act-01
                                    :ARG1 (k / kinase)
                                    :ARG1-of (i / impair-01)))
                        :ARG2 e2))))

# ::id bio.mskcc_0001.28 ::date 2015-01-20T11:13:17 ::annotator SDL-AMR-09 ::preferred
# ::snt Therefore, to further investigate both the impact of feedback phosphorylation and the contribution of heterodimerization to oncogenic B-Raf function, we examined the transformation potential of oncogenic B-Raf proteins containing mutations in either the feedback phosphorylation sites (which exhibit increased heterodimerization) or the S729 14-3-3 binding site (which are unable to heterodimerize).
# ::save-date Wed Feb 4, 2015 ::file bio_mskcc_0001_28.txt
(i / infer-01
      :ARG1 (e / examine-01
            :ARG0 (w / we)
            :ARG1 (p / possible
                  :domain (t / transform-01
                        :ARG0 (e2 / enzyme :name (n / name :op1 "B-Raf")
                              :ARG0-of (c / cause-01
                                    :ARG1 (c2 / cancer))
                              :ARG2-of (m / mutate-01
                                    :ARG1 (o / or
                                          :op1 (p2 / protein-segment
                                                :ARG1-of (p3 / phosphorylate-01
                                                      :subevent-of (f / feedback))
                                                :ARG0-of (e3 / exhibit-01
                                                      :ARG1 (h / heterodimerize-00
                                                            :ARG1-of (i2 / increase-01))))
                                          :op2 (a / amino-acid :mod 729 :name (n4 / name :op1 "serine")
                                                :ARG1-of (b / bind-01
                                                      :ARG2 (p4 / protein :name (n2 / name :op1 "14-3-3")))
                                                :ARG0-of (h2 / heterodimerize-00
                                                      :mod (p5 / possible :polarity -))))))))
            :purpose (i3 / investigate-01
                  :ARG0 w
                  :ARG1 (a2 / and
                        :op1 (i4 / impact-01
                              :ARG0 (p6 / phosphorylate-01
                                    :subevent-of (f3 / feedback))
                              :ARG1 f4)
                        :op2 (c4 / contribute-01
                              :ARG0 (h3 / heterodimerize-00)
                              :ARG2 (f4 / function-01
                                    :ARG0 (e4 / enzyme :name (n3 / name :op1 "B-Raf")
                                          :ARG0-of c))))
                  :degree (f2 / further))))

# ::id bio.mskcc_0001.29 ::date 2015-01-20T12:45:00 ::annotator SDL-AMR-09 ::preferred
# ::snt For these studies, FBm or S729A mutations were incorporated into a number of oncogenic B-Raf proteins that exhibit various levels of kinase activity.
# ::save-date Mon Feb 9, 2015 ::file bio_mskcc_0001_29.txt
(i / incorporate-02
      :ARG1 (o / or
            :op1 (e3 / enzyme :name (n3 / name :op1 "B-Raf")
                  :ARG2-of (m / mutate-01)
                  :ARG1-of (h / have-part-91 :polarity -
                        :ARG2 (p / protein-segment
                              :destination-of (f / feedback))))
            :op2 (e4 / enzyme :name (n4 / name :op1 "B-Raf")
                  :ARG2-of (m2 / mutate-01 :value "S729A")))
      :ARG2 (e / enzyme :name (n / name :op1 "B-Raf")
            :ARG0-of (c / cause-01
                  :ARG1 (c2 / cancer))
            :quant (n2 / number)
            :ARG0-of (e2 / exhibit-01
                  :ARG1 (l / level
                        :mod (v / various)
                        :mod (a / act-01
                              :ARG1 (k / kinase)))))
      :purpose (s / study
            :mod (t / this)))

# ::id bio.mskcc_0001.30 ::date 2015-01-20T14:21:50 ::annotator SDL-AMR-09 ::preferred
# ::snt The proteins were then expressed in NIH 3T3 cells and examined for their abilities to alter cell morphology and induce focus formation.
# ::save-date Tue Jan 20, 2015 ::file bio_mskcc_0001_30.txt
(a / and
      :op1 (e / express-03
            :ARG2 (p / protein)
            :ARG3 (c / cell-line :name (n / name :op1 "NIH" :op2 "3T3")))
      :op2 (e2 / examine-01
            :ARG1 (p2 / possible :mode interrogative
                  :domain (a2 / and
                        :op1 (a3 / alter-01
                              :ARG0 p
                              :ARG1 (m / morphology
                                    :mod (c2 / cell)))
                        :op2 (i / induce-01
                              :ARG0 p
                              :ARG1 (f / form-01
                                    :ARG1 (f2 / focus))))))
      :time (t / then))

# ::id bio.mskcc_0001.31 ::date 2015-01-20T14:44:20 ::annotator SDL-AMR-09 ::preferred
# ::snt As shown in Fig. 4A, the FBm or S729A mutation had no effect on transformation induced by the V600E or G469A B-Raf protein, both of which possess high kinase activity.
# ::save-date Mon Feb 9, 2015 ::file bio_mskcc_0001_31.txt
(a2 / affect-01 :polarity -
      :ARG0 (o / or
            :op1 (m / mutate-01
                  :ARG1 (e / enzyme :name (n / name :op1 "B-Raf")
                        :ARG1-of (h2 / have-part-91 :polarity -
                              :ARG2 (p / protein-segment
                                    :destination-of (f2 / feedback)))))
            :op2 (m3 / mutate-01 :value "S729A"))
      :ARG1 (t / transform-01
            :ARG1-of (i / induce-01
                  :ARG0 (o2 / or
                        :op1 (e2 / enzyme :name (n2 / name :op1 "B-Raf")
                              :ARG2-of (m4 / mutate-01 :value "V600E"))
                        :op2 (e3 / enzyme :name (n3 / name :op1 "B-Raf")
                              :ARG2-of (m5 / mutate-01 :value "G469A"))
                        :ARG0-of (a / act-01
                              :ARG1 (k / kinase)
                              :mod (h / high)))))
      :ARG1-of (s / show-01
            :ARG0 (f / figure :mod "4A")))

# ::id bio.mskcc_0001.32 ::date 2015-01-20T15:12:00 ::annotator SDL-AMR-09 ::preferred
# ::snt However, mutation of the feedback sites significantly increased the transforming activities of B-Raf proteins with intermediate or impaired kinase activity (Fig. 4A).
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_32.txt
(c / contrast-01
      :ARG2 (i / increase-01
            :ARG0 (m / mutate-01
                  :ARG1 (p / protein-segment
                        :destination-of (f / feedback)))
            :ARG1 (o / or
                  :op1 (a3 / act-01
                        :ARG0 (e / enzyme :name (n / name :op1 "B-Raf"))
                        :ARG1 k
                        :degree (i3 / intermediate))
                  :op2 (a2 / act-01
                        :ARG0 (e2 / enzyme :name (n2 / name :op1 "B-Raf"))
                        :ARG1 (k / kinase)
                        :ARG1-of (i2 / impair-01))
                  :ARG0-of (t / transform-01))
            :degree (s / significant)
            :ARG1-of (d / describe-01
                  :ARG0 (f2 / figure :mod "4A"))))

# ::id bio.mskcc_0001.33 ::date 2015-01-20T22:53:13 ::annotator SDL-AMR-09 ::preferred
# ::snt The total number of foci observed and, often, the sizes of the foci were increased, and cells within the foci exhibited a more transformed appearance.
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_33.txt
(a / and
      :op1 (i / increase-01
            :ARG1 (a3 / and
                  :op1 (n / number
                        :ARG2-of (t / total-01
                              :ARG1 (f / focus
                                    :ARG1-of (o / observe-01))))
                  :op2 (s / size
                        :poss f))
            :frequency (o2 / often))
      :op3 (e / exhibit-01
            :ARG0 (c / cell
                  :location f)
            :ARG1 (a2 / appear-02
                  :ARG1 c
                  :ARG1-of (t2 / transform-01
                        :degree (m / more)))))

# ::id bio.mskcc_0001.34 ::date 2015-01-21T02:29:01 ::annotator SDL-AMR-09 ::preferred
# ::snt In contrast, the S729A mutation reduced the transforming activities of the oncogenic proteins with intermediate or impaired kinase activity, causing a reduction in focus number and a flatter cell morphology (Fig. 4A).
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_34.txt
(c / contrast-01
      :ARG2 (r / reduce-01
            :ARG0 (m / mutate-01 :value "S729A")
            :ARG1 (o2 / or
                  :op1 (a / act-01
                        :ARG0 (p / protein
                              :ARG0-of (c2 / cause-01
                                    :ARG1 (c3 / cancer)))
                        :ARG1 (k / kinase)
                        :degree (i / intermediate))
                  :op2 (a2 / act-01
                        :ARG0 (p2 / protein
                              :ARG0-of c2)
                        :ARG1 k
                        :ARG1-of (i2 / impair-01))
                  :ARG0-of (t / transform-01))
            :ARG0-of (c4 / cause-01
                  :ARG1 (a4 / and
                        :op1 (r2 / reduce-01
                              :ARG1 (n / number
                                    :quant-of (f / focus)))
                        :op2 (m2 / morphology
                              :mod (c5 / cell)
                              :mod (f2 / flat
                                    :degree (m3 / more)))))
            :ARG1-of (d / describe-01
                  :ARG0 (f3 / figure :mod "4A"))))

# ::id bio.mskcc_0001.35 ::date 2015-01-21T03:05:03 ::annotator SDL-AMR-09 ::preferred
# ::snt Examination of activated phospho-MEK levels revealed that the FBm and S729 mutations had no effect on MEK activation induced by the high-activity V600E B-Raf protein; however, the FBm and S729A mutations increased and decreased, respectively, the abilities of the intermediate G466A and kinase-impaired D594G B-Raf proteins to activate MEK (Fig. 4B), indicating a correlation between the transformation potential of these proteins and their ability to activate ERK cascade signaling in vivo.
# ::save-date Mon Feb 9, 2015 ::file bio_mskcc_0001_35.txt
(r2 / reveal-01
      :ARG0 (e / examine-01
            :ARG1 (l / level
                  :degree-of (e2 / enzyme :name (n / name :op1 "MEK")
                        :ARG3-of (p / phosphorylate-01)
                        :ARG1-of (a / activate-01))))
      :ARG1 (c / contrast-01
            :ARG1 (a2 / affect-01 :polarity -
                  :ARG0 (a3 / and
                        :op1 (m7 / mutate-01
                              :ARG1 (e9 / enzyme :name (n2 / name :op1 "B-Raf")
                                    :ARG1-of (h2 / have-part-91 :polarity -
                                          :ARG2 (p5 / protein-segment
                                                :destination-of (f2 / feedback)))))
                        :op2 (m / mutate-01
                              :ARG1 (a11 / amino-acid :mod 729 :name (n9 / name :op1 "serine"))))
                  :ARG1 (a4 / activate-01
                        :ARG1 (e3 / enzyme :name (n3 / name :op1 "MEK"))
                        :ARG1-of (i / induce-01
                              :ARG0 (e4 / enzyme :name (n4 / name :op1 "B-Raf")
                                    :ARG2-of (m3 / mutate-01 :value "V600E")
                                    :ARG0-of (a5 / act-02
                                          :degree (h / high))))))
            :ARG2 (a6 / and
                  :op1 (i2 / increase-01
                        :ARG0 (a7 / and
                              :op1 m7
                              :op2 (m4 / mutate-01 :value "S729A"))
                        :ARG1 (p2 / possible
                              :domain (a8 / activate-01
                                    :ARG0 (a9 / and
                                          :op1 (e5 / enzyme :name (n5 / name :op1 "B-Raf")
                                                :ARG2-of (m5 / mutate-01 :value "G466A"
                                                      :degree (i3 / intermediate)))
                                          :op2 (e6 / enzyme :name (n6 / name :op1 "B-Raf")
                                                :ARG2-of (m6 / mutate-01 :value "D594G")
                                                :mod (i4 / impair-01
                                                      :ARG1 (k / kinase))))
                                    :ARG1 e3)))
                  :op2 (d / decrease-01
                        :ARG0 a7)
                  :mod (r / respective)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f / figure :mod "4B"))
                  :ARG0-of (i5 / indicate-01
                        :ARG1 (c2 / correlate-01
                              :ARG1 (p3 / possible
                                    :domain (t / transform-01
                                          :ARG0 a9))
                              :ARG2 (p4 / possible
                                    :domain (a10 / activate-01
                                          :ARG0 a9
                                          :ARG1 (s / signal-01
                                                :ARG0 (e8 / enzyme :name (n8 / name :op1 "ERK"))
                                                :manner (i6 / in-vivo)
                                                :subevent-of (c3 / cascade)))))))))

# ::id bio.mskcc_0001.36 ::date 2015-01-21T05:10:00 ::annotator SDL-AMR-09 ::preferred
# ::snt Not unexpectedly, for all of the oncogenic B-Raf proteins, the S729A mutation, which disrupts heterodimerization with C-Raf, caused a >90% decrease in C-Raf activity levels (Fig. 5B).
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_36.txt
(c / cause-01
      :ARG0 (m / mutate-01 :value "S729A"
            :ARG2 (e / enzyme :name (n / name :op1 "B-Raf")
                  :mod (a / all)
                  :ARG0-of (c2 / cause-01
                        :ARG1 (c3 / cancer)))
            :ARG0-of (d / disrupt-01
                  :ARG1 (h / heterodimerize-00
                        :ARG1 e
                        :ARG2 (e2 / enzyme :name (n2 / name :op1 "C-Raf")))))
      :ARG1 (d2 / decrease-01
            :ARG1 (l / level
                  :mod (a2 / act-02
                        :ARG0 e2))
            :ARG2 (m2 / more-than
                  :op1 (p / percentage-entity :value 90)))
      :ARG1-of (e3 / expect-01)
      :ARG1-of (d3 / describe-01
            :ARG0 (f / figure :mod "5B")))

# ::id bio.mskcc_0001.37 ::date 2015-01-21T07:29:54 ::annotator SDL-AMR-09 ::preferred
# ::snt Together, these findings indicate a correlation between the changes in the transformation potentials of the intermediate and impaired oncogenic B-Raf proteins and their abilities to heterodimerize and activate C-Raf.
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_37.txt
(i / indicate-01
      :ARG0 (t / thing
            :ARG1-of (f / find-01)
            :mod (t2 / this))
      :ARG1 (c / correlate-01
            :ARG1 (c2 / change-01
                  :ARG1 (p / possible
                        :domain (t4 / transform-01
                              :ARG0 (a / and
                                    :op1 (e / enzyme :name (n / name :op1 "B-Raf")
                                          :mod (i2 / intermediate)
                                          :ARG0-of (c3 / cause-01
                                                :ARG1 (c4 / cancer)))
                                    :op2 (e2 / enzyme :name (n2 / name :op1 "B-Raf")
                                          :ARG1-of (i3 / impair-01))))))
            :ARG2 (c5 / capable-41
                  :ARG1 a
                  :ARG2 (a2 / and
                        :op1 (h / heterodimerize-00
                              :ARG1 a
                              :ARG2 (e3 / enzyme :name (n3 / name :op1 "C-Raf")))
                        :op2 (a3 / activate-01
                              :ARG0 a
                              :ARG1 e3))))
      :mod (t3 / together))

# ::id bio.mskcc_0001.38 ::date 2015-01-21T09:11:56 ::annotator SDL-AMR-09 ::preferred
# ::snt To investigate the contributions of the various feedback sites to the overall effect of feedback phosphorylation on B-Raf function, we generated a panel of mutants in which specific feedback phosphorylation sites were incorporated into either WT B-Raf or the intermediate-activity G466A B-Raf protein.
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_38.txt
(g / generate-01
      :ARG0 (w / we)
      :ARG1 (p / panel
            :consist-of (e / enzyme :name (n / name :op1 "B-Raf")
                  :ARG2-of (m / mutate-01
                        :ARG1-of (c2 / cause-01
                              :ARG0 (i / incorporate-02
                                    :ARG1 (p2 / protein-segment
                                          :part-of e
                                          :ARG1-of (p3 / phosphorylate-01
                                                :subevent-of (f / feedback)
                                                :mod (s / specific)))
                                    :ARG2 (o / or
                                          :op1 (e2 / enzyme :name (n2 / name :op1 "B-Raf")
                                                :mod (w2 / wild-type))
                                          :op2 (e3 / enzyme :name (n3 / name :op1 "B-Raf")
                                                :ARG2-of (m2 / mutate-01 :value "G466A")
                                                :ARG0-of (a / act-01
                                                      :degree (i2 / intermediate)))))))))
      :purpose (i3 / investigate-01
            :ARG0 w
            :ARG1 (t / thing
                  :ARG1-of (c / contribute-01
                        :ARG0 (p4 / protein-segment
                              :mod (v / various)
                              :destination-of f)
                        :ARG2 (a2 / affect-01
                              :ARG0 p3
                              :ARG1 (f2 / function-01
                                    :ARG0 (e4 / enzyme :name (n4 / name :op1 "B-Raf")))
                              :mod (o2 / overall))))))

# ::id bio.mskcc_0001.39 ::date 2015-01-21T12:14:33 ::annotator SDL-AMR-09 ::preferred
# ::snt The mutant proteins were then examined for their abilities to heterodimerize with C-Raf and to bind activated Ras under conditions where feedback phosphorylation was induced (in cycling cells for the G466A mutants and in cells treated with PDGF for 30 min for the WT B-Raf mutants).
# ::save-date Thu Mar 12, 2015 ::file bio_mskcc_0001_39.txt
(e / examine-01
      :ARG1 (p2 / possible :mode interrogative
            :domain (a / and
                  :op1 (h / heterodimerize-00
                        :ARG1 (p / protein
                              :ARG2-of (m / mutate-01)
                              :ARG1-of (m2 / mean-01
                                    :ARG2 (a3 / and
                                          :op1 (e4 / enzyme :name (n3 / name :op1 "B-Raf")
                                                :ARG2-of (m3 / mutate-01 :value "G466A")
                                                :location (c / cell
                                                      :mod (c2 / cycle)))
                                          :op2 (e5 / enzyme :name (n4 / name :op1 "B-Raf")
                                                :ARG2-of m
                                                :mod (w / wild-type)
                                                :location (c3 / cell
                                                      :ARG1-of (t2 / treat-04
                                                            :ARG2 (s / small-molecule :name (n5 / name :op1 "PDGF"))
                                                            :duration (t3 / temporal-quantity :quant 30
                                                                  :unit (m4 / minute))))))))
                        :ARG2 (e2 / enzyme :name (n / name :op1 "C-Raf")))
                  :op2 (b / bind-01
                        :ARG1 (e3 / enzyme :name (n2 / name :op1 "Ras")
                              :ARG1-of (a2 / activate-01)))
                  :condition (i / induce-01
                        :ARG1 (p3 / phosphorylate-01
                              :subevent-of (f / feedback)))))
      :time (t / then))

# ::id bio.mskcc_0001.40 ::date 2015-01-21T13:09:21 ::annotator SDL-AMR-09 ::preferred
# ::snt As shown in Fig. 6A, only mutation of the S151 feedback site, which is in close proximity to the Ras binding domain (residues 155 to 227), was found to significantly increase binding to activated Ras.
# ::save-date Thu Mar 12, 2015 ::file bio_mskcc_0001_40.txt
(f / find-01
      :ARG1 (i / increase-01
            :ARG0 (m / mutate-01
                  :ARG1 (a / amino-acid :mod 151 :name (n / name :op1 "serine")
                        :part-of (p / protein-segment
                              :destination-of (f2 / feedback)
                              :ARG1-of (c / close-41
                                    :ARG2 (d / domain
                                          :ARG2-of (b / bind-01
                                                :ARG1 (e / enzyme :name (n2 / name :op1 "Ras")))
                                          :ARG1-of (m2 / mean-01
                                                :ARG2 (b2 / between
                                                      :op1 (r / residue
                                                            :mod (a3 / amino-acid :value 155))
                                                      :op2 (r2 / residue
                                                            :mod (a4 / amino-acid :value 227))))))))
                  :mod (o / only))
            :ARG1 (b3 / bind-01
                  :ARG2 (e4 / enzyme :name (n5 / name :op1 "Ras")
                        :ARG1-of (a2 / activate-01)))
            :degree (s / significant))
      :ARG1-of (s2 / show-01
            :ARG0 (f3 / figure :mod "6A")))

# ::id bio.mskcc_0001.41 ::date 2015-01-21T14:06:45 ::annotator SDL-AMR-09 ::preferred
# ::snt In contrast, mutation of S151A, T401A, and S750A T753A were all found to increase C-Raf binding (Fig. 6A), a finding consistent with peptide studies suggesting that there are multiple points of contact between heterodimerized B- and C-Raf proteins (27).
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_41.txt
(c / contrast-01
      :ARG2 (f / find-01
            :ARG1 (i / increase-01
                  :ARG0 (a / and
                        :op1 (m / mutate-01 :value "S151A")
                        :op2 (m2 / mutate-01 :value "T401A")
                        :op3 (m3 / mutate-01 :value "S750A")
                        :op4 (m4 / mutate-01 :value "T753A"))
                  :ARG1 (b / bind-01
                        :ARG1 (e / enzyme :name (n5 / name :op1 "C-Raf")))
                  :ARG1-of (d / describe-01
                        :ARG0 (f2 / figure :mod "6A")))
            :ARG1-of (c2 / consistent-41
                  :ARG2 (s / study-01
                        :ARG1 (p / peptide)
                        :ARG0-of (s2 / suggest-01
                              :ARG1 (c3 / contact-01
                                    :ARG0 (e2 / enzyme :name (n6 / name :op1 "B-Raf")
                                          :ARG2-of (h / heterodimerize-00))
                                    :ARG1 (e3 / enzyme :name (n7 / name :op1 "C-Raf")
                                          :ARG2-of h)
                                    :quant (m5 / multiple)))
                        :ARG1-of (d2 / describe-01
                              :ARG0 (p2 / publication
                                    :ARG1-of (c4 / cite-01
                                          :ARG2 27)))))))

# ::id bio.mskcc_0001.42 ::date 2015-01-21T14:42:13 ::annotator SDL-AMR-09 ::preferred
# ::snt Interestingly, when the S729A mutation was introduced into the FBm mutant, binding to C-Raf was abolished (Fig. 6A), indicating that the increased heterodimerization observed when the feedback sites are mutated is still dependent on 14-3-3 binding.
# ::save-date Mon Feb 9, 2015 ::file bio_mskcc_0001_42.txt
(a / abolish-01
      :ARG1 (b / bind-01
            :ARG2 (e / enzyme :name (n / name :op1 "C-Raf")))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6A"))
      :time (i / introduce-02
            :ARG1 (m / mutate-01 :value "S729A")
            :ARG2 (e2 / enzyme :name (n3 / name :op1 "B-Raf")
                  :ARG2-of (m2 / mutate-01)
                  :ARG1-of (h2 / have-part-91 :polarity -
                        :ARG2 (p / protein-segment
                              :destination-of (f3 / feedback)))))
      :manner (i2 / interesting)
      :ARG0-of (i3 / indicate-01
            :ARG1 (d2 / depend-01
                  :ARG0 (h / heterodimerize-00
                        :ARG1-of (i4 / increase-01)
                        :ARG1-of (o / observe-01
                              :time (m3 / mutate-01
                                    :ARG1 (p2 / protein-segment
                                          :destination-of (f2 / feedback)))))
                  :ARG1 (b2 / bind-01
                        :ARG2 (p3 / protein :name (n4 / name :op1 "14-3-3")))
                  :mod (s / still))))

# ::id bio.mskcc_0001.43 ::date 2014-11-21T12:50:26 ::annotator ISI-AMR-01 ::preferred
# ::snt Given that oncogenic B-Raf proteins are targets of feedback phosphorylation, we next examined whether they might also be dephosphorylated and recycled in a manner involving the PP2A phosphatase and the Pin1 prolyl-isomerase.
# ::save-date Mon Nov 24, 2014 ::file bio_mskcc_0001_43.txt
(e / examine-01
      :ARG0 (w / we)
      :ARG1 (p2 / possible :mode interrogative
            :domain (a / and
                  :op1 (d / dephosphorylate-01
                        :ARG1 e2)
                  :op2 (r / recycle-01
                        :ARG1 e2)
                  :mod (a2 / also)
                  :manner (i / involve-01
                        :ARG1 (a3 / and
                              :op1 (p4 / phosphatase :name (n2 / name :op1 "PP2A"))
                              :op2 (p3 / prolyl-isomerase :name (n3 / name :op1 "Pin1")))
                        :ARG2 a)))
      :ARG1-of (c / cause-01
            :ARG0 (t / target-01
                  :ARG0 (p / phosphorylate-01
                        :subevent-of (f / feedback))
                  :ARG1 (e2 / enzyme :name (n / name :op1 "B-Raf")
                        :ARG0-of (c2 / cause-01
                              :ARG1 (c3 / cancer)))))
      :time (n4 / next))

# ::id bio.mskcc_0001.44 ::date 2014-11-21T13:03:30 ::annotator ISI-AMR-01 ::preferred
# ::snt As indicated in Fig. 7A, when PP2A was inhibited with okadaic acid treatment, slower-migrating forms of the V600E, G466A, and D594G B-Raf proteins were found to accumulate.
# ::save-date Mon Nov 24, 2014 ::file bio_mskcc_0001_44.txt
(f / find-01
      :ARG1 (a / accumulate-01
            :ARG1 (a2 / and
                  :op1 (e2 / enzyme :name (n / name :op1 "B-Raf")
                        :ARG2-of (m / mutate-01 :value "V600E"))
                  :op2 (e3 / enzyme :name (n4 / name :op1 "B-Raf")
                        :ARG2-of (m4 / mutate-01 :value "G466A"))
                  :op3 (e4 / enzyme :name (n5 / name :op1 "B-Raf")
                        :ARG2-of (m5 / mutate-01 :value "D594G"))
                  :ARG0-of (m2 / migrate-01
                        :manner (s / slow
                              :degree (m3 / more))))
            :condition (i / inhibit-01
                  :ARG1 (e / enzyme :name (n3 / name :op1 "PP2A"))
                  :instrument (t / treat-04
                        :ARG2 (s2 / small-molecule :name (n2 / name :op1 "okadaic" :op2 "acid")))))
      :ARG1-of (i2 / indicate-01
            :ARG0 (f2 / figure :mod "7A")))

# ::id bio.mskcc_0001.45 ::date 2014-11-21T13:16:55 ::annotator ISI-AMR-01 ::preferred
# ::snt Moreover, given their constitutive phosphorylation on S/TP sites (Fig. 3D), these oncogenic B-Raf mutants were found to interact constitutively with Pin1 (Fig. 7B), indicating that oncogenic B-Raf proteins are dephosphorylated and recycled.
# ::save-date Mon Nov 24, 2014 ::file bio_mskcc_0001_45.txt
(a / and
      :op2 (f / find-01
            :ARG1 (i / interact-01
                  :ARG0 (e / enzyme :name (n / name :op1 "B-Raf")
                        :ARG2-of (m / mutate-01)
                        :ARG0-of (c3 / cause-01
                              :ARG1 (c4 / cancer))
                        :mod (t / this))
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "Pin1"))
                  :mod (c5 / constitutive)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (f3 / figure :mod "7B"))
                  :ARG0-of (i2 / indicate-01
                        :ARG1 (a2 / and
                              :op1 (d3 / dephosphorylate-01
                                    :ARG1 e)
                              :op2 (r / recycle-01
                                    :ARG1 e)))
                  :ARG1-of (c / cause-01
                        :ARG0 (p / phosphorylate-01
                              :ARG2 (p2 / protein-segment :value "S/TP"
                                    :part-of e)
                              :mod (c2 / constitutive)
                              :ARG1-of (d / describe-01
                                    :ARG0 (f2 / figure :mod "3D")))))))

# ::id bio.mskcc_0001.46 ::date 2014-11-21T15:05:26 ::annotator ISI-AMR-01 ::preferred
# ::snt Consistent with the model that Pin1 influences B-Raf signaling by facilitating the dephosphorylation of the feedback sites, overexpression of the Pin1 proteins had no effect on the transformation potential of G466A FBm-B-Raf, which lacks the sites of feedback phosphorylation.
# ::save-date Wed Dec 10, 2014 ::file bio_mskcc_0001_46.txt
(a / affect-01 :polarity -
      :ARG0 (e / express-03
            :ARG2 (e2 / enzyme :name (n / name :op1 "Pin1"))
            :degree (t / too))
      :ARG1 (p / possible
            :domain (t2 / transform-01
                  :ARG0 (e3 / enzyme :name (n2 / name :op1 "B-Raf")
                        :ARG1-of (m / mutate-01 :value "G466A")
                        :ARG1-of (h / have-part-91 :polarity -
                              :ARG2 (p2 / protein-segment
                                    :ARG1-of (p3 / phosphorylate-01
                                          :subevent (f / feedback)))))))
      :ARG1-of (c / consistent-41
            :ARG2 (m2 / model
                  :topic (i / influence-01
                        :ARG0 (e4 / enzyme :name (n3 / name :op1 "Pin1"))
                        :ARG1 (s / signal-01
                              :ARG0 (e5 / enzyme :name (n4 / name :op1 "B-Raf")))
                        :manner (f2 / facilitate-01
                              :ARG0 e4
                              :ARG1 (d / dephosphorylate-01
                                    :ARG1 (p4 / protein-segment
                                          :part-of e5
                                          :destination-of (f3 / feedback))))))))

# ::id bio.mskcc_0001.47 ::date 2014-11-22T17:41:50 ::annotator ISI-AMR-01 ::preferred
# ::snt Previous studies have found that both the C-Raf and B-Raf proteins are targets of ERK-dependent feedback phosphorylation
# ::save-date Sat Nov 22, 2014 ::file bio_mskcc_0001_47.txt
(f / find-01
      :ARG0 (s / study
            :time (p / previous))
      :ARG1 (t / target-01
            :ARG0 (p2 / phosphorylate-01
                  :subevent-of (f2 / feedback)
                  :ARG0-of (d / depend-01
                        :ARG1 (e / enzyme :name (n / name :op1 "ERK"))))
            :ARG1 (a / and
                  :op1 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))
                  :op2 (e3 / enzyme :name (n3 / name :op1 "B-Raf")))))

# ::id bio.mskcc_0001.48 ::date 2014-11-22T19:04:35 ::annotator ISI-AMR-01 ::preferred
# ::snt In the case of C-Raf, six sites of feedback phosphorylation have been identified, five of which are direct targets of activated ERK (8)
# ::save-date Mon Nov 24, 2014 ::file bio_mskcc_0001_48.txt
(i / identify-01
      :ARG1 (p / protein-segment :quant 6
            :part-of (e / enzyme :name (n / name :op1 "C-Raf"))
            :ARG1-of (p2 / phosphorylate-01
                  :subevent-of (f / feedback))
            :ARG2-of (i2 / include-91
                  :ARG1 (p3 / protein-segment :quant 5
                        :ARG1-of (t / target-01
                              :ARG0 (e2 / enzyme :name (n2 / name :op1 "ERK")
                                    :ARG1-of (a / activate-01))
                              :manner (d / direct)))))
      :ARG1-of (d2 / describe-01
            :ARG0 (p4 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 8))))

# ::id bio.mskcc_0001.49 ::date 2014-11-22T19:09:15 ::annotator ISI-AMR-01 ::preferred
# ::snt For B-Raf, previous work by Brummer et al. (3) identified the C-terminal S750 and T753 residues as sites phosphorylated by activated ERK.
# ::save-date Tue Nov 25, 2014 ::file bio_mskcc_0001_49.txt
(i / identify-01
      :ARG0 (p / publication
            :ARG1-of (w / work-01
                  :ARG0 (a / and
                        :op1 (p2 / person :name (n / name :op1 "Brummer"))
                        :op2 (p3 / person
                              :mod (o / other)))
                  :time (p6 / previous))
            :ARG1-of (c / cite-01
                  :ARG2 3))
      :ARG1 (a2 / and
            :op1 (r / residue
                  :mod (a3 / amino-acid :mod 750 :name (n2 / name :op1 "serine"))
                  :part-of (p4 / protein-segment :name (n4 / name :op1 "C-terminus")
                        :part-of (e2 / enzyme :name (n6 / name :op1 "B-Raf"))))
            :op2 (r2 / residue
                  :mod (a4 / amino-acid :mod 753 :name (n3 / name :op1 "threonine"))
                  :part-of p4))
      :ARG2 (p5 / phosphorylate-01
            :ARG1 a2
            :ARG2 (e / enzyme :name (n5 / name :op1 "ERK")
                  :ARG1-of (a5 / activate-01))))

# ::id bio.mskcc_0001.50 ::date 2014-11-22T19:21:02 ::annotator ISI-AMR-01 ::preferred
# ::snt Through metabolic labeling experiments, we find here that in addition to the S750 and T753 sites, B-Raf is feedback phosphorylated on two other sites, S151 and T401.
# ::save-date Wed Nov 26, 2014 ::file bio_mskcc_0001_50.txt
(f / find-01
      :ARG0 (w / we)
      :ARG1 (p / phosphorylate-01
            :ARG1 (a / and
                  :op1 (a2 / amino-acid :mod 750 :name (n / name :op1 "serine"))
                  :op2 (a3 / amino-acid :mod 753 :name (n2 / name :op1 "threonine"))
                  :op3 (a4 / amino-acid :mod 151 :name (n3 / name :op1 "serine"))
                  :op4 (a5 / amino-acid :mod 401 :name (n4 / name :op1 "threonine"))
                  :part-of (e2 / enzyme :name (n5 / name :op1 "B-Raf")))
            :subevent-of (f2 / feedback))
      :medium (h / here)
      :manner (e / experiment-01
            :ARG2 (l / label-01
                  :mod (m / metabolism))))

# ::id bio.mskcc_0001.51 ::date 2014-11-22T19:29:50 ::annotator ISI-AMR-01 ::preferred
# ::snt These residues are phosphorylated by activated ERK in vitro,
# ::save-date Sat Nov 22, 2014 ::file bio_mskcc_0001_51.txt
(p / phosphorylate-01
      :ARG1 (r / residue
            :mod (t / this))
      :ARG2 (e / enzyme :name (n / name :op1 "ERK")
            :ARG1-of (a / activate-01))
      :manner (i / in-vitro))

# ::id bio.mskcc_0001.52 ::date 2014-11-22T19:31:23 ::annotator ISI-AMR-01 ::preferred
# ::snt As has been observed for C-Raf, we find that the hyperphosphorylated B-Raf protein is subsequently dephosphorylated in a manner requiring the activities of the PP2A phosphatase and Pin1 prolyl-isomerase, indicating that the feedback phosphorylation/dephosphorylation cycle is a conserved regulatory mechanism for the Raf proteins.
# ::save-date Wed Nov 26, 2014 ::file bio_mskcc_0001_52.txt
(f / find-01
      :ARG0 (w / we)
      :ARG1 (d / dephosphorylate-01
            :ARG1 (e / enzyme :name (n / name :op1 "B-Raf")
                  :ARG3-of (h / hyperphosphorylate-00))
            :ARG1-of (r / resemble-01
                  :ARG2 (d2 / dephosphorylate-01
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "C-Raf")
                              :ARG3-of (h2 / hyperphosphorylate-00))
                        :ARG1-of (o / observe-01)))
            :manner (r2 / require-01
                  :ARG0 d
                  :ARG1 (a2 / and
                        :op1 (a / act-02
                              :ARG0 (p / phosphatase :name (n3 / name :op1 "PP2A")))
                        :op2 (a4 / act-02
                              :ARG0 (p2 / prolyl-isomerase :name (n4 / name :op1 "Pin1")))))
            :ARG0-of (i / indicate-01
                  :ARG1 (m / mechanism
                        :ARG0-of (r3 / regulate-01
                              :ARG1 (e3 / enzyme :name (n5 / name :op1 "Raf")))
                        :ARG1-of (c / conserve-01)
                        :domain (c2 / cycle
                              :subevent (p3 / phosphorylate-01)
                              :subevent (d3 / dephosphorylate-01)
                              :mod (f3 / feedback))))
            :time (a3 / after
                  :op1 h)))

# ::id bio.mskcc_0001.53 ::date 2015-01-21T14:48:03 ::annotator SDL-AMR-09 ::preferred
# ::snt Through mutational analysis, we find that feedback phosphorylation disrupts the abilities of B-Raf to bind activated Ras and to heterodimerize with C-Raf.
# ::save-date Wed Jan 21, 2015 ::file bio_mskcc_0001_53.txt
(f / find-01
      :ARG0 (w / we)
      :ARG1 (d / disrupt-01
            :ARG0 (p / phosphorylate-01
                  :subevent-of (f2 / feedback))
            :ARG1 (c / capable-41
                  :ARG1 (e / enzyme :name (n / name :op1 "B-Raf"))
                  :ARG2 (a2 / and
                        :op1 (b / bind-01
                              :ARG1 e
                              :ARG2 (e2 / enzyme :name (n2 / name :op1 "Ras")
                                    :ARG1-of (a / activate-01)))
                        :op2 (h / heterodimerize-00
                              :ARG1 e
                              :ARG2 (e3 / enzyme :name (n3 / name :op1 "C-Raf"))))))
      :manner (a3 / analyze-01
            :ARG0 w
            :ARG1 (m / mutate-01)))

# ::id bio.mskcc_0001.54 ::date 2015-01-21T15:23:22 ::annotator SDL-AMR-09 ::preferred
# ::snt Although phosphorylation of the S151 site appears to have the greatest effect on Ras binding, our results indicate that phosphorylation of all the feedback sites contributes to the inhibition of C-Raf binding.
# ::save-date Thu Feb 5, 2015 ::file bio_mskcc_0001_54.txt
(i / indicate-01
      :ARG0 (t / thing
            :ARG2-of (r / result-01)
            :poss (w / we))
      :ARG1 (c / contribute-01
            :ARG0 (p / phosphorylate-01
                  :ARG1 (p2 / protein-segment
                        :mod (a / all)
                        :destination-of (f / feedback)))
            :ARG2 (i2 / inhibit-01
                  :ARG1 (b / bind-01
                        :ARG2 (e / enzyme :name (n / name :op1 "C-Raf")))))
      :concession (a2 / appear-02
            :ARG1 (a3 / affect-01
                  :ARG0 (p3 / phosphorylate-01
                        :ARG1 (a4 / amino-acid :mod 151 :name (n2 / name :op1 "serine")))
                  :ARG1 (b2 / bind-01
                        :ARG2 (e2 / enzyme :name (n3 / name :op1 "Ras")))
                  :mod (g / great
                        :degree (m / most)))))

# ::id bio.mskcc_0001.55 ::date 2015-01-21T15:38:56 ::annotator SDL-AMR-09 ::preferred
# ::snt This finding is consistent with those of peptide binding studies conducted by Rushworth et al. (27) indicating that there are multiple points of contact between heterodimerized B-Raf and C-Raf proteins.
# ::save-date Wed Jan 21, 2015 ::file bio_mskcc_0001_55.txt
(c / consistent-41
      :ARG1 (t / thing
            :mod (t2 / this)
            :ARG1-of (f / find-01)
            :ARG0-of (i / indicate-01
                  :ARG1 (c4 / contact-01
                        :ARG0 (e / enzyme :name (n2 / name :op1 "B-Raf")
                              :ARG1-of (h / heterodimerize-00))
                        :ARG1 (e2 / enzyme :name (n3 / name :op1 "C-Raf")
                              :ARG1-of h)
                        :quant (m / multiple))))
      :ARG2 (t3 / thing
            :ARG1-of (f2 / find-01
                  :ARG0 (s / study-01
                        :ARG1 (b / bind-01
                              :ARG1 (p / peptide))
                        :ARG1-of (c2 / conduct-01
                              :ARG0 (a / and
                                    :op1 (p2 / person :name (n / name :op1 "Rushworth"))
                                    :op2 (p3 / person
                                          :mod (o / other))))))
            :ARG1-of (d / describe-01
                  :ARG0 (p4 / publication
                        :ARG1-of (c3 / cite-01
                              :ARG2 27)))))

# ::id bio.mskcc_0001.56 ::date 2015-01-21T15:50:56 ::annotator SDL-AMR-09 ::preferred
# ::snt Interestingly, these peptide binding studies also indicate that homodimerized B-Raf and C-Raf proteins have multiple contact points (27), suggesting that feedback phosphorylation of the Raf proteins may disrupt Raf homodimers as well
# ::save-date Wed Jan 21, 2015 ::file bio_mskcc_0001_56.txt
(i / indicate-01
      :ARG0 (s / study-01
            :ARG1 (b / bind-01
                  :ARG1 (p / peptide))
            :mod (t / this))
      :ARG1 (c / contact-01
            :ARG0 (a2 / and
                  :op1 (e / enzyme :name (n / name :op1 "B-Raf"))
                  :op2 (e2 / enzyme :name (n2 / name :op1 "C-Raf"))
                  :ARG1-of (h / homodimerize-00))
            :quant (m / multiple))
      :manner (i2 / interesting)
      :mod (a / also)
      :ARG1-of (d / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 27)))
      :ARG0-of (s2 / suggest-01
            :ARG1 (p3 / possible
                  :domain (d2 / disrupt-01
                        :ARG0 (p4 / phosphorylate-01
                              :ARG1 (e3 / enzyme :name (n3 / name :op1 "Raf"))
                              :subevent-of (f / feedback))
                        :ARG1 (h2 / homodimer
                              :part e3)
                        :mod (a3 / as-well)))))

# ::id bio.mskcc_0001.57 ::date 2014-11-24T15:21:00 ::annotator ISI-AMR-01 ::preferred
# ::snt Taken together, these findings suggest a model whereby the binding of a 14-3-3 dimer to the C-terminal pS621 site of C-Raf and the C-terminal pS729 site of B-Raf provides the stable docking event that then allows the two proteins to make additional contacts (Fig. 9).
# ::save-date Wed Nov 26, 2014 ::file bio_mskcc_0001_57.txt
(s / suggest-01
      :ARG0 (t / thing
            :ARG1-of (f / find-01)
            :mod (t2 / this)
            :ARG1-of (t3 / take-01
                  :mod (t4 / together)))
      :ARG1 (m / model
            :topic (p / provide-01
                  :ARG0 (a / and
                        :op1 (b / bind-01
                              :ARG1 (d / dimer :name (n / name :op1 "14-3-3"))
                              :ARG2 (a2 / amino-acid :mod 621 :name (n2 / name :op1 "serine")
                                    :ARG3-of (p2 / phosphorylate-01)
                                    :part-of (p3 / protein-segment :name (n3 / name :op1 "C-terminus")
                                          :part-of (e / enzyme :name (n4 / name :op1 "C-Raf")))))
                        :op2 (b3 / bind-01
                              :ARG1 d
                              :ARG2 (a3 / amino-acid :mod 729 :name (n5 / name :op1 "serine")
                                    :ARG3-of (p4 / phosphorylate-01)
                                    :part-of (p5 / protein-segment :name (n6 / name :op1 "C-terminus")
                                          :part-of (e2 / enzyme :name (n7 / name :op1 "B-Raf"))))))
                  :ARG1 (d2 / dock-01
                        :ARG0-of (a4 / allow-01
                              :ARG1 (c / contact-01
                                    :ARG0 e
                                    :ARG1 e2
                                    :mod (a5 / additional)
                                    :time (a6 / after
                                          :op1 a)))
                        :mod (s2 / stable)))))

# ::id bio.ras_0001.1 ::date 2014-08-13T14:22:25 ::annotator ISI-AMR-01 ::preferred
# ::snt The most frequently mutated oncogenes in the deadliest cancers responsible for human mortality are KRAS , PIK3CA and BRAF .
# ::save-date Wed Aug 13, 2014 ::file bio_ras_0001_1.txt
(o / oncogene
      :domain (a / and
            :op1 (g / gene :name (n / name :op1 "KRAS"))
            :op2 (g2 / gene :name (n2 / name :op1 "PIK3CA"))
            :op3 (g3 / gene :name (n3 / name :op1 "BRAF")))
      :location (c / cancer
            :ARG0-of (k / kill-01
                  :ARG1 (h / human)
                  :degree (m / most)))
      :ARG1-of (m2 / mutate-01
            :frequency (f / frequent
                  :degree (m3 / most))))

# ::id bio.ras_0001.2 ::date 2014-08-13T16:12:45 ::annotator ISI-AMR-01 ::preferred
# ::snt Importantly the signaling enzymes encoded by PIK3CA and BRAF are , in part , regulated by direct binding to activated forms of the Ras proteins suggesting that dysregulation of this key step in signaling is critical for tumor formation .
# ::save-date Wed Dec 10, 2014 ::file bio_ras_0001_2.txt
(r / regulate-01
      :ARG0 (b / bind-01
            :ARG1 e
            :ARG2 (m / macro-molecular-complex
                  :part (e3 / enzyme :name (n3 / name :op1 "Ras")
                        :ARG1-of (a2 / activate-01)))
            :manner (d / direct))
      :ARG1 (e / enzyme
            :ARG0-of (s / signal-01)
            :ARG1-of (e2 / encode-01
                  :ARG0 (a / and
                        :op1 (g / gene :name (n / name :op1 "PIK3CA"))
                        :op2 (g2 / gene :name (n2 / name :op1 "BRAF")))))
      :degree (p / part)
      :mod (i / important)
      :ARG0-of (s2 / suggest-01
            :ARG1 (c / critical
                  :topic (f / form-01
                        :ARG1 (t / tumor))
                  :domain (i2 / impair-01
                        :ARG1 r))))

# ::id bio.ras_0001.3 ::date 2014-08-13T16:08:20 ::annotator ISI-AMR-01 ::preferred
# ::snt Ras acts as a molecular switch that is activated upon GTP loading and deactivated upon hydrolysis of GTP to GDP .
# ::save-date Wed Dec 10, 2014 ::file bio_ras_0001_3.txt
(s / switch
      :domain (e / enzyme :name (n / name :op1 "Ras"))
      :ARG1-of (a / activate-01
            :ARG0 (l / load-01
                  :ARG1 e
                  :ARG2 (s2 / small-molecule :name (n2 / name :op1 "GTP"))))
      :ARG1-of (d / deactivate-01
            :ARG0 (h / hydrolyze-01
                  :ARG1 s2
                  :ARG3 (s3 / small-molecule :name (n3 / name :op1 "GDP"))))
      :mod (m / molecule))

# ::id bio.ras_0001.4 ::date 2014-08-13T17:11:08 ::annotator ISI-AMR-01 ::preferred
# ::snt This switch mechanism is common to a wide variety of GTP - binding proteins and is mediated by a conserved structure called the G - domain that consists of five conserved G boxes .
# ::save-date Thu Sep 25, 2014 ::file bio_ras_0001_4.txt
(s / share-01
      :ARG0 (p / protein
            :ARG2-of (b / bind-01
                  :ARG1 (s4 / small-molecule :name (n / name :op1 "GTP")))
            :mod (v / various
                  :degree (w / wide)))
      :ARG1 (m / mechanism
            :topic (s2 / switch)
            :mod (t / this))
      :manner (s3 / structure :name (n2 / name :op1 "G-domain")
            :ARG1-of (c2 / conserve-01)
            :part (p3 / protein-segment :quant 5 :name (n3 / name :op1 "G" :op2 "box")
                  :ARG1-of (c3 / conserve-01))))

# ::id bio.ras_0001.5 ::date 2014-08-13T18:43:18 ::annotator ISI-AMR-01 ::preferred
# ::snt Under physiological conditions , the rate of GDP or GTP release from the G - domain is slow .
# ::save-date Thu Sep 25, 2014 ::file bio_ras_0001_5.txt
(s / slow-41
      :ARG1 (r / release-01
            :ARG1 (o / or
                  :op1 (s2 / small-molecule :name (n / name :op1 "GDP"))
                  :op2 (s3 / small-molecule :name (n2 / name :op1 "GTP")))
            :ARG2 (p3 / protein-segment :name (n3 / name :op1 "G-domain")))
      :condition (p2 / physiology))

# ::id bio.ras_0001.6 ::date 2014-08-13T16:59:02 ::annotator ISI-AMR-01 ::preferred
# ::snt As a consequence the GDP produced by GTP hydrolysis on Ras is trapped and the bulk of cellular Ras accumulates in the GDP - bound ‘off’ state , despite the high GTP / GDP ratio in the cytosol ( 1 – 3 ) .
# ::save-date Wed Dec 10, 2014 ::file bio_ras_0001_6.txt
(c / cause-01
      :ARG1 (a / and
            :op1 (t / trap-01
                  :ARG1 (s / small-molecule :name (n / name :op1 "GDP")
                        :ARG3-of (h / hydrolyze-01
                              :ARG1 (s2 / small-molecule :name (n2 / name :op1 "GTP")
                                    :ARG1-of (b3 / bind-01
                                          :ARG2 (e / enzyme :name (n3 / name :op1 "Ras")))))))
            :op2 (a2 / accumulate-01
                  :ARG1 (e3 / enzyme :name (n4 / name :op1 "Ras")
                        :ARG1-of (i / include-91
                              :ARG2 (e2 / enzyme :name (n5 / name :op1 "Ras")
                                    :location (c5 / cell))
                              :ARG3 (b / bulk))
                        :ARG1-of (d / deactivate-01)
                        :ARG2-of (b2 / bind-01
                              :ARG1 s))
                  :concession (h2 / high
                        :domain (r / ratio-of
                              :op1 s2
                              :op2 s
                              :location (c6 / cytosol)))))
      :ARG1-of (a3 / attest-01
            :ARG0 (p4 / publication
                  :ARG1-of (c7 / cite-01
                        :ARG2 (v / value-interval :op1 1 :op2 3)))))

# ::id bio.ras_0001.7 ::date 2014-08-13T18:57:28 ::annotator ISI-AMR-01 ::preferred
# ::snt Growth factors can turn on Ras by activating Guanine nucleotide Exchange Factors ( GEFs ) or by inhibiting the GTPase Activating Proteins ( GAPs ) or by both mechanisms .
# ::save-date Wed Dec 10, 2014 ::file bio_ras_0001_7.txt
(p5 / possible
      :domain (t / turn-13
            :ARG0 (s / small-molecule :name (n4 / name :op1 "growth" :op2 "factor"))
            :ARG1 (e2 / enzyme :name (n / name :op1 "Ras"))
            :manner (o / or
                  :op1 (a / activate-01
                        :ARG0 s
                        :ARG1 (p2 / protein :name (n2 / name :op1 "guanine" :op2 "nucleotide" :op3 "exchange" :op4 "factor")))
                  :op2 (i / inhibit-01
                        :ARG0 s
                        :ARG1 (p3 / protein
                              :ARG0-of (a2 / activate-01
                                    :ARG1 (e / enzyme :name (n3 / name :op1 "GTPase")))))
                  :op3 (a3 / and
                        :op1 a
                        :op2 i))))

# ::id bio.ras_0001.8 ::date 2014-08-13T19:05:56 ::annotator ISI-AMR-01 ::preferred
# ::snt RasGEFs bind to Ras and lower the transition energy for the nucleotide exchange of the bound GDP for the more abundant cytosolic GTP , whereas RasGAPs bind to Ras and catalyze GTP hydrolysis .
# ::save-date Wed Dec 10, 2014 ::file bio_ras_0001_8.txt
(c / contrast-01
      :ARG1 (a / and
            :op1 (b / bind-01
                  :ARG1 (p / protein :name (n / name :op1 "RasGEF"))
                  :ARG2 (m2 / macro-molecular-complex
                        :part (e3 / enzyme :name (n2 / name :op1 "Ras"))))
            :op2 (l / lower-01
                  :ARG0 p
                  :ARG1 (e / energy
                        :mod (t / transition-01)
                        :poss (e2 / exchange-01
                              :ARG1 (s2 / small-molecule :name (n4 / name :op1 "GDP")
                                    :ARG1-of (b2 / bind-01
                                          :ARG2 e3))
                              :ARG3 (s / small-molecule :name (n5 / name :op1 "GTP")
                                    :mod (a2 / abundant
                                          :degree (m / more)
                                          :compared-to s2)
                                    :location (c3 / cytosol))))))
      :ARG2 (a3 / and
            :op1 (b3 / bind-01
                  :ARG1 (p5 / protein :name (n3 / name :op1 "RasGAP"))
                  :ARG2 (m3 / macro-molecular-complex
                        :part (e4 / enzyme :name (n6 / name :op1 "Ras"))))
            :op2 (c2 / catalyze-01
                  :ARG0 p5
                  :ARG1 (h / hydrolyze-01
                        :ARG1 s))))

# ::id bio.ras_0001.9 ::date 2014-08-13T20:35:42 ::annotator ISI-AMR-01 ::preferred
# ::snt The most prevalent oncogenic mutations in Ras ( Gly12 and Gly13 in the G1 box , and Gln61 in the G3 box ) preserve the GTP bound state by inhibiting intrinsic GTPase activity and by interfering with the ability of GAPs .
# ::save-date Wed Dec 10, 2014 ::file bio_ras_0001_9.txt
(p / preserve-01
      :ARG0 (m / mutation
            :ARG1-of (p2 / prevail-02
                  :degree (m2 / most)
                  :compared-to (e / enzyme :name (n / name :op1 "Ras")))
            :ARG0-of (c / cause-01
                  :ARG1 (c2 / cancer))
            :location (a / and
                  :op1 (p4 / protein-segment :name (n2 / name :op1 "Gly12")
                        :location (p7 / protein-segment :name (n5 / name :op1 "G1" :op2 "box")
                              :location e))
                  :op2 (p5 / protein-segment :name (n3 / name :op1 "Gly13")
                        :location p7)
                  :op3 (p6 / protein-segment :name (n4 / name :op1 "Gln61")
                        :location (p8 / protein-segment :name (n6 / name :op1 "G3" :op2 "box")
                              :location e))))
      :ARG1 (b / bind-01
            :ARG1 (s / small-molecule :name (n7 / name :op1 "GTP"))
            :ARG2 e)
      :manner (a2 / and
            :op1 (i / inhibit-01
                  :ARG0 m
                  :ARG1 (a3 / act-02
                        :ARG0 (e2 / enzyme :name (n8 / name :op1 "GTPase"))
                        :mod (i3 / intrinsic)))
            :op2 (i2 / interfere-01
                  :ARG0 m
                  :ARG1 (c4 / capable-41
                        :ARG1 (p10 / protein :name (n9 / name :op1 "GAP"))))))

# ::id bio.ras_0001.10 ::date 2014-08-13T21:50:34 ::annotator ISI-AMR-01 ::preferred
# ::snt Other less frequently observed mutations , such as those found in the G4 and G5 boxes , increase the rate of nucleotide exchange , thereby mimicking the GEFs and increasing the GTP - bound state ( 1 – 7 ) .
# ::save-date Wed Dec 10, 2014 ::file bio_ras_0001_10.txt
(i / increase-01
      :ARG0 (m / mutation
            :ARG1-of (o / observe-01
                  :frequency (f / frequent
                        :degree (l / less)))
            :mod (o2 / other)
            :example (m2 / mutation
                  :location (o3 / or
                        :op1 (p / protein-segment :name (n / name :op1 "G4" :op2 "box"))
                        :op2 (p2 / protein-segment :name (n2 / name :op1 "G5" :op2 "box")))))
      :ARG1 (r / rate
            :degree-of (e / exchange-01
                  :ARG1 (n3 / nucleotide)))
      :manner-of (m3 / mimic-01
            :ARG0 m
            :ARG1 (p3 / protein :name (n4 / name :op1 "GEF")))
      :ARG0-of (c / cause-01
            :ARG1 (i2 / increase-01
                  :ARG1 (n7 / number
                        :quant-of (e2 / enzyme :name (n5 / name :op1 "Ras")
                              :ARG2-of (b / bind-01
                                    :ARG1 (s / small-molecule :name (n6 / name :op1 "GTP")))))))
      :ARG1-of (a / attest-01
            :ARG0 (p6 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 (v / value-interval :op1 1 :op2 7)))))

# ::id bio.ras_0002.1 ::date 2015-01-13T21:00:03 ::annotator SDL-AMR-09 ::preferred
# ::snt Activated Ras controls diverse signaling pathways that ultimately determine Ras - induced cellular responses such as cell proliferation , survival , differentiation and motility .
# ::save-date Wed Jan 14, 2015 ::file bio_ras_0002_1.txt
(c / control-01
      :ARG0 (e / enzyme :name (n / name :op1 "Ras")
            :ARG1-of (a / activate-01))
      :ARG1 (p / pathway
            :mod (d / diverse)
            :ARG0-of (s / signal-01)
            :ARG0-of (d2 / determine-01
                  :ARG1 (r / respond-01
                        :ARG0 (c2 / cell)
                        :ARG2 (a2 / and
                              :op1 (p2 / proliferate-01
                                    :ARG0 c2)
                              :op2 (s2 / survive-01
                                    :ARG0 c2)
                              :op3 (d3 / differentiate-01
                                    :ARG1 c2)
                              :op4 (m / motility
                                    :mod c2))
                        :ARG1-of (i / induce-01
                              :ARG0 e))
                  :time (u / ultimate))))

# ::id bio.ras_0002.2 ::date 2015-01-13T20:53:19 ::annotator SDL-AMR-09 ::preferred
# ::snt These multiple Ras functions depend on its binding to a range of functionally diverse effector molecules such as Raf , PI3K , AF6 and RASSFs  ( 1 ) .
# ::save-date Thu Feb 5, 2015 ::file bio_ras_0002_2.txt
(d / depend-01
      :ARG0 (t3 / thing
            :quant (m / multiple)
            :mod (t / this)
            :ARG1-of (f / function-01
                  :ARG0 (e / enzyme :name (n / name :op1 "Ras"))))
      :ARG1 (b / bind-01
            :ARG1 e
            :ARG2 (m2 / molecule
                  :mod (e3 / effector)
                  :example (a / and
                        :op1 (e2 / enzyme :name (n2 / name :op1 "Raf"))
                        :op2 (e4 / enzyme :name (n3 / name :op1 "PI3K"))
                        :op3 (e5 / enzyme :name (n4 / name :op1 "AF6"))
                        :op4 (p / protein :name (n5 / name :op1 "RASSF")))
                  :quant (r / range)
                  :ARG0-of (f2 / function-01
                        :mod (d2 / diverse))))
      :ARG1-of (d3 / describe-01
            :ARG0 (p2 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 1))))

# ::id bio.ras_0002.3 ::date 2015-01-14T04:48:20 ::annotator SDL-AMR-09 ::preferred
# ::snt The enhancement of specific effector pathways plays a critical role in maintaining an appropriate biological response ( 8 ) .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0002_3.txt
(p / play-02
      :ARG0 (e / enhance-01
            :ARG1 (p2 / pathway
                  :mod (e2 / effector)
                  :mod (s / specific)))
      :ARG1 (r / role
            :mod (c / critical)
            :topic (m / maintain-01
                  :ARG0 e
                  :ARG1 (t / thing
                        :ARG2-of (r2 / respond-01)
                        :mod (b / biology)
                        :mod (a / appropriate))))
      :ARG1-of (d / describe-01
            :ARG2 (p3 / publication
                  :ARG1-of (c2 / cite-01
                        :ARG2 8))))

# ::id bio.ras_0002.4 ::date 2015-01-14T06:53:00 ::annotator SDL-AMR-09 ::preferred
# ::snt The specificity in Ras - induced signaling is primarily determined by the balance between Ras affinity for each of its effectors and the local concentrations of those effectors .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0002_4.txt
(d / determine-01
      :ARG0 (b / balance-01
            :ARG1 (a / affinity
                  :poss (e / enzyme :name (n / name :op1 "Ras"))
                  :topic (e2 / effector
                        :mod (e3 / each)
                        :poss e))
            :ARG2 (c / concentrate-02
                  :ARG1 e2
                  :mod (l / local)))
      :ARG1 (s / specificity
            :mod (s2 / signal-01
                  :ARG1-of (i / induce-01
                        :ARG0 e)))
      :mod (p / primary))

# ::id bio.ras_0002.5 ::date 2015-01-14T07:23:18 ::annotator SDL-AMR-09 ::preferred
# ::snt In addition , scaffold proteins have been shown to guide activation of specific effector pathway(s) . For example , SHOC2 / Sur-8 bridges Ras and Raf to specifically enhance the Raf / MEK / ERK pathway without enhancing PI3K / AKT signaling ( 9 , 10 ) .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0002_5.txt
(m / multi-sentence
      :snt1 (a4 / and
            :op2 (s / show-01
                  :ARG1 (g / guide-01
                        :ARG0 (p / protein
                              :mod (s5 / scaffold))
                        :ARG1 (a / activate-01
                              :ARG1 (p2 / pathway
                                    :mod (e5 / effector)
                                    :mod (s2 / specific))))))
      :snt2 (e8 / exemplify-01
            :ARG0 (b / bridge-01
                  :ARG0 (m2 / macro-molecular-complex
                        :part (e3 / enzyme :name (n3 / name :op1 "SHOC2"))
                        :part (e4 / enzyme :name (n4 / name :op1 "Sur-8")))
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "Raf"))
                  :purpose (e6 / enhance-01
                        :ARG0 m2
                        :ARG1 (p4 / pathway :name (n7 / name :op1 "Raf/MEK/ERK"))
                        :mod (s3 / specific))
                  :manner (e7 / enhance-01 :polarity -
                        :ARG0 m2
                        :ARG1 (s4 / signal-01
                              :ARG0 (p5 / pathway :name (n8 / name :op1 "PI3K/AKT"))))
                  :ARG1-of (d / describe-01
                        :ARG0 (p6 / publication
                              :ARG1-of (c / cite-01
                                    :ARG2 (a3 / and :op1 9 :op2 10)))))))

# ::id bio.ras_0003.1 ::date 2015-01-19T01:16:07 ::annotator SDL-AMR-09 ::preferred
# ::snt We utilized an unbiased mass spectrometry - based approach to identify ubiquitination sites of Ras .
# ::save-date Mon Jan 19, 2015 ::file bio_ras_0003_1.txt
(u / utilize-01
      :ARG0 (w / we)
      :ARG1 (a / approach-02
            :ARG1-of (b / bias-01 :polarity -)
            :ARG1-of (b2 / base-02
                  :ARG2 (s / spectrometry
                        :mod (m / mass))))
      :purpose (i / identify-01
            :ARG0 w
            :ARG1 (p / protein-segment
                  :part-of (e / enzyme :name (n / name :op1 "Ras"))
                  :ARG1-of (u2 / ubiquitinate-01))))

# ::id bio.ras_0003.2 ::date 2015-01-19T01:53:15 ::annotator SDL-AMR-09 ::preferred
# ::snt His - tagged ubiquitin and Flag - tagged K-Ras4B ( K-Ras hereafter ) were expressed in HEK293T cells at levels similar to endogenous K-Ras ( Fig. 1B ) and subjected to sequential affinity chromatography .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0003_2.txt
(a3 / and
  :op1 (e2 / express-03
         :ARG2 (a / and
                 :op1 (p / protein
                        :name (n / name
                                :op1 "ubiquitin")
                        :ARG1-of (t / tag-01
                                   :ARG2 (a2 / amino-acid
                                           :name (n3 / name
                                                   :op1 "histidine"))))
                 :op2 (e / enzyme
                        :name (n2 / name
                                :op1 "K-Ras4B")
                        :name (n7 / name
                                :op1 "K-Ras")
                        :ARG1-of (t2 / tag-01
                                   :ARG2 (p2 / protein-segment
                                           :name (n4 / name
                                                   :op1 "Flag")))))
         :ARG3 (c / cell-line
                 :name (n5 / name
                         :op1 "HEK293T"))
         :degree (l / level
                   :ARG1-of (r / resemble-01
                              :ARG2 (l2 / level
                                      :degree-of (e4 / express-03
                                                   :ARG2 (e3 / enzyme
                                                           :name (n6 / name
                                                                   :op1 "K-Ras")
                                                           :mod (e5 / endogenous))))))
         :ARG1-of (d / describe-01
                    :ARG0 (f / figure
                            :mod "1B")))
  :op2 (s / subject-01
         :ARG1 a
         :ARG2 (c2 / chromatography
                 :mod (a4 / affinity)
                 :mod (s2 / sequence))))

# ::id bio.ras_0003.3 ::date 2015-01-19T02:56:52 ::annotator SDL-AMR-09 ::preferred
# ::snt His - ubiquitinated proteins were purified by Co2+ metal affinity chromatography in 8M urea denaturing conditions .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0003_3.txt
(p / purify-01
      :ARG1 (p2 / protein
            :ARG3-of (u / ubiquitinate-01
                  :mod (a / amino-acid :name (n / name :op1 "histidine"))))
      :manner (c / chromatography
            :mod (a2 / affinity
                  :topic (m2 / metal :name (n2 / name :op1 "Co2+")))
            :condition (d2 / denature-00
                  :ARG1 p2
                  :instrument (s / small-molecule :name (n3 / name :op1 "urea")
                        :mod (c2 / concentration-quantity :quant 8
                              :unit (m / molar))))))

# ::id bio.ras_0003.4 ::date 2015-01-19T05:25:54 ::annotator SDL-AMR-09 ::preferred
# ::snt His - ubiquitinated K-Ras was subsequently purified with anti - Flag resin .
# ::save-date Mon Jan 19, 2015 ::file bio_ras_0003_4.txt
(p / purify-01
      :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
            :ARG3-of (u / ubiquitinate-01
                  :mod (a / amino-acid :name (n2 / name :op1 "histidine"))))
      :time (s / subsequent)
      :instrument (r / resin
            :ARG0-of (c / counter-01
                  :ARG1 (p2 / protein-segment :name (n3 / name :op1 "Flag")))))

# ::id bio.ras_0003.5 ::date 2015-01-19T05:43:28 ::annotator SDL-AMR-09 ::preferred
# ::snt Following purification , mono- and di- ubiquitinated K-Ras appeared to be the major ubiquitination forms , which is consistent with the endogenous K-Ras ubiquitination pattern ( Fig. 1 , A and B ) .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0003_5.txt
(a / appear-02
      :ARG1 (f2 / form
            :mod (u2 / ubiquitinate-01)
            :mod (m / major)
            :domain (e / enzyme :name (n / name :op1 "K-Ras")
                  :ARG3-of (u / ubiquitinate-01
                        :quant (o / or :op1 1 :op2 2))))
      :ARG1-of (f / follow-01
            :ARG2 (p / purify-01
                  :ARG1 e))
      :ARG1-of (c / consistent-41
            :ARG2 (p2 / pattern
                  :topic (u3 / ubiquitinate-01
                        :ARG1 (e2 / enzyme :name (n2 / name :op1 "K-Ras")
                              :mod (e3 / endogenous)))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (f3 / figure :mod "1A")
                  :op2 (f4 / figure :mod "1B"))))

# ::id bio.ras_0003.6 ::date 2015-01-19T06:56:05 ::annotator SDL-AMR-09 ::preferred
# ::snt H-Ras ubiquitination sites were also determined by the same approach .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0003_6.txt
(d / determine-01
      :ARG1 (p / protein-segment
            :ARG1-of (u / ubiquitinate-01)
            :part-of (e / enzyme :name (n / name :op1 "H-Ras")))
      :mod (a / also)
      :manner (a2 / approach-02
            :ARG1-of (s / same-41)))

# ::id bio.ras_0003.7 ::date 2015-01-19T07:05:34 ::annotator SDL-AMR-09 ::preferred
# ::snt Tandem mass spectrometric analysis of tryptic fragments from the bands migrating at the positions expected for mono- and di- ubiquitinated Ras revealed ubiquitination at Lys residues 104 and 147 of K-Ras , and Lys residues 117 , 147 and 170 for H-Ras ( fig. S1C ) .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0003_7.txt
(r / reveal-01
      :ARG0 (a / analyze-01
            :ARG1 (f / fragment
                  :source (b / band
                        :ARG0-of (m / migrate-01
                              :ARG1 (p / position
                                    :ARG2-of (b2 / be-located-at-91
                                          :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                                                :ARG3-of (u / ubiquitinate-01
                                                      :quant (o / or :op1 1 :op2 2)))
                                          :ARG1-of (e4 / expect-01)))))
                  :mod (e5 / enzyme :name (n9 / name :op1 "trypsin")))
            :manner (s / spectrometry
                  :mod (m2 / mass)
                  :mod (t2 / tandem)))
      :ARG1 (u2 / ubiquitinate-01
            :ARG1 (a2 / and
                  :op1 (a3 / and
                        :op1 (r2 / residue
                              :mod (a4 / amino-acid :mod 104 :name (n4 / name :op1 "lysine")))
                        :op2 (r3 / residue
                              :mod (a5 / amino-acid :mod 147 :name (n5 / name :op1 "lysine")))
                        :part-of (e2 / enzyme :name (n2 / name :op1 "K-Ras")))
                  :op2 (a6 / and
                        :op1 (r4 / residue
                              :mod (a7 / amino-acid :mod 117 :name (n6 / name :op1 "lysine")))
                        :op2 (r5 / residue
                              :mod (a8 / amino-acid :mod 147 :name (n7 / name :op1 "lysine")))
                        :op3 (r6 / residue
                              :mod (a9 / amino-acid :mod 170 :name (n8 / name :op1 "lysine")))
                        :part-of (e3 / enzyme :name (n3 / name :op1 "H-Ras")))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "S1C")))

# ::id bio.ras_0003.8 ::date 2015-01-19T07:59:53 ::annotator SDL-AMR-09 ::preferred
# ::snt The tryptic peptide with ubiquitination at Lys147 ( K147 ) was the most frequently observed peptide for both K-Ras and H-Ras , while Lys117 appeared as a secondary major ubiquitination site in H-Ras .
# ::save-date Fri Feb 6, 2015 ::file bio_ras_0003_8.txt
(c / contrast-01
      :ARG1 (o / observe-01
            :ARG1 (p / peptide
                  :frequency (f / frequent
                        :degree (m / most))
                  :part-of (a / and
                        :op1 (e / enzyme :name (n / name :op1 "K-Ras"))
                        :op2 (e2 / enzyme :name (n2 / name :op1 "H-Ras"))))
            :domain (p2 / peptide
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e3 / enzyme :name (n3 / name :op1 "trypsin")))
                  :part (a2 / amino-acid :mod 147 :name (n4 / name :op1 "lysine")
                        :ARG1-of (u / ubiquitinate-01))))
      :ARG2 (a3 / appear-01
            :ARG1 (p3 / protein-segment
                  :ARG1-of (u2 / ubiquitinate-01)
                  :part-of (e4 / enzyme :name (n6 / name :op1 "H-Ras"))
                  :mod (m2 / major)
                  :mod (s / secondary)
                  :domain (a4 / amino-acid :mod 117 :name (n5 / name :op1 "lysine")))))

# ::id bio.bmtr_0001.1 ::date 2014-12-03T18:05:22
# ::snt Sasaki et al., “Ubiquitination of Ras enhances activation and facilitates binding to select downstream effectors” (PMC3437993)
# ::save-date Wed Dec 10, 2014 ::user consensus ::file bio_bmtr_0001_1.txt
(p / publication-91
      :ARG0 (a / and
            :op1 (p2 / person :name (n / name :op1 "Sasaki"))
            :op2 (p3 / person
                  :mod (o / other)))
      :ARG1 (a2 / and
            :op1 (e / enhance-01
                  :ARG0 (u / ubiquitinate-01
                        :ARG1 (e3 / enzyme :name (n2 / name :op1 "Ras")))
                  :ARG1 (a3 / activate-01))
            :op2 (f / facilitate-01
                  :ARG0 u
                  :ARG1 (b / bind-01
                        :ARG2 (e2 / effector
                              :location (d / downstream)
                              :mod (s2 / select)))))
      :ARG8 "PMC3437993")

# ::id bio.bmtr_0001.2 ::date 2014-12-03T21:45:59
# ::snt We utilized an unbiased mass spectrometry-based approach to identify ubiquitination sites of Ras.
# ::save-date Wed Dec 10, 2014 ::user consensus ::file bio_bmtr_0001_2.txt
(u / utilize-01
      :ARG0 (w / we)
      :ARG1 (a / approach-02
            :ARG1-of (b / base-02
                  :ARG2 (s / spectrometry
                        :mod (m / mass)))
            :ARG1-of (b2 / bias-01 :polarity -))
      :purpose (i / identify-01
            :ARG0 w
            :ARG1 (p / protein-segment
                  :part-of (e / enzyme :name (n / name :op1 "Ras"))
                  :ARG1-of (u2 / ubiquitinate-01))))

# ::id bio.bmtr_0001.3 ::date 2014-12-03T21:53:14
# ::snt His-tagged ubiquitin and Flag-tagged K-Ras4B (K-Ras hereafter) were expressed in HEK293T cells at levels similar to endogenous K-Ras (Fig. 1B) and subjected to sequential affinity chromatography.
# ::save-date Wed Dec 10, 2014 ::user consensus ::file bio_bmtr_0001_3.txt
(a3 / and
      :op1 (e / express-03
            :ARG2 (a / and
                  :op1 (p / protein :name (n2 / name :op1 "ubiquitin")
                        :ARG1-of (t / tag-01
                              :ARG2 (p3 / protein-segment
                                    :part (a2 / amino-acid :name (n5 / name :op1 "histidine")))))
                  :op2 (e5 / enzyme :name (n3 / name :op1 "K-Ras4B") :name (n4 / name :op1 "K-Ras")
                        :ARG1-of (t2 / tag-01
                              :ARG2 (p4 / protein-segment :name (n6 / name :op1 "Flag")))))
            :ARG3 (c / cell-line :name (n / name :op1 "HEK293T"))
            :degree (l / level
                  :ARG1-of (r / resemble-01
                        :ARG2 (l2 / level
                              :degree-of (e3 / express-03
                                    :ARG2 (e4 / enzyme :name (n7 / name :op1 "K-Ras")
                                          :mod (e2 / endogenous))
                                    :ARG3 c))))
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod "1B")))
      :op2 (s2 / subject-01
            :ARG1 a
            :ARG2 (c2 / chromatography
                  :mod (a4 / affinity)
                  :mod (s3 / sequence))))

# ::id bio.bmtr_0001.4 ::date 2014-12-09T14:55:44
# ::snt His-ubiquitinated proteins were purified by Co2+ metal affinity chromatography in 8M urea denaturing conditions.
# ::save-date Wed Dec 10, 2014 ::user consensus ::file bio_bmtr_0001_4.txt
(p / purify-01
  :ARG1 (p2 / protein
          :ARG3-of (u / ubiquitinate-01
                     :mod (a / amino-acid :name (n / name :op1 "histidine"))))
  :manner (c / chromatography
            :mod (a2 / affinity
                   :topic (m / metal :name (n2 / name :op1 "Co2+")))
            :mod (d / denature-00
                   :ARG1 p2
                   :instrument (s / small-molecule :name (n3 / name :op1 "urea")
                                 :mod (c2 / concentration-quantity :quant 8
                                        :unit (m2 / molar))))))

# ::id bio.bmtr_0001.5 ::date 2014-12-09T22:13:53
# ::snt His-ubiquitinated K-Ras was subsequently purified with anti-Flag resin.
# ::save-date Tue Dec 9, 2014 ::user ulf ::file bio_bmtr_0001_5.txt
(p / purify-01
      :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
            :ARG3-of (u / ubiquitinate-01
                  :mod (a / amino-acid :name (n2 / name :op1 "histidine"))))
      :time (s / subsequent)
      :instrument (r / resin
            :ARG0-of (c / counter-01
                  :ARG1 (p2 / protein-segment :name (n3 / name :op1 "Flag")))))

# ::id bio.bmtr_0001.6 ::date 2014-12-09T22:40:15
# ::snt Following purification, mono- and di- ubiquitinated K-Ras appeared to be the major ubiquitination forms, which is consistent with the endogenous K-Ras ubiquitination pattern (Fig. 1, A and B).
# ::save-date Wed Dec 10, 2014 ::user consensus ::file bio_bmtr_0001_6.txt
(a / appear-02
      :ARG1 (h / have-quant-91
            :ARG1 (u / ubiquitinate-01
                  :ARG3 (e / enzyme :name (n / name :op1 "K-Ras")))
            :ARG2 (o / or :op1 1 :op2 2)
            :degree (m / most)
            :ARG1-of (f / follow-01
                  :ARG2 (p / purify-01
                        :ARG1 e))
            :ARG1-of (c / consistent-41
                  :ARG2 (p2 / pattern
                        :topic (u2 / ubiquitinate-01
                              :ARG1 (e2 / enzyme :name (n2 / name :op1 "K-Ras")
                                    :mod (e3 / endogenous))))))
      :ARG1-of (d / describe-01
            :ARG0 (a2 / and
                  :op1 (f2 / figure :mod "1A")
                  :op2 (f3 / figure :mod "1B"))))

# ::id bio.bmtr_0001.7 ::date 2014-12-09T22:54:17
# ::snt H-Ras ubiquitination sites were also determined by the same approach.
# ::save-date Tue Dec 9, 2014 ::user ulf ::file bio_bmtr_0001_7.txt
(d / determine-01
      :ARG1 (p / protein-segment
            :ARG1-of (u / ubiquitinate-01)
            :part-of (e / enzyme :name (n / name :op1 "H-Ras")))
      :manner (a / approach-02
            :mod (s / same))
      :mod (a2 / also))

# ::id bio.bmtr_0001.8 ::date 2014-12-05T20:16:13
# ::snt Tandem mass spectrometric analysis of tryptic fragments from the bands migrating at the positions expected for mono- and di-ubiquitinated Ras revealed ubiquitination at Lys residues 104 and 147 of K-Ras, and Lys residues 117, 147 and 170 for H-Ras (fig. S1C).
# ::save-date Mon Dec 15, 2014 ::user consensus ::file bio_bmtr_0001_8.txt
(r / reveal-01
      :ARG0 (a / analyze-01
            :ARG1 (p3 / protein-segment
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e2 / enzyme :name (n2 / name :op1 "trypsin")))
                  :source (b / band
                        :ARG0-of (m / migrate-01
                              :ARG1 (p / position
                                    :ARG2-of (b2 / be-located-at-91
                                          :ARG1 (e5 / enzyme :name (n / name :op1 "Ras")
                                                :ARG3-of (u / ubiquitinate-01
                                                      :quant (o / or :op1 1 :op2 2)))
                                          :ARG1-of (e / expect-01))))))
            :manner (s / spectrometry
                  :mod (m2 / mass)
                  :mod (t / tandem)))
      :ARG1 (u2 / ubiquitinate-01
            :ARG1 (a2 / and
                  :op1 (a8 / and
                        :op1 (r2 / residue
                              :mod (a3 / amino-acid :mod 104 :name (n3 / name :op1 "lysine")))
                        :op2 (r3 / residue
                              :mod (a4 / amino-acid :mod 147 :name (n4 / name :op1 "lysine")))
                        :part-of (e4 / enzyme :name (n5 / name :op1 "K-Ras")))
                  :op2 (a9 / and
                        :op1 (r4 / residue
                              :mod (a5 / amino-acid :mod 117 :name (n6 / name :op1 "lysine")))
                        :op2 (r5 / residue
                              :mod (a6 / amino-acid :mod 147 :name (n7 / name :op1 "lysine")))
                        :op3 (r6 / residue
                              :mod (a7 / amino-acid :mod 170 :name (n8 / name :op1 "lysine")))
                        :part-of (e3 / enzyme :name (n9 / name :op1 "H-Ras")))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "S1C")))

# ::id bio.bmtr_0001.9 ::date 2014-12-09T22:57:04
# ::snt The tryptic peptide with ubiquitination at Lys147 (K147) was the most frequently observed peptide for both K-Ras and H-Ras, while Lys117 appeared as a secondary major ubiquitination site in H-Ras.
# ::save-date Tue Dec 9, 2014 ::user ulf ::file bio_bmtr_0001_9.txt
(c / contrast-01
      :ARG1 (p / peptide
            :ARG1-of (o / observe-01
                  :frequency (f / frequent
                        :degree (m / most)))
            :part-of (e2 / enzyme
                  :mod (o2 / or
                        :op1 (e3 / enzyme :name (n3 / name :op1 "K-Ras"))
                        :op2 (e4 / enzyme :name (n4 / name :op1 "H-Ras"))))
            :domain (p2 / peptide
                  :part (a / amino-acid :mod 147 :name (n / name :op1 "lysine")
                        :ARG3-of (u / ubiquitinate-01))
                  :ARG3-of (h / hydrolyze-01
                        :ARG2 (e / enzyme :name (n2 / name :op1 "trypsin")))
                  :part-of e2))
      :ARG2 (a3 / appear-01
            :ARG1 (p3 / protein-segment
                  :part-of (e5 / enzyme :name (n5 / name :op1 "H-Ras"))
                  :ARG1-of (u2 / ubiquitinate-01)
                  :mod (m2 / major)
                  :mod (s / secondary)
                  :domain (a2 / amino-acid :mod 117 :name (n6 / name :op1 "lysine")))))

# ::id bio.bmtr_0001.10 ::date 2014-12-18T10:39:24 ::authors ulf
# ::snt To examine the effect of ubiquitination on GTP loading, we purified wild-type K-Ras, oncogenic G12V-K-Ras mutant or the ubiquitinated subfraction of wild-type K-Ras from 32P-orthophosphate labeled cells and utilized thin layer chromatography (TLC) and high performance liquid chromatography (HPLC) to assess the ratio of 32P-GTP to 32P-GDP that co-purified with each form of K-Ras.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user consensus ::file bio_bmtr_0001_10.txt
(a2 / and
      :op1 (p / purify-01
            :ARG0 (w / we)
            :ARG1 (a / and
                  :op1 (o / or
                        :op1 (e / enzyme :name (n2 / name :op1 "K-Ras")
                              :mod (w2 / wild-type))
                        :op2 (e2 / enzyme :name (n3 / name :op1 "K-Ras")
                              :ARG0-of (c / cause-01
                                    :ARG1 (c2 / cancer))
                              :ARG2-of (m / mutate-01 :value "G12V"))
                        :op3 (e3 / enzyme :name (n4 / name :op1 "K-Ras")
                              :mod (w3 / wild-type)
                              :ARG3-of (u / ubiquitinate-01)
                              :mod (s2 / subfraction)))
                  :op2 s4
                  :op3 s5)
            :source (c3 / cell
                  :ARG1-of (l / label-01
                        :ARG2 (s3 / small-molecule :name (n5 / name :op1 "orthophosphate")
                              :part (p2 / phosphorus
                                    :mod (m2 / molecular-mass :value 32))))))
      :op2 (u2 / utilize-01
            :ARG0 w
            :ARG1 (a5 / and
                  :op1 (c4 / chromatography
                        :mod (l3 / layer
                              :mod (t / thin)))
                  :op2 (c5 / chromatography
                        :mod (l4 / liquid
                              :ARG0-of (p3 / perform-01
                                    :degree (h / high)))))
            :purpose (a3 / assess-01
                  :ARG0 w
                  :ARG1 (r / ratio-of
                        :op1 (s4 / small-molecule :name (n6 / name :op1 "GTP")
                              :part (p4 / phosphorus
                                    :mod (m3 / molecular-mass :value 32)))
                        :op2 (s5 / small-molecule :name (n7 / name :op1 "GDP")
                              :part (p5 / phosphorus
                                    :mod (m4 / molecular-mass :value 32))))))
      :purpose (e4 / examine-01
            :ARG0 w
            :ARG1 (a4 / affect-01
                  :ARG0 (u3 / ubiquitinate-01)
                  :ARG1 (l2 / load-01
                        :ARG2 (s / small-molecule :name (n / name :op1 "GTP"))))))

# ::id bio.bmtr_0001.11 ::date 2014-12-18T12:35:31 ::authors ulf
# ::snt As expected based on previous studies, wild-type K-Ras bound primarily 32P-GDP, while G12V-Ras bound 32P-GTP (Fig.2, A and B).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user consensus ::file bio_bmtr_0001_11.txt
(c / contrast-01
      :ARG1 (b / bind-01
            :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                  :mod (w / wild-type))
            :ARG2 (s / small-molecule :name (n2 / name :op1 "GDP")
                  :part (p / phosphorus
                        :mod (m / molecular-mass :value 32)))
            :mod (p2 / primary))
      :ARG2 (b2 / bind-01
            :ARG1 (e2 / enzyme :name (n3 / name :op1 "Ras")
                  :ARG2-of (m2 / mutate-01 :value "G12V"))
            :ARG2 (s2 / small-molecule :name (n4 / name :op1 "GTP")
                  :part (p3 / phosphorus
                        :mod (m3 / molecular-mass :value 32))))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f / figure :mod "2A")
                  :op2 (f2 / figure :mod "2B")))
      :ARG1-of (e3 / expect-01
            :ARG1-of (b3 / base-02
                  :ARG2 (s4 / study
                        :time (p4 / previous)))))

# ::id bio.bmtr_0001.12 ::date 2014-12-18T17:04:39 ::authors ulf
# ::snt Interestingly, the ubiquitinated subfraction of wild-type K-Ras retained a significant amount of 32P-GTP.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Thu Dec 18, 2014 ::user ulf ::file bio_bmtr_0001_12.txt
(r / retain-01
      :ARG0 (e / enzyme :name (n / name :op1 "K-Ras")
            :mod (w / wild-type)
            :ARG3-of (u / ubiquitinate-01)
            :mod (s2 / subfraction))
      :ARG1 (s / small-molecule :name (n2 / name :op1 "GTP")
            :part (p / phosphorus
                  :mod (m / molecular-mass :value 32))
            :quant (s3 / significant))
      :ARG2-of (i / interest-01))

# ::id bio.bmtr_0001.13 ::date 2014-12-18T17:10:57 ::authors ulf
# ::snt These results are consistent with a model in which ubiquitination of Lys147 (or Lys117), destabilizes GDP binding, allowing spontaneous GDP/GTP exchange.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user consensus ::file bio_bmtr_0001_13.txt
(c / consistent-41
      :ARG1 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / this))
      :ARG2 (m / model
            :topic (d / destabilize-01
                  :ARG0 (u / ubiquitinate-01
                        :ARG1 (o / or
                              :op1 (a / amino-acid :mod 147 :name (n2 / name :op1 "lysine"))
                              :op2 (a3 / amino-acid :mod 117 :name (n5 / name :op1 "lysine"))))
                  :ARG1 (b / bind-01
                        :ARG2 (s / small-molecule :name (n / name :op1 "GDP")))
                  :ARG0-of (a2 / allow-01
                        :ARG1 (e / exchange-01
                              :ARG1 (s3 / small-molecule :name (n3 / name :op1 "GDP"))
                              :ARG3 (s4 / small-molecule :name (n4 / name :op1 "GTP"))
                              :mod (s2 / spontaneous))))))

# ::id bio.bmtr_0001.14 ::date 2014-12-22T16:19:51 ::authors ulf
# ::snt It could be argued that GTP loading occurs prior to ubiquitination and that the GTP bound form of K-Ras, via interaction with effectors, is preferentially mono-ubiquitinated via a feedback mechanism.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user ulf ::file bio_bmtr_0001_14.txt
(p / possible
      :domain (a / argue-01
            :ARG1 (a2 / and
                  :op1 (l / load-01
                        :ARG2 (s / small-molecule :name (n / name :op1 "GTP"))
                        :time (p2 / prior
                              :op1 (u / ubiquitinate-01)))
                  :op2 (u2 / ubiquitinate-01 :quant 1
                        :ARG1 (e / enzyme :name (n2 / name :op1 "K-Ras")
                              :ARG1-of (b / bind-01
                                    :ARG2 (s2 / small-molecule :name (n3 / name :op1 "GTP"))))
                        :ARG1-of (p3 / prefer-01)
                        :manner (i / interact-01
                              :ARG0 e
                              :ARG1 (e2 / effector))
                        :manner (f / feedback)))))

# ::id bio.bmtr_0001.15 ::date 2014-12-22T16:27:59 ::authors ulf
# ::snt While it is difficult to eliminate this possibility, it is unlikely since, as shown in fig. S1B, the T35 mutant of K-Ras, which fails to interact with downstream effectors (fig. S1B) undergoes comparable monobuiquitination to wild type Ras.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user consensus ::file bio_bmtr_0001_15.txt
(c / contrast-01
      :ARG1 (d / difficult
            :domain (e3 / eliminate-01
                  :ARG1 (t / this
                        :mod (p / possible))))
      :ARG2 (l / likely :polarity -
            :domain t
            :ARG1-of (c2 / cause-01
                  :ARG0 (u / ubiquitinate-01 :quant 1
                        :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                              :ARG2-of (m / mutate-01 :value "T35")
                              :ARG0-of (i / interact-01 :polarity -
                                    :ARG1 (e4 / effector
                                          :location (d2 / downstream))
                                    :ARG1-of (d3 / describe-01
                                          :ARG0 f)))
                        :ARG1-of (s / show-01
                              :ARG0 (f / figure :mod "S1B"))
                        :mod (c3 / comparable
                              :topic (u2 / ubiquitinate-01
                                    :ARG1 (e2 / enzyme :name (n2 / name :op1 "Ras")
                                          :mod (w / wild-type))))))))

# ::id bio.bmtr_0001.16 ::date 2014-12-22T16:52:11 ::authors ulf
# ::snt These results, along with the crystal structure, support a model in which mono-ubiquitination at a Lys residue directly involved in GDP binding either enhances nucleotide exchange on K-Ras, impairs GTP hydrolysis, or both.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user consensus ::file bio_bmtr_0001_16.txt
(s3 / support-01
      :ARG0 (a / and
            :op1 (t / thing
                  :mod (t2 / this)
                  :ARG2-of (r / result-01))
            :op2 (s4 / structure
                  :poss (c / crystal)))
      :ARG1 (m / model
            :topic (o / or
                  :op1 (e2 / enhance-01
                        :ARG0 (u / ubiquitinate-01 :quant 1
                              :ARG1 (r2 / residue
                                    :mod (a2 / amino-acid :name (n4 / name :op1 "lysine"))
                                    :ARG1-of (i / involve-01
                                          :ARG2 (b / bind-01
                                                :ARG2 (s / small-molecule :name (n / name :op1 "GDP")))
                                          :manner (d / direct))))
                        :ARG1 (e3 / exchange-01
                              :ARG1 (n5 / nucleotide)
                              :ARG4 (e / enzyme :name (n2 / name :op1 "K-Ras"))))
                  :op2 (i2 / impair-01
                        :ARG0 u
                        :ARG1 (h / hydrolyze-01
                              :ARG1 (s2 / small-molecule :name (n3 / name :op1 "GTP"))))
                  :op3 (a3 / and
                        :op1 e2
                        :op2 i2))))

# ::id bio.bmtr_0001.17 ::date 2014-12-22T15:12:07 ::authors ulf
# ::snt To corroborate this finding, we measure the activity of Ras by the GST-RBD pull-down assay.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user ulf ::file bio_bmtr_0001_17.txt
(m / measure-01
      :ARG0 (w / we)
      :ARG1 (a / act-02
            :ARG0 (e / enzyme :name (n / name :op1 "Ras")))
      :ARG2 (a2 / assay-00
            :manner (p / pull-00
                  :ARG2 (p2 / protein :name (n2 / name :op1 "GST-RBD"))))
      :purpose (c / corroborate-01
            :ARG0 m
            :ARG1 (t / thing
                  :ARG1-of (f / find-01)
                  :mod (t2 / this))))

# ::id bio.bmtr_0001.18 ::date 2014-12-22T15:16:55 ::authors ulf
# ::snt To ensure that ubiquitinated Ras was being detected, the protein pulled down by GST-RBD was subjected to a second affinity purification on a cobalt column to purify the Flag-His-tagged K-Ras.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user consensus ::file bio_bmtr_0001_18.txt
(s / subject-01
      :ARG1 (p / protein
            :ARG1-of (p2 / pull-00
                  :ARG2 (p3 / protein :name (n3 / name :op1 "GST-RBD"))))
      :ARG2 (p4 / purify-01
            :ARG1 p
            :ord (o / ordinal-entity :value 2)
            :purpose (p5 / purify-01
                  :ARG0 p4
                  :ARG1 (e2 / enzyme :name (n2 / name :op1 "K-Ras")
                        :ARG1-of (t / tag-01
                              :ARG2 (a2 / and
                                    :op1 (p6 / protein-segment :name (n4 / name :op1 "Flag"))
                                    :op2 (p7 / protein-segment
                                          :part (a3 / amino-acid :name (n5 / name :op1 "histidine")))))))
            :mod (a / affinity)
            :location (c / column
                  :consist-of (c2 / cobalt)))
      :purpose (e3 / ensure-01
            :ARG0 s
            :ARG1 (d / detect-01
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                        :ARG3-of (u / ubiquitinate-01)))))

# ::id bio.bmtr_0001.19 ::date 2014-12-22T15:30:38 ::authors ulf
# ::snt As predicted, only a very small fraction of wild-type K-Ras was pulled down by the GST-RBD (Fig. 2C and fig. S1D), consistent with very little wild-type K-Ras being in the GTP state under these conditions (Fig.2, A and B).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user ulf ::file bio_bmtr_0001_19.txt
(p / pull-00
      :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
            :mod (w / wild-type)
            :quant (f / fraction
                  :mod (s2 / small
                        :degree (v / very))
                  :mod (o / only)))
      :ARG2 (p2 / protein :name (n3 / name :op1 "GST-RBD"))
      :ARG1-of (p3 / predict-01)
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f2 / figure :mod "2C")
                  :op2 (f3 / figure :mod "S1D")))
      :ARG1-of (c / consistent-41
            :ARG2 (b / bind-01
                  :ARG1 (e2 / enzyme :name (n4 / name :op1 "K-Ras")
                        :mod (w2 / wild-type)
                        :quant (l / little
                              :degree (v2 / very)))
                  :ARG2 (s / small-molecule :name (n2 / name :op1 "GTP"))
                  :condition (t / this)
                  :ARG1-of (d2 / describe-01
                        :ARG0 (a2 / and
                              :op1 (f4 / figure :mod "2A")
                              :op2 (f5 / figure :mod "2B"))))))

# ::id bio.bmtr_0001.20 ::date 2014-12-22T15:36:10 ::authors ulf
# ::snt However, a much greater fraction of the ubiquitinated-K-Ras was pulled down by the GST-RBD (Fig. 2C and fig. S1D).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user ulf ::file bio_bmtr_0001_20.txt
(c / contrast-01
      :ARG2 (p / pull-00
            :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                  :ARG3-of (u / ubiquitinate-01)
                  :quant (f / fraction
                        :mod (g / great
                              :degree (m / more)
                              :quant (m2 / much))))
            :ARG2 (p2 / protein :name (n2 / name :op1 "GST-RBD"))
            :ARG1-of (d / describe-01
                  :ARG0 (a / and
                        :op1 (f2 / figure :mod "2C")
                        :op2 (f3 / figure :mod "S1D")))))

# ::id bio.bmtr_0001.21 ::date 2014-12-22T14:32:40 ::authors ulf
# ::snt These results are consistent with a greater fraction of ubiquitinated K-Ras being in the GTP state (Fig. 2, A and B).
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Mon Dec 22, 2014 ::user ulf ::file bio_bmtr_0001_21.txt
(c / consistent-41
      :ARG1 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / this))
      :ARG2 (b / bind-01
            :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
                  :ARG3-of (u / ubiquitinate-01)
                  :degree (f3 / fraction
                        :mod (g / great
                              :degree (m / more))))
            :ARG2 (s / small-molecule :name (n2 / name :op1 "GTP")))
      :ARG1-of (d / describe-01
            :ARG0 (a / and
                  :op1 (f / figure :mod "2A")
                  :op2 (f2 / figure :mod "2B"))))

# ::id bio.bmtr_0002.1 ::date 2014-12-10T12:17:16
# ::snt Turke et al. “MEK inhibition leads to PI3K/AKT activation by relieving a negative feedback on ERBB receptors” (PMC3515079)
# ::save-date Wed Dec 10, 2014 ::user ulf ::file bio_bmtr_0002_1.txt
(p / publication-91
      :ARG0 (a / and
            :op1 (p2 / person :name (n / name :op1 "Turke"))
            :op2 (p3 / person
                  :mod (o / other)))
      :ARG1 (l / lead-03
            :ARG0 (i / inhibit-01
                  :ARG1 (e / enzyme :name (n2 / name :op1 "MEK")))
            :ARG2 (a2 / activate-01
                  :ARG1 (p4 / pathway :name (n3 / name :op1 "PI3K/AKT")))
            :manner (r / relieve-01
                  :ARG0 i
                  :ARG1 (f / feedback
                        :mod (n4 / negative)
                        :destination (r2 / receptor :name (n5 / name :op1 "ERBB")))))
      :ARG8 "PMC3515079")

# ::id bio.bmtr_0002.2 ::date 2014-12-14T20:21:31
# ::snt We hypothesized that the MEK/ERK pathway may suppress trans-phosphorylation of ERBB3 by directly phosphorylating the JM domains of EGFR and HER2, and that this could be a dominant MEK inhibitor-induced feedback leading to AKT activation in these cancers.
# ::save-date Mon Dec 15, 2014 ::user ulf ::file bio_bmtr_0002_2.txt
(h / hypothesize-01
      :ARG0 (w / we)
      :ARG1 (a / and
            :op1 (p / possible
                  :domain (s / suppress-01
                        :ARG0 (p2 / pathway :name (n / name :op1 "MEK/ERK"))
                        :ARG1 (p3 / phosphorylate-01
                              :ARG1 (e / enzyme :name (n2 / name :op1 "ERBB3")))
                        :manner (p4 / phosphorylate-01
                              :ARG0 p2
                              :ARG1 (a2 / and
                                    :op1 (p5 / protein-segment :name (n3 / name :op1 "JM" :op2 "domain")
                                          :part-of (e2 / enzyme :name (n4 / name :op1 "EGFR")))
                                    :op2 (p6 / protein-segment :name (n5 / name :op1 "JM" :op2 "domain")
                                          :part-of (e3 / enzyme :name (n6 / name :op1 "HER2"))))
                              :manner (d / direct))))
            :op2 (p7 / possible
                  :domain (f / feedback
                        :ARG1-of (i / induce-01
                              :ARG0 (m / molecular-physical-entity
                                    :ARG0-of (i2 / inhibit-01
                                          :ARG1 (e4 / enzyme :name (n7 / name :op1 "MEK")))))
                        :ARG0-of (d2 / dominate-01)
                        :ARG0-of (l / lead-03
                              :ARG2 (a3 / activate-01
                                    :ARG1 (e5 / enzyme :name (n8 / name :op1 "AKT"))
                                    :location (c / cancer
                                          :mod (t / this))))
                        :domain s))))

# ::id bio.bmtr_0002.3 ::date 2014-12-14T20:37:51
# ::snt We used tandem mass spectrometry to measure the effects of AZD6244 on phosphorylation of this JM domain threonine residue in both EGFR-mutant and HER2- amplified cancer models.
# ::save-date Mon Dec 15, 2014 ::user consensus ::file bio_bmtr_0002_3.txt
(u / use-01
      :ARG0 (w / we)
      :ARG1 (s / spectrometry
            :mod (m / mass)
            :mod (t / tandem))
      :ARG2 (m2 / measure-01
            :ARG0 w
            :ARG1 (a / affect-01
                  :ARG0 (s2 / small-molecule :name (n / name :op1 "AZD6244"))
                  :ARG1 (p / phosphorylate-01
                        :ARG1 (r / residue
                              :mod (a2 / amino-acid :name (n2 / name :op1 "threonine"))
                              :part-of (p2 / protein-segment :name (n3 / name :op1 "JM" :op2 "domain"))
                              :mod (t2 / this)))
                  :condition (a4 / and
                        :op1 (m3 / model
                              :topic (c / cancer
                                    :mod (m4 / mutate-01
                                          :ARG1 (e / enzyme :name (n4 / name :op1 "EGFR")))))
                        :op2 (m5 / model
                              :topic (c3 / cancer
                                    :mod (a3 / amplify-01
                                          :ARG1 (e2 / enzyme :name (n5 / name :op1 "HER2")))))))))

# ::id bio.bmtr_0002.4 ::date 2014-12-14T20:53:57
# ::snt Targeting both the phosphorylated and non-phosphorylated peptide forms, we detected a 66% average decrease in EGFR T669 phosphorylation and a 75% decrease in HER2 T677 phosphorylation upon treatment with AZD6244 (Figure 5B, Supplemental Figure 8).
# ::save-date Mon Dec 15, 2014 ::user consensus ::file bio_bmtr_0002_4.txt
(d / detect-01
      :ARG0 (w / we)
      :ARG1 (a / and
            :op1 (d2 / decrease-01
                  :ARG1 (p / phosphorylate-01
                        :ARG1 (a3 / amino-acid :mod 669 :name (n / name :op1 "threonine")
                              :part-of (e / enzyme :name (n2 / name :op1 "EGFR"))))
                  :ARG2 (p2 / percentage-entity :value 66
                        :ARG2-of (a2 / average-01)))
            :op2 (d3 / decrease-01
                  :ARG1 (p3 / phosphorylate-01
                        :ARG1 (a4 / amino-acid :mod 677 :name (n3 / name :op1 "threonine")
                              :part-of (e2 / enzyme :name (n4 / name :op1 "HER2"))))
                  :ARG2 (p4 / percentage-entity :value 75)))
      :ARG2 (t2 / target-01
            :ARG0 w
            :ARG1 (a6 / and
                  :op1 (p5 / protein-segment
                        :ARG3-of (p7 / phosphorylate-01))
                  :op2 (p6 / protein-segment
                        :ARG3-of (p8 / phosphorylate-01 :polarity -))))
      :condition (t / treat-04
            :ARG2 (s / small-molecule :name (n5 / name :op1 "AZD6244")))
      :ARG1-of (d4 / describe-01
            :ARG0 (a5 / and
                  :op1 (f / figure :mod "5B")
                  :op2 (f2 / figure :mod 8
                        :ARG2-of (s2 / supplement-01)))))

# ::id bio.bmtr_0002.5 ::date 2014-12-14T21:08:29
# ::snt Phospho-specific antibodies confirmed that treatment with AZD6244 inhibited phosphorylation of T669 of EGFR and the analogous T677 of HER2 (Figure 5A).
# ::save-date Sun Dec 14, 2014 ::user ulf ::file bio_bmtr_0002_5.txt
(c / confirm-01
      :ARG0 (a / antibody
            :mod (s / specific
                  :topic (p / phosphorylate-01)))
      :ARG1 (i / inhibit-01
            :ARG0 (t / treat-04
                  :ARG2 (s2 / small-molecule :name (n / name :op1 "AZD6244")))
            :ARG1 (a3 / and
                  :op1 (p2 / phosphorylate-01
                        :ARG1 (a2 / amino-acid :mod 669 :name (n2 / name :op1 "threonine")
                              :part-of (e / enzyme :name (n3 / name :op1 "EGFR"))))
                  :op2 (p3 / phosphorylate-01
                        :ARG1 (a4 / amino-acid :mod 677 :name (n4 / name :op1 "threonine")
                              :mod (a5 / analogous
                                    :topic a2)
                              :part-of (e2 / enzyme :name (n5 / name :op1 "HER2"))))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5A")))

# ::id bio.bmtr_0002.6 ::date 2014-12-14T21:17:43
# ::snt Together these data indicate that loss of this inhibitory threonine phosphorylation on the JM domains of EGFR and HER2 occurs in cancer cell lines following MEK inhibition, presumably due to differential subcellular localization and/or binding proteins.
# ::save-date Mon Dec 15, 2014 ::user consensus ::file bio_bmtr_0002_6.txt
(i / indicate-01
      :ARG0 (d / data
            :mod (t / this)
            :mod (t2 / together))
      :ARG1 (l / lose-01
            :ARG1 (p / phosphorylate-01
                  :ARG1 (a / amino-acid :name (n / name :op1 "threonine")
                        :part-of (p2 / protein-segment :name (n2 / name :op1 "JM" :op2 "domain")
                              :part-of (o / or
                                    :op1 (e / enzyme :name (n3 / name :op1 "EGFR"))
                                    :op2 (e2 / enzyme :name (n4 / name :op1 "HER2")))))
                  :ARG0-of (i2 / inhibit-01)
                  :mod (t3 / this))
            :location (c / cell-line
                  :mod (c2 / cancer))
            :ARG1-of (f / follow-01
                  :ARG2 (i3 / inhibit-01
                        :ARG1 (e3 / enzyme :name (n5 / name :op1 "MEK"))))
            :ARG1-of (c3 / cause-01
                  :ARG0 (a2 / and-or
                        :op1 (l2 / location
                              :location (c4 / cell)
                              :ARG1-of (d2 / differ-02))
                        :op2 (p4 / protein
                              :ARG1-of (b / bind-01)
                              :ARG1-of (d3 / differ-02)))
                  :ARG1-of (p3 / presume-01))))

# ::id bio.bmtr_0002.7 ::date 2014-12-15T14:06:48
# ::snt Mutation of T669 and T677 abrogates MEK inhibitor-induced suppression of ERBB3 Activation
# ::save-date Mon Dec 15, 2014 ::user ulf ::file bio_bmtr_0002_7.txt
(a / abrogate-01
      :ARG0 (m / mutate-01
            :ARG1 (a2 / and
                  :op1 (a3 / amino-acid :mod 669 :name (n / name :op1 "threonine"))
                  :op2 (a4 / amino-acid :mod 677 :name (n2 / name :op1 "threonine"))))
      :ARG1 (s / suppress-01
            :ARG1 (a5 / activate-01
                  :ARG1 (e / enzyme :name (n3 / name :op1 "ERBB3")))
            :ARG1-of (i / induce-01
                  :ARG0 (m2 / molecular-physical-entity
                        :ARG0-of (i2 / inhibit-01
                              :ARG1 (e2 / enzyme :name (n4 / name :op1 "MEK")))))))

# ::id bio.bmtr_0002.8 ::date 2014-12-15T14:16:53
# ::snt We hypothesized that MEK inhibition activates AKT by inhibiting ERK activity, which blocks an inhibitory threonine phosphorylation on the JM domains of EGFR and HER2, thereby increasing ERBB3 phosphorylation.
# ::save-date Mon Dec 15, 2014 ::user ulf ::file bio_bmtr_0002_8.txt
(h / hypothesize-01
      :ARG0 (w / we)
      :ARG1 (a / activate-01
            :ARG0 (i / inhibit-01
                  :ARG1 (e / enzyme :name (n / name :op1 "MEK")))
            :ARG1 (e2 / enzyme :name (n2 / name :op1 "AKT"))
            :manner (i2 / inhibit-01
                  :ARG0 i
                  :ARG1 (a2 / act-02
                        :ARG0 (e3 / enzyme :name (n3 / name :op1 "ERK")))
                  :ARG0-of (b / block-01
                        :ARG1 (p / phosphorylate-01
                              :ARG1 (a3 / amino-acid :name (n4 / name :op1 "threonine")
                                    :part-of (p2 / protein-segment :name (n5 / name :op1 "JM" :op2 "domain")
                                          :part-of (o / or
                                                :op1 (e4 / enzyme :name (n6 / name :op1 "EGFR"))
                                                :op2 (e5 / enzyme :name (n7 / name :op1 "HER2")))))
                              :ARG0-of (i3 / inhibit-01))
                        :ARG0-of (i4 / increase-01
                              :ARG1 (p3 / phosphorylate-01
                                    :ARG1 (e6 / enzyme :name (n8 / name :op1 "ERBB3"))))))))

# ::id bio.bmtr_0002.9 ::date 2014-12-15T14:52:21
# ::snt To test this hypothesis, we transiently transfected CHO-KI cells, which do not express ERBB receptors endogenously, with wild-type ERBB3 with either wild-type EGFR or EGFR T669A.
# ::save-date Wed Dec 17, 2014 ::user consensus ::file bio_bmtr_0002_9.txt
(t / transfect-00
      :ARG0 (w / we)
      :ARG1 (c / cell
            :source (c2 / cell-line :name (n / name :op1 "CHO-KI"))
            :ARG3-of (e3 / express-03 :polarity -
                  :ARG2 (r / receptor :name (n4 / name :op1 "ERBB"))
                  :mod (e4 / endogenous)))
      :ARG2 (a / and
            :op1 (e5 / enzyme :name (n5 / name :op1 "ERBB3")
                  :mod (w3 / wild-type))
            :op2 (o / or
                  :op1 (e / enzyme :name (n2 / name :op1 "EGFR")
                        :mod (w2 / wild-type))
                  :op2 (e2 / enzyme :name (n3 / name :op1 "EGFR")
                        :ARG2-of (m / mutate-01 :value "T669A"))))
      :mod (t2 / transient)
      :purpose (t3 / test-01
            :ARG0 w
            :ARG1 (t5 / thing
                  :ARG1-of (h / hypothesize-01)
                  :mod (t4 / this))))

# ::id bio.bmtr_0002.10 ::date 2014-12-15T15:05:31
# ::snt In cells transfected with wild-type EGFR, MEK inhibition led to feedback activation of phospho-ERBB3 and phosho-EGFR, recapitulating the results we had observed in our panel of cancer cell lines (Figure 6A).
# ::save-date Wed Dec 17, 2014 ::user consensus ::file bio_bmtr_0002_10.txt
(l / lead-03
      :ARG0 (i / inhibit-01
            :ARG1 (e / enzyme :name (n / name :op1 "MEK")))
      :ARG2 (a / activate-01
            :ARG1 (a2 / and
                  :op1 (e3 / enzyme :name (n3 / name :op1 "ERBB3")
                        :ARG3-of (p / phosphorylate-01))
                  :op2 (e4 / enzyme :name (n4 / name :op1 "EGFR")
                        :ARG3-of (p2 / phosphorylate-01)))
            :subevent-of (f / feedback))
      :location (c / cell
            :ARG1-of (t / transfect-00
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "EGFR")
                        :mod (w / wild-type))))
      :ARG0-of (r / recapitulate-01
            :ARG1 (t2 / thing
                  :ARG2-of (r2 / result-01)
                  :ARG1-of (o / observe-01
                        :ARG0 (w2 / we)
                        :location (p3 / panel
                              :consist-of (c2 / cell-line
                                    :mod (c3 / cancer))
                              :poss w2))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod "6A")))

# ::id bio.bmtr_0002.11 ::date 2014-12-17T01:40:22 ::authors bbadarau
# ::snt In contrast, the EGFR T669A mutant increased both basal EGFR and ERBB3 tyrosine phosphorylation that was not augmented by MEK inhibition.
# ::note Sentence+ loaded by script SntLoaderUlf1.7.pl
# ::save-date Wed Dec 17, 2014 ::user bbadarau ::file bio_bmtr_0002_11.txt
(c / contrast-01
  :ARG2 (i / increase-01
          :ARG0 (e4 / enzyme
                  :name (n4 / name
                          :op1 "EGFR")
                  :ARG2-of (m / mutate-01
                             :value "T669A"))
          :ARG1 (a / and
                  :op1 (p2 / phosphorylate-01
                         :ARG1 (a2 / amino-acid
                                 :name (n5 / name
                                         :op1 "tyrosine")
                                 :part-of (e / enzyme
                                            :name (n / name
                                                    :op1 "EGFR")))
                         :mod (b / basal))
                  :op2 (p3 / phosphorylate-01
                         :ARG1 (a3 / amino-acid
                                 :name (n6 / name
                                         :op1 "tyrosine"))
                         :part-of (e2 / enzyme
                                    :name (n2 / name
                                            :op1 "ERBB3"))
                         :mod b)
                  :ARG1-of (a4 / augment-01
                             :ARG0 (i2 / inhibit-01
                                     :ARG1 (e3 / enzyme
                                             :name (n3 / name
                                                     :op1 "MEK")))
                             :polarity -))))

# ::id bio.bmtr_0002.12 ::date 2014-12-15T15:37:12
# ::snt As a control, we treated CHO-KI cells expressing EGFR T669A with HRG ligand to induce maximal ERBB3 phosphorylation (Figure 6A), indicating that the lack of induction of phospho-ERBB3 in EGFR T669A expressing cells following MEK inhibition was not simply due to the saturation of the system with phospho-ERBB3.
# ::save-date Wed Dec 17, 2014 ::user ulf ::file bio_bmtr_0002_12.txt
(t / treat-04
      :ARG0 (w / we)
      :ARG1 (c / cell
            :source (c2 / cell-line :name (n / name :op1 "CHO-KI"))
            :ARG3-of (e / express-03
                  :ARG2 (e2 / enzyme :name (n2 / name :op1 "EGFR")
                        :ARG2-of (m / mutate-01 :value "T669A"))))
      :ARG2 (l / ligand :name (n3 / name :op1 "HRG"))
      :purpose (i / induce-01
            :ARG0 w
            :ARG1 (p / phosphorylate-01
                  :ARG1 (e3 / enzyme :name (n4 / name :op1 "ERBB3"))
                  :degree (m2 / maximum))
            :ARG0-of (i2 / indicate-01
                  :ARG1 (c3 / cause-01 :polarity -
                        :ARG0 (l2 / lack-01
                              :ARG1 (i3 / induce-01
                                    :ARG1 (p3 / phosphorylate-01
                                          :ARG1 e3)
                                    :location (c4 / cell
                                          :ARG3-of (e5 / express-03
                                                :ARG2 (e6 / enzyme :name (n6 / name :op1 "EGFR")
                                                      :ARG2-of (m3 / mutate-01 :value "T669A"))))
                                    :ARG2-of (f2 / follow-01
                                          :ARG1 (i4 / inhibit-01
                                                :ARG1 (e7 / enzyme :name (n7 / name :op1 "MEK"))))))
                        :ARG1 (s / saturate-01
                              :ARG1 (s2 / system)
                              :ARG2 (e4 / enzyme :name (n5 / name :op1 "ERBB3")
                                    :ARG3-of (p2 / phosphorylate-01)))
                        :mod (s3 / simple))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6A"))
      :ARG2-of (c5 / control-01))

# ::id bio.bmtr_0002.13 ::date 2014-12-15T18:12:14
# ::snt We observed analogous results in CHO-KI cells expressing wild-type ERBB3 in combination with wild-type or T677A mutant HER2 (Figure 6B).
# ::save-date Wed Dec 17, 2014 ::user ulf ::file bio_bmtr_0002_13.txt
(o / observe-01
      :ARG0 (w / we)
      :ARG1 (t / thing
            :ARG2-of (r / result-01
                  :ARG1 (c / cell
                        :source (c2 / cell-line :name (n / name :op1 "CHO-KI"))
                        :ARG3-of (e / express-03
                              :ARG2 (e2 / enzyme :name (n2 / name :op1 "ERBB3")
                                    :mod (w2 / wild-type)
                                    :accompanier (o2 / or
                                          :op1 (e3 / enzyme :name (n3 / name :op1 "HER2")
                                                :mod (w3 / wild-type))
                                          :op2 (e4 / enzyme :name (n4 / name :op1 "HER2")
                                                :ARG2-of (m / mutate-01 :value "T677A")))))))
            :mod (a / analogous))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "6B")))

# ::id bio.bmtr_0002.14 ::date 2014-12-15T18:52:18
# ::snt Together these results support the hypothesis that inhibition of ERK-mediated phosphorylation of a conserved JM domain threonine residue leads to feedback activation of EGFR, HER2, and ERBB3 (Figure 7).
# ::save-date Fri Dec 19, 2014 ::user consensus ::file bio_bmtr_0002_14.txt
(s / support-01
      :ARG0 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / together)
            :mod (t3 / this))
      :ARG1 (h / hypothesize-01
            :ARG1 (l / lead-03
                  :ARG0 (i / inhibit-01
                        :ARG1 (p / phosphorylate-01
                              :ARG1 (r2 / residue
                                    :mod (a3 / amino-acid :name (n5 / name :op1 "threonine"))
                                    :part-of (p2 / protein-segment :name (n6 / name :op1 "JM" :op2 "domain")
                                          :ARG1-of (c / conserve-01)))
                              :ARG1-of (m / mediate-01
                                    :ARG0 (e4 / enzyme :name (n4 / name :op1 "ERK")))))
                  :ARG2 (a / activate-01
                        :ARG1 (a2 / and
                              :op1 (e / enzyme :name (n / name :op1 "EGFR"))
                              :op2 (e2 / enzyme :name (n2 / name :op1 "HER2"))
                              :op3 (e3 / enzyme :name (n3 / name :op1 "ERBB3")))
                        :subevent-of (f / feedback))))
      :ARG1-of (d / describe-01
            :ARG0 (f2 / figure :mod 7)))

# ::id bio.bmtr_0004.1 ::date 2015-01-06T01:27:24
# ::snt Site-Specific Monoubiquitination Activates Ras by Impeding GTPase Activating Protein (PMC3537887)
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_1.txt
(p / publication-91
      :ARG1 (a / activate-01
            :ARG0 (u / ubiquitinate-01 :quant 1
                  :mod (s / specific
                        :prep-to (p3 / protein-segment)))
            :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
            :manner (i / impede-01
                  :ARG0 u
                  :ARG1 (p2 / protein :name (n2 / name :op1 "GTPase" :op2 "Activating" :op3 "Protein"))))
      :ARG8 "PMC3537887")

# ::id bio.bmtr_0004.2 ::date 2015-01-06T08:06:39
# ::snt Passage 1-1 (Results)
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0004_2.txt
(p / passage :mod "1-1"
      :topic (t / thing
            :ARG2-of (r / result-01)))

# ::id bio.bmtr_0004.3 ::date 2015-01-06T08:58:49
# ::snt We next considered the effect of Ras monoubiquitination on GAP-mediated hydrolysis.
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0004_3.txt
(c / consider-02
      :ARG0 (w / we)
      :ARG1 (a / affect-01
            :ARG0 (u / ubiquitinate-01 :quant 1
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras")))
            :ARG1 (h / hydrolyze-01
                  :ARG1-of (m / mediate-01
                        :ARG0 (p / protein :name (n2 / name :op1 "GAP")))))
      :time (n3 / next))

# ::id bio.bmtr_0004.4 ::date 2015-01-06T09:08:59
# ::snt To this end we compared the rate of GTP hydrolysis for Ras and mUbRas in the presence of the catalytic domains of two GAPs, NF1 (NF1-333) and p120GAP(GAP-334).
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_4.txt
(c / compare-01
      :ARG0 (w / we)
      :ARG1 (r / rate
            :degree-of (h / hydrolyze-01
                  :ARG1 (s / small-molecule :name (n / name :op1 "GTP")
                        :ARG1-of (b / bind-01
                              :ARG2 (e / enzyme :name (n2 / name :op1 "Ras"))))
                  :condition (a / and
                        :op1 (d2 / domain :name (n10 / name :op1 "NF1-333")
                              :part-of (p4 / protein :name (n12 / name :op1 "NF1")
                                    :ARG1-of (i / include-91
                                          :ARG2 (p6 / protein :name (n13 / name :op1 "GAP")))))
                        :op2 (d3 / domain :name (n11 / name :op1 "GAP-334")
                              :part-of (p7 / protein :name (n14 / name :op1 "p120GAP")
                                    :ARG1-of (i2 / include-91
                                          :ARG2 p6)))
                        :ARG0-of (c2 / catalyze-01))))
      :ARG2 (r2 / rate
            :degree-of (h2 / hydrolyze-01
                  :ARG1 (s2 / small-molecule :name (n9 / name :op1 "GTP")
                        :ARG1-of (b2 / bind-01
                              :ARG2 (e2 / enzyme :name (n3 / name :op1 "Ras")
                                    :ARG3-of (u / ubiquitinate-01 :quant 1))))
                  :condition a))
      :purpose (t / this))

# ::id bio.bmtr_0004.5 ::date 2015-01-06T10:21:04
# ::snt At a GAP-to-Ras ratio of 1:500, we observed an order of magnitude increase in the rate of GTP hydrolysis for unmodified Ras relative to the intrinsic rate of GTP hydrolysis.
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0004_5.txt
(o / observe-01
      :ARG0 (w / we)
      :ARG1 (i / increase-01
            :ARG1 (r / rate
                  :degree-of (h / hydrolyze-01
                        :ARG1 (s / small-molecule :name (n / name :op1 "GTP")
                              :ARG1-of (b / bind-01
                                    :ARG2 (e / enzyme :name (n2 / name :op1 "Ras")
                                          :ARG1-of (m2 / modify-01 :polarity -))))))
            :ARG4 (p2 / product-of
                  :op1 (a / about :op1 10)
                  :op2 (r3 / rate
                        :mod (i2 / intrinsic)
                        :degree-of (h2 / hydrolyze-01
                              :ARG1 (s2 / small-molecule :name (n5 / name :op1 "GTP")))))
            :condition (e3 / equal-01
                  :ARG1 (r4 / ratio-of
                        :op1 (p / protein :name (n3 / name :op1 "GAP"))
                        :op2 (e2 / enzyme :name (n4 / name :op1 "Ras")))
                  :ARG2 "1/500")))

# ::id bio.bmtr_0004.6 ::date 2015-01-06T10:36:40
# ::snt No increase in the rate of GTP hydrolysis was observed for mUbRas in the presence of the same GAP-to Ras ratio (Fig. 5b).
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_6.txt
(o / observe-01
      :ARG1 (i / increase-01 :polarity -
            :ARG1 (r / rate
                  :degree-of (h / hydrolyze-01
                        :ARG1 (s / small-molecule :name (n / name :op1 "GTP")
                              :ARG1-of (b / bind-01
                                    :ARG2 (e / enzyme :name (n4 / name :op1 "Ras")
                                          :ARG3-of (u / ubiquitinate-01 :quant 1))))))
            :condition (r2 / ratio-of
                  :op1 (p2 / protein :name (n2 / name :op1 "GAP"))
                  :op2 (e2 / enzyme :name (n3 / name :op1 "Ras"))
                  :ARG1-of (s2 / same-41)))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "5b")))

# ::id bio.bmtr_0004.7 ::date 2015-01-06T10:42:11
# ::snt Therefore, mUbRas is insensitive to GAP-mediated regulation, similar to an oncogenic Ras-G12V mutation.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_7.txt
(c / cause-01
      :ARG1 (s / sensitive-41 :polarity -
            :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                  :ARG3-of (u / ubiquitinate-01 :quant 1))
            :ARG2 (r / regulate-01
                  :ARG1 e
                  :ARG1-of (m / mediate-01
                        :ARG0 (p / protein :name (n2 / name :op1 "GAP"))))
            :ARG1-of (r2 / resemble-01
                  :ARG2 (m2 / mutate-01 :value "G12V"
                        :ARG2 (e2 / enzyme :name (n3 / name :op1 "Ras"))
                        :ARG0-of (c2 / cause-01
                              :ARG1 (c3 / cancer))))))

# ::id bio.bmtr_0004.8 ::date 2015-01-06T11:02:39
# ::snt We obtained similar results using K-Ras (Supplementary Figure 6), indicating that the effects of monoubiquitination on Ras are not isoform-specific.
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0004_8.txt
(o / obtain-01
      :ARG0 (w / we)
      :ARG1 (t / thing
            :ARG2-of (r / result-01)
            :ARG1-of (r2 / resemble-01)
            :ARG1-of (d / describe-01
                  :ARG0 (f / figure :mod 6
                        :ARG2-of (s / supplement-01)))
            :ARG0-of (i / indicate-01
                  :ARG1 (s2 / specific :polarity -
                        :domain (a / affect-01
                              :ARG0 (u2 / ubiquitinate-01 :quant 1)
                              :ARG1 (e2 / enzyme :name (n2 / name :op1 "Ras")))
                        :topic (i2 / isoform))))
      :manner (u / use-01
            :ARG0 w
            :ARG1 (e / enzyme :name (n / name :op1 "K-Ras"))))

# ::id bio.bmtr_0004.9 ::date 2015-01-06T11:13:11
# ::snt To verify that the differences between the enzymatic and chemical ubiquitination linkers (seven bonds and five bonds, respectively) do not alter GAP-responsiveness, we placed an additional cysteine at the c-terminus of Ubiquitin (Ubiquitin-C77), thereby creating a linker one bond longer than the native linker.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_9.txt
(p / place-01
      :ARG0 (w / we)
      :ARG1 (a / amino-acid :name (n / name :op1 "cysteine")
            :mod (a2 / additional))
      :ARG2 (p2 / protein-segment :name (n2 / name :op1 "C-terminus")
            :part-of (p3 / protein :name (n3 / name :op1 "ubiquitin")))
      :manner-of (b4 / become-01
            :ARG1 a
            :ARG2 (a5 / amino-acid :mod 77 :name (n4 / name :op1 "cysteine")
                  :part-of p3))
      :ARG0-of (c / create-01
            :ARG1 (p6 / protein-segment
                  :mod (l / long
                        :degree (m2 / more
                              :quant (b / bond :quant 1))
                        :compared-to (p7 / protein-segment
                              :mod (n7 / native)
                              :ARG0-of (l3 / link-01)))
                  :ARG0-of (l2 / link-01)))
      :ARG1-of (h / have-purpose-91
            :ARG2 (v / verify-01
                  :ARG0 w
                  :ARG1 (a4 / alter-01 :polarity -
                        :ARG0 (d / differ-02
                              :ARG1 (a3 / and
                                    :op1 (p8 / protein-segment
                                          :consist-of (b2 / bond :quant 7)
                                          :ARG0-of (l4 / link-01)
                                          :location-of (u2 / ubiquitinate-01
                                                :mod (e / enzyme)))
                                    :op2 (p9 / protein-segment
                                          :location-of (u / ubiquitinate-01
                                                :mod (c2 / chemical))
                                          :consist-of (b3 / bond :quant 5)
                                          :ARG0-of (l5 / link-01))))
                        :ARG1 (r / respond-01
                              :ARG0 (p5 / protein :name (n5 / name :op1 "GAP")))))))

# ::id bio.bmtr_0004.10 ::date 2015-01-06T11:14:24
# ::snt We measured the rate of GAP-mediated GTP hydrolysis and observed that the response of Ras ligated to Ubiquitin-C77 was identical to Ras ligated to Ubiquitin-G76C (Fig. 5b).
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_10.txt
(a / and
      :op1 (m / measure-01
            :ARG0 (w / we)
            :ARG1 (r / rate
                  :degree-of (h / hydrolyze-01
                        :ARG1 (s / small-molecule :name (n / name :op1 "GTP"))
                        :ARG1-of (m2 / mediate-01
                              :ARG0 (p / protein :name (n2 / name :op1 "GAP"))))))
      :op2 (o / observe-01
            :ARG0 w
            :ARG1 (i / identical-41
                  :ARG1 (t / thing
                        :ARG2-of (r2 / respond-01
                              :ARG0 (e / enzyme :name (n5 / name :op1 "Ras")
                                    :ARG1-of (l / ligate-01
                                          :ARG3 (a2 / amino-acid :mod 77 :name (n7 / name :op1 "cysteine")
                                                :part-of (p4 / protein :name (n8 / name :op1 "ubiquitin")))))))
                  :ARG2 (t2 / thing
                        :ARG2-of (r3 / respond-01
                              :ARG0 (e2 / enzyme :name (n4 / name :op1 "Ras")
                                    :ARG1-of (l2 / ligate-01
                                          :ARG3 (a3 / amino-acid :mod 76 :name (n3 / name :op1 "cysteine")
                                                :part-of (p2 / protein :name (n9 / name :op1 "ubiquitin")
                                                      :ARG3-of (m3 / mutate-01 :value "G76C")))))))
                  :ARG1-of (d / describe-01
                        :ARG0 (f / figure :mod "5b")))))

# ::id bio.bmtr_0004.11 ::date 2015-01-06T12:31:02
# ::snt These results indicate that variations in the linker length on this scale (1-2 bonds) do not influence the sensitivity of mUbRas to GAP downregulation.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_11.txt
(i / indicate-01
      :ARG0 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / this))
      :ARG1 (i2 / influence-01 :polarity -
            :ARG0 (v2 / vary-01
                  :ARG1 (p2 / protein-segment
                        :ARG0-of (l2 / link-01))
                  :ARG2 (o / or
                        :op1 (b / bond :quant 1)
                        :op2 (b2 / bond :quant 2))
                  :ARG5 (l / length))
            :ARG1 (s / sensitive-41
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                        :ARG3-of (u / ubiquitinate-01 :quant 1))
                  :ARG2 (d / downregulate-01
                        :ARG1 e
                        :ARG2 (p / protein :name (n2 / name :op1 "GAP"))))))

# ::id bio.bmtr_0004.12 ::date 2015-01-06T12:43:54
# ::snt To validate the use of an in vitro system to dissect the mechanism of Ras regulation, we measured the sensitivity of mUbRas to GAP-mediated hydrolysis in a cellular reconstitution system.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_12.txt
(m / measure-01
      :ARG0 (w / we)
      :ARG1 (s / sensitive-41
            :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                  :ARG3-of (u / ubiquitinate-01 :quant 1))
            :ARG2 (h / hydrolyze-01
                  :ARG1-of (m2 / mediate-01
                        :ARG0 (p / protein :name (n2 / name :op1 "GAP"))))
            :location (s2 / system
                  :ARG0-of (r / reconstitute-01
                        :ARG1 (c / cell))))
      :ARG1-of (h2 / have-purpose-91
            :ARG2 (v / validate-01
                  :ARG0 w
                  :ARG1 (u2 / use-01
                        :ARG0 w
                        :ARG1 (s3 / system
                              :mod (i / in-vitro))
                        :ARG2 (d / dissect-01
                              :ARG0 w
                              :ARG1 (r2 / regulate-01
                                    :ARG1 (e2 / enzyme :name (n3 / name :op1 "Ras"))))))))

# ::id bio.bmtr_0004.13 ::date 2015-01-06T12:53:31
# ::snt We immunoprecipitated Ras from HEK293T cells and compared the sensitivity of the monoubiquitinated and unmodified fractions of Ras to regulation by GAP.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_13.txt
(a / and
      :op1 (i / immunoprecipitate-00
            :ARG0 (w / we)
            :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
            :ARG2 (c / cell-line :name (n2 / name :op1 "HEK293T")))
      :op2 (c2 / compare-01
            :ARG0 w
            :ARG1 (s / sensitive-41
                  :ARG1 (f / fraction
                        :part-of e
                        :ARG1-of (u / ubiquitinate-01 :quant 1))
                  :ARG2 (r / regulate-01
                        :ARG0 (p / protein :name (n3 / name :op1 "GAP"))
                        :ARG1 f))
            :ARG2 (s2 / sensitive-41
                  :ARG1 (f2 / fraction
                        :part-of e
                        :ARG1-of (m / modify-01 :polarity -))
                  :ARG2 (r2 / regulate-01
                        :ARG0 p
                        :ARG1 f2))))

# ::id bio.bmtr_0004.14 ::date 2015-01-06T13:00:57
# ::snt As seen in Figure 5c, monoubiquitinated K-Ras is less sensitive than the unmodified protein to GAP-mediated GTP hydrolysis.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_14.txt
(s / sensitive-41
      :ARG1 (e / enzyme :name (n / name :op1 "K-Ras")
            :ARG1-of (u / ubiquitinate-01 :quant 1))
      :ARG2 (h / hydrolyze-01
            :ARG1 (s2 / small-molecule :name (n2 / name :op1 "GTP"))
            :ARG1-of (m2 / mediate-01
                  :ARG0 (p2 / protein :name (n3 / name :op1 "GAP"))))
      :degree (l / less)
      :compared-to (e2 / enzyme :name (n4 / name :op1 "K-Ras")
            :ARG1-of (m / modify-01 :polarity -))
      :ARG1-of (s3 / see-01
            :medium (f / figure :mod "5c")))

# ::id bio.bmtr_0004.15 ::date 2015-01-06T13:05:57
# ::snt These data support our in vitro findings that monoubiquitination increases the population of active, GTP-bound Ras through a defect in sensitivity to GAP-mediated regulation.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_15.txt
(s / support-01
      :ARG0 (d / data
            :mod (t / this))
      :ARG1 (f / find-01
            :ARG0 (w / we)
            :ARG1 (i / increase-01
                  :ARG0 (u / ubiquitinate-01 :quant 1)
                  :ARG1 (p / population
                        :consist-of (e / enzyme :name (n / name :op1 "Ras")
                              :ARG1-of (a / activate-01)
                              :ARG2-of (b / bind-01
                                    :ARG1 (s2 / small-molecule :name (n2 / name :op1 "GTP")))))
                  :manner (d2 / defect
                        :topic (s3 / sensitive-41
                              :ARG2 (r / regulate-01
                                    :ARG1-of (m / mediate-01
                                          :ARG0 (p2 / protein :name (n3 / name :op1 "GAP")))))))
            :manner (i2 / in-vitro)))

# ::id bio.bmtr_0004.16 ::date 2015-01-06T13:16:30
# ::snt Passage 1-2 (Discussion/Conclusion)
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0004_16.txt
(p / passage :mod "1-2"
      :topic (s / slash
            :op1 (t / thing
                  :ARG1-of (d / discuss-01))
            :op2 (t2 / thing
                  :ARG1-of (c / conclude-01))))

# ::id bio.bmtr_0004.17 ::date 2015-01-06T13:19:56
# ::snt It was established recently that monoubiquitination increases the proportion of Ras that is in the activated (GTP-bound) state, that monoubiquitination enhances association with the downstream effectors Raf and PI3-Kinase, and that mutation of the primary site of monoubiquitination impairs oncogenic Ras-mediated tumorigenesis.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_17.txt
(e / establish-01
      :ARG1 (a / and
            :op1 (i / increase-01
                  :ARG0 (u / ubiquitinate-01 :quant 1)
                  :ARG1 (p / proportion
                        :quant-of (e2 / enzyme :name (n / name :op1 "Ras"))
                        :ARG1-of (a2 / activate-01)
                        :ARG1-of (b / bind-01
                              :ARG2 (s / small-molecule :name (n2 / name :op1 "GTP")))))
            :op2 (e3 / enhance-01
                  :ARG0 u
                  :ARG1 (a3 / associate-01
                        :ARG2 (a4 / and
                              :op1 (e4 / effector :name (n3 / name :op1 "Raf")
                                    :mod (d / downstream))
                              :op2 (e5 / effector :name (n4 / name :op1 "PI3-Kinase")))))
            :op3 (i2 / impair-01
                  :ARG0 (m2 / mutate-01
                        :ARG1 (p3 / protein-segment
                              :mod (p2 / primary)
                              :part-of u))
                  :ARG1 (c3 / create-01
                        :ARG1 (t / tumor)
                        :ARG1-of (m3 / mediate-01
                              :ARG0 (e6 / enzyme :name (n5 / name :op1 "Ras")
                                    :ARG0-of (c / cause-01
                                          :ARG1 (c2 / cancer)))))))
      :time (r / recent))

# ::id bio.bmtr_0004.18 ::date 2015-01-06T13:33:35
# ::snt Here we show that monoubiquitination decreases the sensitivity of Ras to GAP-mediated hydrolysis.
# ::save-date Tue Jan 6, 2015 ::user nnistor ::file bio_bmtr_0004_18.txt
(s / show-01
      :ARG0 (w / we)
      :ARG1 (d / decrease-01
            :ARG0 (u / ubiquitinate-01 :quant 1)
            :ARG1 (s2 / sensitive-41
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
                  :ARG2 (h / hydrolyze-01
                        :ARG1-of (m / mediate-01
                              :ARG0 (p / protein :name (n2 / name :op1 "GAP"))))))
      :location (h2 / here))

# ::id bio.bmtr_0004.19 ::date 2015-01-06T13:36:10
# ::snt A major advance was our ability to easily generate mUbRas, modified at a single site, in a form suitable for detailed biophysical studies.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_19.txt
(a / advance
      :mod (m / major)
      :domain (c / capable-41
            :ARG1 (w / we)
            :ARG2 (g / generate-01
                  :ARG0 w
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras")
                        :ARG3-of (u / ubiquitinate-01 :quant 1)
                        :ARG1-of (m2 / modify-01
                              :location (p / protein-segment
                                    :mod (s2 / single))))
                  :ARG4 (f / form
                        :ARG1-of (s3 / suit-01
                              :ARG2 (s4 / study-01
                                    :ARG1 (b / biophysical)
                                    :ARG1-of (d / detail-01)))))
            :manner (e2 / easy)))

# ::id bio.bmtr_0004.20 ::date 2015-01-06T13:41:51
# ::snt This chemical ligation strategy will likely be useful for the study of other monoubiquitinated proteins.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_20.txt
(l / likely
      :domain (u / useful
            :domain (s / strategy
                  :mod (l2 / ligate-01
                        :mod (c / chemical))
                  :mod (t / this))
            :purpose (s2 / study-01
                  :ARG1 (p / protein
                        :ARG1-of (u2 / ubiquitinate-01 :quant 1)
                        :mod (o / other)))))

# ::id bio.bmtr_0004.21 ::date 2015-01-06T02:02:31
# ::snt Surprisingly, monoubiquitination did not alter the intrinsic activity of Ras, despite the size of the modification.
# ::save-date Tue Jan 6, 2015 ::user madalina ::file bio_bmtr_0004_21.txt
(s / surprise-01
      :ARG0 (a / alter-01 :polarity -
            :ARG0 (u / ubiquitinate-01 :quant 1)
            :ARG1 (a2 / act-02
                  :ARG0 (e / enzyme :name (n / name :op1 "Ras"))
                  :mod (i / intrinsic)))
      :concession (t / thing
            :ARG2-of (s2 / size-01
                  :ARG1 (m / modify-01))))

# ::id bio.bmtr_0004.22 ::date 2015-01-06T02:13:25
# ::snt Our modeling and NMR analyses indicated that Ubiquitin dynamically samples a broad surface area of Ras that alters switch region dynamics.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_22.txt
(i / indicate-01
      :ARG0 (a / and
            :op1 (m / model-01
                  :ARG0 (w / we))
            :op2 (a2 / analyze-01
                  :ARG0 w
                  :instrument (n / NMR)))
      :ARG1 (s / sample-01
            :ARG0 (p / protein :name (n2 / name :op1 "ubiquitin"))
            :ARG1 (a3 / area
                  :mod (s2 / surface
                        :mod (b / broad))
                  :part-of (e / enzyme :name (n3 / name :op1 "Ras")))
            :manner (d / dynamic)
            :ARG0-of (a4 / alter-01
                  :ARG1 (d2 / dynamic
                        :location (r / region
                              :mod (s3 / switch-01))))))

# ::id bio.bmtr_0004.23 ::date 2015-01-06T02:48:52
# ::snt These results led us to examine the effect of monoubiquitination on the interaction of Ras with its cognate GEF and GAPs, which also target the switch domains.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_23.txt
(l / lead-03
      :ARG0 (t / thing
            :ARG2-of (r / result-01)
            :mod (t2 / this))
      :ARG1 (w / we)
      :ARG2 (e / examine-01
            :ARG0 w
            :ARG1 (a / affect-01
                  :ARG0 (u / ubiquitinate-01 :quant 1)
                  :ARG1 (i / interact-01
                        :ARG0 (e2 / enzyme :name (n / name :op1 "Ras"))
                        :ARG1 (a2 / and
                              :op1 (p / protein :name (n2 / name :op1 "GEF"))
                              :op2 (p2 / protein :name (n3 / name :op1 "GAP"))
                              :mod (c / cognate
                                    :prep-with e2)
                              :ARG0-of (t3 / target-01
                                    :ARG1 (d / domain
                                          :mod (s / switch-01))
                                    :mod (a3 / also)))))))

# ::id bio.bmtr_0004.24 ::date 2015-01-06T03:38:45
# ::snt The analysis revealed that monoubiquitination abrogates GAP-mediated GTP hydrolysis.
# ::save-date Tue Jan 6, 2015 ::user madalina ::file bio_bmtr_0004_24.txt
(r / reveal-01
      :ARG0 (a / analyze-01)
      :ARG1 (a2 / abrogate-01
            :ARG0 (u / ubiquitinate-01 :quant 1)
            :ARG1 (h / hydrolyze-01
                  :ARG1 (s / small-molecule :name (n / name :op1 "GTP"))
                  :ARG1-of (m / mediate-01
                        :ARG0 (p / protein :name (n2 / name :op1 "GAP"))))))

# ::id bio.bmtr_0004.25 ::date 2015-01-06T03:44:41
# ::snt All other activities, including the ability to bind regulators, were largely preserved and our kinetic modeling suggests that the GAP defect will dominate.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_25.txt
(a3 / and
      :op1 (p / preserve-01
            :ARG1 (a / act-02
                  :mod (a2 / all)
                  :mod (o / other)
                  :ARG2-of (i / include-01
                        :ARG1 (p2 / possible
                              :domain (b / bind-01
                                    :ARG1 (m2 / molecular-physical-entity
                                          :ARG0-of (r / regulate-01))))))
            :mod (l / large))
      :op2 (s / suggest-01
            :ARG0 (m / model-01
                  :ARG0 (w / we)
                  :mod (k / kinetic))
            :ARG1 (d / dominate-01
                  :ARG1 (d2 / defect
                        :mod (p3 / protein :name (n / name :op1 "GAP"))))))

# ::id bio.bmtr_0004.26 ::date 2015-01-06T06:25:29
# ::snt Furthermore, this outcome was specific to monoubiquitination at position 147.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_26.txt
(a / and
      :op2 (s / specific
            :prep-to (u / ubiquitinate-01 :quant 1
                  :ARG1 (a2 / amino-acid :mod 147))
            :domain (o / outcome
                  :mod (t / this))))

# ::id bio.bmtr_0004.27 ::date 2015-01-06T07:18:02
# ::snt Thus our work establishes an entirely new mode of Ras activation in which signaling is sustained even in the absence of hormone stimulus or oncogene mutation.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0004_27.txt
(e / establish-01
      :ARG0 (w / work-01
            :ARG0 (w2 / we))
      :ARG1 (m / mode
            :mod (n / new
                  :degree (e2 / entire))
            :mod (a / activate-01
                  :ARG1 (e3 / enzyme :name (n2 / name :op1 "Ras")))
            :ARG0-of (s / sustain-01
                  :ARG1 (s2 / signal-01)
                  :concession (l / lack-01
                        :ARG1 (o / or
                              :op1 (s3 / stimulus
                                    :mod (h / hormone))
                              :op2 (m2 / mutate-01
                                    :ARG0-of (c / cause-01
                                          :ARG1 (c2 / cancer))))))))

# ::id bio.bmtr_0005.1 ::date 2015-01-06T07:32:43
# ::snt Phosphorylation of ASPP2 by RAS/MAPK Pathway Is Critical for Its Full Pro-Apoptotic Function (PMC3847091)
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_1.txt
(p5 / publication-91
      :ARG1 (c / critical
            :domain (p / phosphorylate-01
                  :ARG1 (p2 / protein :name (n / name :op1 "ASPP2"))
                  :ARG2 (p3 / pathway :name (n2 / name :op1 "RAS/MAPK")))
            :prep-for (f / function-01
                  :ARG0 p2
                  :ARG1 (a / apoptosis
                        :ARG1-of (f3 / favor-01))
                  :mod (f2 / full)))
      :ARG8 "PMC3847091")

# ::id bio.bmtr_0005.2 ::date 2015-01-06T07:47:04
# ::snt Passage 1-1 (Results)
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_2.txt
(p / passage :mod "1-1"
      :topic (t / thing
            :ARG2-of (r / result-01)))

# ::id bio.bmtr_0005.3 ::date 2015-01-06T07:52:16
# ::snt It has recently been shown that oncogenic RAS can enhance the apoptotic function of p53 via ASPP1 and ASPP2.
# ::save-date Tue Jan 6, 2015 ::user madalina ::file bio_bmtr_0005_3.txt
(s / show-01
      :ARG1 (p / possible
            :domain (e / enhance-01
                  :ARG0 (e2 / enzyme :name (n / name :op1 "Ras")
                        :ARG0-of (c / cause-01
                              :ARG1 (c2 / cancer)))
                  :ARG1 (f / function-01
                        :ARG0 (p2 / protein :name (n2 / name :op1 "p53"))
                        :ARG1 (a / apoptosis))
                  :instrument (a2 / and
                        :op1 (p3 / protein :name (n3 / name :op1 "ASPP1"))
                        :op2 (p4 / protein :name (n4 / name :op1 "ASPP2")))))
      :time (r / recent))

# ::id bio.bmtr_0005.4 ::date 2015-01-06T08:05:46
# ::snt Mechanistically ASPP1 and ASPP2 bind RAS-GTP and potentiates RAS signalling to enhance p53 mediated apoptosis [2].
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_4.txt
(b / bind-01
      :ARG1 (a2 / and
            :op1 (p / protein :name (n / name :op1 "ASPP1"))
            :op2 (p2 / protein :name (n2 / name :op1 "ASPP2")))
      :ARG2 (m3 / macro-molecular-complex
            :part (e / enzyme :name (n3 / name :op1 "Ras"))
            :part (s / small-molecule :name (n4 / name :op1 "GTP")))
      :manner (m / mechanistic)
      :ARG0-of (p3 / potentiate-00
            :ARG1 (s2 / signal-01
                  :ARG0 e)
            :purpose (e2 / enhance-01
                  :ARG1 (a / apoptosis
                        :ARG1-of (m2 / mediate-01
                              :ARG0 (p4 / protein :name (n5 / name :op1 "p53"))))))
      :ARG1-of (d / describe-01
            :ARG0 (p5 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 2))))

# ::id bio.bmtr_0005.5 ::date 2015-01-07T00:52:41
# ::snt As RAS is upstream of several signalling cascades [13], we queried whether the activity of ASPP2 is regulated by the activation of a RAS-mediated signalling pathway.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_5.txt
(q / query-01
      :ARG0 (w / we)
      :ARG2 (r / regulate-01
            :ARG0 (a / activate-01
                  :ARG0 (p / pathway
                        :ARG0-of (s / signal-01
                              :ARG1-of (m / mediate-01
                                    :ARG0 e))))
            :ARG1 (a2 / act-02
                  :ARG0 (p2 / protein :name (n2 / name :op1 "ASPP2"))))
      :ARG1-of (c / cause-01
            :ARG0 (b / be-located-at-91
                  :ARG1 (e / enzyme :name (n / name :op1 "Ras"))
                  :ARG2 (r2 / relative-position
                        :op1 (c2 / cascade
                              :subevent (s2 / signal-01)
                              :quant (s3 / several))
                        :direction (u / upstream))
                  :ARG1-of (d / describe-01
                        :ARG0 (p3 / publication
                              :ARG0-of (c3 / cite-01
                                    :ARG2 13))))))

# ::id bio.bmtr_0005.6 ::date 2015-01-07T01:51:47
# ::snt One of the most studied downstream pathways of RAS signalling is the Raf-MAPK pathway.
# ::save-date Wed Jan 7, 2015 ::user madalina ::file bio_bmtr_0005_6.txt
(i / include-91
      :ARG1 (p / pathway :name (n / name :op1 "Raf-MAPK"))
      :ARG2 (p2 / pathway
            :ARG1-of (s / study-01
                  :degree (m / most))
            :mod (d / downstream)
            :location-of (s2 / signal-01
                  :ARG0 (e / enzyme :name (n2 / name :op1 "Ras")))))

# ::id bio.bmtr_0005.7 ::date 2015-01-07T02:19:05
# ::snt Interestingly, we observed two conserved putative MAPK phosphorylation sites in ASPP1 and ASPP2.
# ::save-date Wed Jan 7, 2015 ::user madalina ::file bio_bmtr_0005_7.txt
(o / observe-01
      :ARG0 (w2 / we)
      :ARG1 (a / and
            :op1 (p3 / protein-segment :quant 2
                  :ARG1-of (c / conserve-01)
                  :ARG1-of (p2 / phosphorylate-01
                        :ARG0 (p4 / pathway :name (n / name :op1 "MAPK"))
                        :ARG2-of (t / think-01))
                  :part-of (a2 / and
                        :op1 (p5 / protein :name (n2 / name :op1 "ASPP1"))
                        :op2 (p6 / protein :name (n3 / name :op1 "ASPP2")))))
      :ARG2-of (i / interest-01
            :ARG1 w2))

# ::id bio.bmtr_0005.8 ::date 2015-01-07T02:54:52
# ::snt The ASPP1 sites are at residues 671 and 746, and the ASPP2 sites are at residues 698 and 827 (Figure 1A).
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_8.txt
(a4 / and
      :op1 (b / be-located-at-91
            :ARG1 (p / protein-segment
                  :part-of (p2 / protein :name (n / name :op1 "ASPP1")))
            :ARG2 (a2 / and
                  :op1 (r / residue
                        :mod (a / amino-acid :mod 671))
                  :op2 (r2 / residue
                        :mod (a3 / amino-acid :mod 746))))
      :op2 (b2 / be-located-at-91
            :ARG1 (p3 / protein-segment
                  :part-of (p4 / protein :name (n2 / name :op1 "ASPP2")))
            :ARG2 (a5 / and
                  :op1 (r3 / residue
                        :mod (a6 / amino-acid :mod 698))
                  :op2 (r4 / residue
                        :mod (a7 / amino-acid :mod 827))))
      :ARG1-of (d / describe-01
            :ARG0 (f / figure :mod "1A")))

# ::id bio.bmtr_0005.9 ::date 2015-01-07T01:10:14
# ::snt We thus tested whether RAS activation may regulate ASPP2 phosphorylation.
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_9.txt
(c / cause-01
  :ARG1 (t / test-01
          :ARG0 (w / we)
          :ARG1 (p / possible
                  :mode interrogative
                  :domain (r / regulate-01
                            :ARG0 (a / activate-01
                                    :ARG1 (e / enzyme
                                            :name (n / name
                                                    :op1 "RAS")))
                            :ARG1 (p2 / phosphorylate-01
                                    :ARG1 (p3 / protein
                                            :name (n2 / name
                                                    :op1 "ASPP2")))))))

# ::id bio.bmtr_0005.10 ::date 2015-01-07T01:19:03
# ::snt An in vitro phophorylation assay was performed with a purified C-terminus fragment of ASPP2 (693-1128) containing both MAPK putative phosphorylation sites.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_10.txt
(a / assay-00
      :ARG1 (p / phosphorylate-01
            :ARG1 (p2 / protein-segment
                  :part-of (p3 / protein-segment :name (n / name :op1 "C-terminus")
                        :part-of (p4 / protein :name (n2 / name :op1 "ASPP2")))
                  :ARG1-of (p5 / purify-01)
                  :mod (b / between
                        :op1 (a2 / amino-acid :mod 693)
                        :op2 (a3 / amino-acid :mod 1128))
                  :ARG0-of (c / contain-01
                        :ARG1 (p6 / protein-segment
                              :ARG1-of (p7 / phosphorylate-01
                                    :ARG2 (e / enzyme :name (n4 / name :op1 "MAPK"))
                                    :ARG1-of (t / think-01))
                              :mod (b2 / both))))
            :manner (i / in-vitro)))

# ::id bio.bmtr_0005.11 ::date 2015-01-07T01:50:22
# ::snt When compared to p38 SAPK, MAPK1 was clearly able to phosphorylate the ASPP2 fragment in vitro (Figure 1B, left and middle panels).
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_11.txt
(p / possible
  :mod (c / clear)
  :domain (p2 / phosphorylate-01
            :ARG1 (p3 / protein-segment
                    :part-of (p4 / protein
                               :name (n2 / name
                                       :op1 "ASPP2")))
            :ARG2 (e / enzyme
                    :name (n / name
                            :op1 "MAPK1"))
            :manner (i / in-vitro))
  :compared-to (p5 / possible
                 :domain (p6 / phosphorylate-01
                           :ARG1 p3
                           :ARG2 (e2 / enzyme
                                   :name (n3 / name
                                           :op1 "p38"
                                           :op2 "SAPK"))))
  :ARG1-of (d / describe-01
             :ARG0 (a / and
                     :op1 (p7 / panel
                            :location (l / left))
                     :op2 (p8 / panel
                            :location (m / middle))
                     :part-of (f / figure
                                :mod "1B"))))

# ::id bio.bmtr_0005.12 ::date 2015-01-07T02:20:07
# ::snt As shown in Figure S1, histone 2B phosphorylated by p38 SAPK had high levels of incorporated 32P, suggesting that p38 SAPK was active; while under the same conditions, ASPP2 (693-1128) fragment phosphorylated by p38 SAPK had very low levels of incorporated 32P, indicating that p38 SAPK is not an efficient kinase for ASPP2 phosphorylation.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_12.txt
(s / show-01
      :ARG0 (f / figure :mod "S1")
      :ARG1 (c / contrast-01
            :ARG1 (h / have-part-91
                  :ARG1 (p8 / protein :name (n / name :op1 "Histone" :op2 "2B")
                        :ARG3-of (p2 / phosphorylate-01
                              :ARG2 (e / enzyme :name (n2 / name :op1 "p38" :op2 "SAPK"))))
                  :ARG2 (p / phosphorus
                        :mod (m / molecular-mass :value 32)
                        :quant (l / level
                              :mod (h3 / high))
                        :ARG1-of (i / incorporate-02
                              :ARG2 p8))
                  :ARG0-of (s2 / suggest-01
                        :ARG1 (a / activate-01
                              :ARG1 e)))
            :ARG2 (h4 / have-part-91
                  :ARG1 (p3 / protein-segment
                        :mod (b / between
                              :op1 (a2 / amino-acid :mod 693)
                              :op2 (a3 / amino-acid :mod 1128))
                        :part (p5 / protein :name (n3 / name :op1 "ASPP2"))
                        :ARG3-of (p6 / phosphorylate-01
                              :ARG2 e))
                  :ARG2 (p4 / phosphorus
                        :mod (m2 / molecular-mass :value 32)
                        :quant (l2 / level
                              :mod (l3 / low
                                    :degree (v / very)))
                        :ARG1-of (i2 / incorporate-02
                              :ARG2 p3))
                  :ARG0-of (i3 / indicate-01
                        :ARG1 (e2 / efficient-41 :polarity -
                              :ARG1 e
                              :ARG2 (p7 / phosphorylate-01
                                    :ARG1 p5
                                    :ARG2 e)))
                  :condition (t / thing
                        :ARG1-of (s3 / same-41
                              :ARG2 (t2 / thing
                                    :condition-of h))))))

# ::id bio.bmtr_0005.13 ::date 2015-01-07T02:45:06
# ::snt The phosphorylated ASPP2 fragment by MAPK1 was digested by trypsin and fractioned on a high performance liquid chromatography (HPLC).
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_13.txt
(a / and
      :op1 (d / digest-01
            :ARG0 (e / enzyme :name (n / name :op1 "trypsin"))
            :ARG1 (p / protein-segment
                  :part-of (p2 / protein :name (n2 / name :op1 "ASPP2"))
                  :ARG3-of (p3 / phosphorylate-01
                        :ARG2 (e2 / enzyme :name (n3 / name :op1 "MAPK1")))))
      :op2 (f / fraction-01
            :ARG1 p
            :manner (c / chromatography
                  :mod (l / liquid
                        :ARG0-of (p4 / perform-01
                              :degree (h / high))))))

# ::id bio.bmtr_0005.14 ::date 2015-01-07T02:59:19
# ::snt Each eluted fraction was measured for its radioactivity content (Figure 1B, right panel).
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_14.txt
(m / measure-01
  :ARG1 (f / fraction
          :ARG3-of (e / elute-00)
          :mod (e2 / each))
  :purpose (t / thing
             :mod (r2 / radioactive)
             :ARG1-of (c / contain-01
                        :ARG0 f))
  :ARG1-of (d / describe-01
             :ARG0 (p / panel
                     :location (r / right)
                     :part-of (f2 / figure
                                :mod "1B"))))

# ::id bio.bmtr_0005.15 ::date 2015-01-07T03:12:21
# ::snt The fractions representing these radioactive peaks were analysed by mass spectrometry.
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_15.txt
(a / analyze-01
      :ARG1 (f / fraction
            :ARG0-of (r / represent-01
                  :ARG1 (p / peak
                        :mod (r2 / radioactive)
                        :mod (t / this))))
      :manner (s / spectrometry
            :mod (m / mass)))

# ::id bio.bmtr_0005.16 ::date 2015-01-07T03:17:37
# ::snt Of the two radioactive peaks, one represented the linker region between the GST and our ASPP2 fragment and the other corresponded to a fragment of the same mass as that containing the second putative phosphorylation site, serine 827.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_16.txt
(a / and
      :op1 (r / represent-01
            :ARG0 (p / peak
                  :ARG1-of (i / include-91
                        :ARG2 (p2 / peak :quant 2
                              :mod (r2 / radioactive))))
            :ARG1 (r4 / region
                  :ARG0-of (l / link-01
                        :ARG1 (a2 / and
                              :op1 (e / enzyme :name (n / name :op1 "GST"))
                              :op2 (p3 / protein-segment
                                    :part-of (p4 / protein :name (n2 / name :op1 "ASPP2"))
                                    :poss (w / we))))))
      :op2 (c / correspond-02
            :ARG1 (p5 / peak
                  :mod (o / other)
                  :ARG1-of (i2 / include-91
                        :ARG2 p2))
            :ARG2 (p6 / protein-segment
                  :mod (m / mass
                        :domain (p7 / protein-segment
                              :ARG1-of (p8 / phosphorylate-01)
                              :ord (o2 / ordinal-entity :value 2)
                              :ARG1-of (e2 / equal-01
                                    :ARG2 (a3 / amino-acid :mod 827 :name (n3 / name :op1 "serine"))
                                    :ARG1-of (t / think-01)))))))

# ::id bio.bmtr_0005.17 ::date 2015-01-07T04:57:02
# ::snt Hence ASPP2 can be phosphorylated at serine 827 by MAPK1 in vitro.
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_17.txt
(c / cause-01
  :ARG1 (p / possible
          :domain (p2 / phosphorylate-01
                    :ARG1 (a / amino-acid
                            :name (n / name
                                    :op1 "serine")
                            :mod 827
                            :part-of (p3 / protein
                                       :name (n2 / name
                                               :op1 "ASPP2")))
                    :ARG2 (e / enzyme
                            :name (n3 / name
                                    :op1 "MAPK1"))
                    :manner (i / in-vitro))))

# ::id bio.bmtr_0005.18 ::date 2015-01-07T05:01:25
# ::snt Passage 1-2 (Discussion/Conclusion)
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_18.txt
(p / passage :mod "1-2"
      :topic (s / slash
            :op1 (t2 / thing
                  :ARG1-of (d / discuss-01))
            :op2 (t / thing
                  :ARG1-of (c / conclude-01))))

# ::id bio.bmtr_0005.19 ::date 2015-01-07T05:12:17
# ::snt We and others have recently shown that ASPP2 can potentiate RAS signaling by binding directly via the ASPP2 N-terminus [2,6].
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_19.txt
(s / show-01
      :ARG0 (a / and
            :op1 (w / we)
            :op2 (p / person
                  :mod (o / other)))
      :ARG1 (p2 / possible
            :domain (p3 / potentiate-00
                  :ARG0 (p4 / protein :name (n / name :op1 "ASPP2"))
                  :ARG1 (s2 / signal-01
                        :ARG0 (e / enzyme :name (n2 / name :op1 "RAS")))
                  :manner (b / bind-01
                        :ARG1 e
                        :ARG2 (p5 / protein-segment :name (n3 / name :op1 "N-terminus")
                              :part-of p4)
                        :manner (d / direct))))
      :time (r / recent)
      :ARG1-of (d2 / describe-01
            :ARG0 (p6 / publication
                  :ARG1-of (c / cite-01
                        :ARG2 (v / value-interval :op1 2 :op2 6)))))

# ::id bio.bmtr_0005.20 ::date 2015-01-07T05:23:11
# ::snt Moreover, the RAS-ASPP interaction enhances the transcription function of p53 in cancer cells [2].
# ::save-date Wed Jan 7, 2015 ::user bbadarau ::file bio_bmtr_0005_20.txt
(a / and
      :op2 (e / enhance-01
            :ARG0 (i / interact-01
                  :ARG0 (e2 / enzyme :name (n / name :op1 "RAS"))
                  :ARG1 (p / protein :name (n2 / name :op1 "ASPP")))
            :ARG1 (t / transcribe-01
                  :ARG1 (p2 / protein :name (n3 / name :op1 "p53"))
                  :location (c2 / cell
                        :mod (c3 / cancer)))
            :ARG1-of (d / describe-01
                  :ARG0 (p3 / publication
                        :ARG1-of (c4 / cite-01
                              :ARG2 2)))))

# ::id bio.bmtr_0005.21 ::date 2015-01-07T05:39:33
# ::snt Until now, it has been unclear how RAS could affect ASPP2 to enhance p53 function.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_21.txt
(c / clear :polarity -
      :domain (t / thing
            :manner-of (p / possible
                  :domain (a / affect-01
                        :ARG0 (e / enzyme :name (n / name :op1 "RAS"))
                        :ARG1 (p2 / protein :name (n3 / name :op1 "ASPP2"))
                        :ARG0-of (c2 / cause-01
                              :ARG1 (e2 / enhance-01
                                    :ARG1 (f / function-01
                                          :ARG0 (p3 / protein :name (n4 / name :op1 "p53"))))))))
      :time (u / until
            :op1 (n2 / now)))

# ::id bio.bmtr_0005.22 ::date 2015-01-07T05:10:22
# ::snt We show here that ASPP2 is phosphorylated by the RAS/Raf/MAPK pathway and that this phosphorylation leads to its increased translocation to the cytosol/nucleus and increased binding to p53, providing an explanation of how RAS can activate p53 pro-apoptotic functions (Figure 5).
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_22.txt
(s / show-01
      :ARG0 (w / we)
      :ARG1 (p / phosphorylate-01
            :ARG1 (p3 / protein :name (n2 / name :op1 "ASPP2"))
            :ARG2 (p2 / pathway :name (n / name :op1 "RAS/Raf/MAPK"))
            :ARG0-of (l / lead-03
                  :ARG2 (a / and
                        :op1 (i / increase-01
                              :ARG1 (t / translocate-00
                                    :ARG1 p3
                                    :ARG2 (s2 / slash
                                          :op1 (c / cytosol)
                                          :op2 (n3 / nucleus))))
                        :op2 (i2 / increase-01
                              :ARG1 (b / bind-01
                                    :ARG1 p3
                                    :ARG2 (p4 / protein :name (n4 / name :op1 "p53"))))))
            :ARG0-of (e2 / explain-01
                  :ARG1 (p5 / possible
                        :domain (a2 / activate-01
                              :ARG0 (e / enzyme :name (n5 / name :op1 "RAS"))
                              :ARG1 (f / function-01
                                    :ARG0 p4
                                    :ARG1 (a3 / apoptosis
                                          :ARG1-of (f2 / favor-01))))))
            :ARG1-of (d / describe-01
                  :ARG0 (f3 / figure :mod 5)))
      :location (h / here))

# ::id bio.bmtr_0005.23 ::date 2015-01-07T05:40:37
# ::snt Additionally, RAS/Raf/MAPK pathway activation stabilizes ASPP2 protein, although the underlying mechanism remains to be investigated.
# ::save-date Thu Jan 8, 2015 ::user cjconsensus ::file bio_bmtr_0005_23.txt
(a / and
      :op2 (s / stabilize-01
            :ARG0 (a2 / activate-01
                  :ARG1 (p / pathway :name (n / name :op1 "RAS/Raf/MAPK")))
            :ARG1 (p2 / protein :name (n2 / name :op1 "ASPP2"))
            :concession (r / remain-01
                  :ARG1 (m / mechanism
                        :ARG0-of (u / underlie-01
                              :ARG1 s))
                  :ARG3 (i / investigate-01
                        :ARG1 m))))
